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Abstract  
Background: Vitamin D has been shown to play a critical role in several systems other 
than the skeleton system. This study investigates the role of vitamin D in the 
development and progression of cardiovascular disease, particularly atherosclerosis.  
Hypothesis: Adequate blood concentrations of vitamin D have a role in preventing 
atherosclerosis disease and reducing atherosclerosis risk factors. 
Methods: Participants n=97 aged (Mean±SD) 48.2±8.4 years from both sexes 
segregated into n=33 controls, n=30 at-risk, and n=34 diagnosed with 
atherosclerosis. Background characteristics and vitamin D status were assessed from 
serum 25(OH)D, diet, supplements, and sun exposure. Atherosclerosis status and risk 
factors were assessed using a combination of clinical records, fasted blood (to 
ascertain C-reactive protein (CRP), blood glucose (FBG), and lipids profiles) and 
vascular structural and functional characteristics (including carotid-radial pulse wave 
velocity (PWV), central-blood pressure (cBP), peripheral-blood pressure (pBP), 
carotid intima-media thickness (IMT), and carotid inter-adventitial diameter (IAD)).  
Results: Amongst the participants 51.5% were vitamin D deficient, 25(OH)D <20 
ng/mL and 28.9% were insufficient 25(OH)D < 30 ng/mL. 25(OH)D levels were 
associated with all of the sources of the vitamin (P<0.01). Participants health status 
displayed distinct values for age, waist-to-hip ratio, CRP, FBG, low-density 
lipoprotein, triglycerides, pBP, cBP, IMT, and IAD (P<0.05). No association was 
observed between 25(OH)D concentrations and measured atherosclerosis 
characteristics in the pooled sample. Indeed, when vitamin D supplements were used 
25(OH)D was negatively associated with CRP in the at-risk group and pBP in those 
diagnosed with atherosclerosis. When supplements were not used 25(OH)D was 
negatively associated with IMT in the control group (P<0.05). 
Conclusion: The current study supports the previous reports on the incidence of 
vitamin D deficiency in Saudi Arabia. However, the current data do not show any link 
between 25(OH)D and critical to markers of atherosclerosis. Further Longitudinal 
experimental research is needed to clarify the association.  
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Chapter 1 - Introduction 
1.1. Background 
Like all living beings, humans require nutrients to live and function. These nutrients 
are obtained mainly from food and drinks except for some exceptions, such as the 
sunlight to obtain vitamin D. Essential nutrients include protein, carbohydrates, fat, 
vitamins, and minerals and trace elements. Each nutrient has specific functions in the 
body, and as such, each nutrient is a key requirement for overall health.  
In the past, observations of clinical disease like Scurvy, Beriberi, and Rickets led to 
the discovery of many nutrient deficiencies. Today, researchers are attempting to 
discover the further implication of nutrients-associated physiological dysfunction 
ranging from severe or moderate. Also, key, is the identification of nutrients impact 
not just on the easily recognisable characteristic symptoms but also on the 
development of certain diseases, including at the early stages of said diseases. 
Moreover, nutrient-related research is important in order to distinguish the risks of 
developing a disease. 
This body of work went beyond research into the effects of vitamin D deficiency on 
bone health and systematically investigated the impact of vitamin D in the 
cardiovascular system, in particular, the incidence and development of 
atherosclerosis. Special models had to be designed to analyse the sources of the 
vitamin from diet and sun exposure to investigate these data in a country that has an 
abundant source of the sun-derived vitamin, however, most of its dwellers are 
reportedly deficient. In addition, assessments of atherosclerosis status were 
performed using current and new techniques to ensure a clear and accurate 
assessment. Moreover, to have a complete understanding of the situation, 
investigation of the factors that have an impact on both vitamin D and atherosclerosis 
disease, as well as the inter-relationship between these parameters were considered. 
Furthermore, to discover the association between the nutrient and the disease, 
analyses were to be carried on participants with different health statuses.   
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 1.2. Structure of the thesis 
This PhD thesis focuses on finding the association between serum 25 (OH)D 
concentration and other factors and markers that affect vitamin D status and 
atherosclerosis disease. Therefore, after the introduction in chapter 1, chapter 2 
provides a literature review, which is an overview of vitamin D and atherosclerosis 
disease as reported in existing peer-reviewed journal articles on any link between 
vitamin D and atherosclerosis disease. After that, Chapter 3 clarifies the study aims 
and objectives. 
Chapters 4 to 7 provide methods, results, and discussions of each section of the 
studies. Briefly, chapter 4 analyses and discusses quantification of the vitamin D 
status from circulating 25(OH)D levels, vitamin D supplements, dietary intake, and 
sun exposure. Chapter 5 analyses and discusses how lifestyle factors (i.e. gender, age, 
education level, occupation, socioeconomic status, smoking, body mass index (BMI) 
and waist-to-hip ratio (WHR)) affect circulating 25(OH)D levels. Chapter 6 analyses 
and discusses the relationships between circulating 25(OH)D concentrations and 
other blood markers of health (including C-reactive protein (CRP) , fasting blood 
glucose (FBG), total cholesterol (TC), high-density lipoprotein (HDL), low-density 
lipoprotein (LDL), and triglycerides (TG) as indicators of the markers discussed 
above). Chapter 7 analyses and discusses the association between circulating 
25(OH)D levels and vascular structural and functional characteristics (i.e. carotid-
radial pulse wave velocity (PWV), central blood pressure (cBP), peripheral blood 
pressure (pBP) carotid intima-media thickness (IMT), carotid artery inter-adventitial 
diameter (IAD)). Finally, chapter 8 provides a general discussion of the whole PhD 
study, the study limitations and recommendations for future work. 
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Chapter 2 - Literature review 
2.1. Vitamin D  
2.1.1. Introduction 
In recent years, vitamin D deficiency or insufficiency has been shown to be a common 
international problem (Holick, 2017). Humans and other mammals mainly produce 
the ‘sunshine vitamin’ (vitamin D) when exposed to ultraviolet B (UVB) radiation, 
which is provided by sunlight (Lehmann and Meurer, 2010; Lips, 2010). Vitamin D is 
a hormone produced by sterols in the body, through the photolytic action of 
ultraviolet light in the skin (Holick, 1995; Combs, 2012). However, many factors 
diminish that process, such as the seasons, latitude, skin pigmentation, aging, 
sunscreen use, total body coverage, obesity, and smoking (Valle et al., 2011). 
Furthermore, small amounts of vitamin D are present in certain food: oily fish, liver, 
egg yolk and portobello mushrooms (Ross et al., 2011). Nevertheless, typically, 
dietary vitamin D represents 10 to 20 % of the circulating level of vitamin D (Dalan et 
al., 2014). However, this could be increased by eating fortified food or taking 
supplements (Combs, 2012). Apart from the well-known role of vitamin D in calcium 
homeostasis and bone metabolism, recent studies have suggested a diverse range of 
biological actions for the various forms of vitamin D, such as in cell growth and 
differentiation, the immune system, and hormonal system (Giovannucci, 2009; 
Adamczak, 2017; Bostock et al., 2017). However, those actions and roles are under 
investigation and studies are needed to confirm or deny their effectiveness 
(Lertratanakul et al., 2014; Faridi et al., 2017; Holick, 2017).   
2.1.2. Vitamin D metabolism  
Vitamin D is an essential fat-soluble vitamin. The most important forms of the vitamin 
in humans are, Ergocalciferol (D2) and Cholecalciferol (D3) (Lehmann and Meurer, 
2010). The human body can convert 7-dehydrocholesterol present in the skin to pre-
vitamin D3 when exposed to UV radiation (280-320 nanometres (nm)); this 
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compound can then be converted into vitamin D3 (Valle et al., 2011). Other sources 
of vitamin D include foods that contain or are fortified with vitamin D. Vitamin D2 is 
produced from ergosterol by yeast when it is exposed to ultraviolet radiation (Combs, 
2012). Vitamin D2 is manufactured by the food industry from lanolin, via exposure to 
ultraviolet radiation (Holick, 2009). Both vitamin D2 and D3 are commercially available 
as supplements. In addition, both types of vitamin D can be stored in and released 
from fat cells (Holick, 2007). 
In the liver, vitamin D is converted to calcidiol [25-hydroxycholecalciferol, 25-hydroxy 
vitamin D, 25(OH)D], which is the major circulating form of vitamin D (Lehmann and 
Meurer, 2010). During circulation in the blood, vitamin D binds to vitamin D binding 
protein (VDBP) for transport to the targeted cells (Adriana et al., 2005). 25(OH)D is a 
biologically inactive form of the vitamin thus it must be transported to the kidneys 
and converted to calcitriol (1,25-dihydoroxyvitamin D) by 25-hydroxyvitamin D-1α–
hydroxylase (CYP27B1) (Holick, 2009). Calcitriol [1,25-(OH)2 D] is the most active form 
of vitamin D in the body,  however, it has a half-life of 2 to 3 weeks compared to 4 to 
6 weeks for 25(OH)D (Combs, 2012). Once the active form of vitamin D has reached 
the desired cell, it is released from its binding protein and attaches to the vitamin D 
receptor (VDR) which is available in most of the body tissues and on most cells (Holick 
and Chen, 2008; Quraishi and Camargo, 2012) (figure 2-1).  
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Figure 2-1 Vitamin D metabolism in the body (Obi et al., 2015) 
2.1.3. Factors that influence circulating and bound levels of vitamin D 
Vitamin D levels are affected by a variety of factors for instance, distance from the 
equator, skin tone, and some diseases (Holick et al., 2011). The UV levels are lower 
at higher latitudes (above 35°) because of the filtering of sunlight by the atmospheric 
thereby influencing the body’s ability to synthesise vitamin D (Binkley et al., 2007; 
Holick, 2007 Mithal et al., 2009). It has also been demonstrated that cloth, window 
glass, and the use of sunscreen all prevent the absorption of this radiation by more 
than 95% (Holick et al., 2011; Aljefree et al., 2017a). Moreover, people with dark tone 
skin have some natural sun protection and require more time, three to five times 
longer, than people with light coloured skin when exposing their skin to the sunlight 
for effective vitamin D levels to be reached (Holick et al., 2011; Combs, 2012; Al-
Daghri et al., 2016). Ageing also magnifies the reduction of 7-dehydrocholesterol in 
the skin and thereby further decreases the ability to produce and metabolise vitamin 
D in the body (Arain et al., 2015). In addition, obesity decreases the bioavailability of 
vitamin D, as the vitamin is sequestered in fat cells (Ardawi et al., 2012). Patients with 
fat malabsorption syndromes, bariatric patients, and those with nephrotic syndrome 
are often unable to absorb vitamin D (Holick et al., 2011). Some medications also 
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reduce or prevent the absorption or the ability to metabolise vitamin D such as 
anticonvulsants and HIV medications (Lehmann and Meurer, 2010). Some diseases 
also reduce the body’s ability to absorb or produce vitamin D, i.e. liver or kidney 
diseases (as hepatic or renal disease), metabolic bone disease (e.g. osteoporosis), 
cancer, or hypercortisolism (Holick and Chen, 2008; Holick et al., 2011; van Schoor 
and Lips, 2011). 
In Saudi Arabia, there are additional factors that influence circulating levels of 
vitamin D, as a direct result of the climate and lifestyle. Saudis usually avoid spending 
time outdoors to shelter from the scorching sun, which is imperative as temperatures 
rise up to above 48°C during the summer in most of the regions, particularly in the 
centre, west, and south of the country (Sadat-Ali et al., 2014; Al-Daghri et al., 2016). 
Indeed, sunstroke is a common illness in Saudi Arabia for those who fail to avoid the 
sun (Ministry of Health, 2017). On the other hand, skin cancer is not a common illness 
in Saudi Arabia when compared to other countries at the same latitude (Al-Daghri et 
al., 2016; Al-Dawsari and Amra, 2016). It is the ninth most common malignancy and 
represents approximately 3.2% of all newly diagnosed cases of cancer in Saudi Arabia 
(Al-Dawsari and Amra, 2016). Outdoor clothing style is another factor that limits sun 
exposure. Men usually wear a Thoup, which appears as a dress with long sleeves 
(usually white), as well as a Shomak on their head, which is a triangular piece of cloth 
and functions as protection from the excessive sun (Al‐Agha et al., 2016; Aljefree et 
al., 2017b). Contrastingly, women mostly wear dark veils that cover their entire 
bodies. They also wear a scarf to cover their head; in addition, some women use a 
Niqab that covers their face, for cultural and religious reasons (Ardawi et al., 2012; 
Sadat-Ali et al., 2014). 
2.1.4. Measurement of vitamin D 
Determination of serum 25(OH)D levels is considered to provide an accurate and 
reliable reflection of vitamin D status other than the 1,25(OH)2D (Ford, 2013; Holick, 
2017). Serum 25(OH)D reflects both oral intake and subcutaneous vitamin D 
production. Currently, three different methods of measuring 25(OH)D have been 
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defined: liquid chromatography in tandem with mass spectrometry (LC-MS), 
radioimmunoassay (RIA), and a competitive protein binding assay (CPBA) (Holick, 
2009; Sadat-Ali et al., 2014). In general, LC-MS is considered the gold standard, even 
though it is a very complex technique (Ford, 2013). Whilst, the RIA is a fast and robust 
measurement, it can be affected by the presence of other substances which 
contribute 10-15 % of the 25(OH)D status (Holick, 2009; Alyami et al., 2014). The 
CPBA technique is a reliable technique for measuring 25(OH)D in serum or plasma 
(van den Ouweland et al., 2013). The assay uses vitamin D binding protein (VDBP) as 
a capture protein.  In fact, the CPBA has a 93% concordance rate when compared to 
the gold standard and has 100% cross-reactivity with 25(OH)D  (Lensmeyer et al., 
2006; Reis et al., 2009; Abdel-Wareth et al., 2013). 
A consensus has not been reached at the present time as to what should be 
considered to be a deficiency of vitamin D (Ford, 2013). The current study considering 
guidelines from the Saudi Ministry of Health and findings from pioneer studies in 
classing serum concentrations as follows; 25(OH)D < 20 nanogram per millilitre 
(ng/mL) considered deficient, 20 ≤ 30 ng/mL is insufficient, and > 30 ng/mL is 
adequate vitamin D serum levels (Alyami et al., 2014; Dalan et al., 2014; Sadat-Ali et 
al., 2014; Panel., 2014; Al-Daghri et al., 2016). 
2.1.5. Vitamin D status worldwide 
Hypovitaminosis D (vitamin D deficiency) occurs in 30 to 50 % of people, even in 
places where there is adequate sunshine all year round (Menezes et al., 2014). 
Vitamin D deficiency remains prevalent in Middle-Eastern countries and South Asia 
mainly due to clothing styles, skin tone and lack of outdoor activities (mean 25(OH)D 
in males 17.6 ng/mL and 11.2 ng/mL in females) (Okano, 2003; Mithal et al., 2009). 
Similarly, in Africa low serum 25(OH)D is a common issue, which is probably caused 
by dark skin colour and a tradition of fully-covered clothing in some parts of the 
continent (mean 25(OH)D in males 20.5 ng/mL and 12.5 ng/mL in females) (Lips, 
2010). Conversely, in Europe, people in Nordic countries show a higher vitamin D 
status than those in the Mediterranean countries, which is arguably due to the lighter 
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skin colour and the high consumption of cod liver oil. However, in winter months, 
25(OH)D concentrations decrease by up to 15ng/ml below summer month levels (van 
Schoor and Lips, 2011). Furthermore, the United States and Canada generally have 
populations with sufficient 25(OH)D concentrations (mean = 26.4 ng/mL) probably as 
a result of milk supplementation with vitamin D and the common use of supplements 
(Arain et al., 2015). Similarly, populations in Latin America have levels comparable to 
those in North America due to the habit of doing lots of outdoor activities and 
extensive exposure to sunlight (mean 25(OH)D 27.2 ng/mL) (van Schoor and Lips, 
2011).  In contrast, vitamin D deficiency is prevalent in Australia and New Zealand 
(mean 25(OH)D = 16.7 ng/mL) (Mithal et al., 2009). 
2.1.6. Vitamin D status in Saudi Arabia 
Saudi Arabia has ample sunlight for adequate vitamin D production, and yet there is 
a high prevalence of vitamin D deficiency across all age groups (mean 25(OH)D = 12.7 
ng/mL in males and 6.3 ng/mL in females) (van Schoor and Lips, 2011). Saudi Arabia 
is located in the South West of Asia between latitude (between 16° N and 33° N) 
(figure 2-2). During the summer months, the temperature can rise to 48°C, and it is 
mostly sunny all year round (AccuWeather, 2015). However, the extreme high 
temperature, lifestyle and other factors decrease the advantages gained from an 
abundance of sunshine. Many studies have examined the vitamin D status and 
confirmed the prevalence of vitamin D deficiency in the Saudi population (Ardawi et 
al., 2012; Aljefree et al., 2016; Kaddam et al., 2017). Table 2-1 shows studies 
measuring 25(OH)D status in different regions of Saudi Arabia. 
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Figure 2-2 Map of Saudi Arabia showing the geographical location of the country on the world map 
(inset)  and its regions and main cities. 
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Table 2-1 Studies determining vitamin D status in Saudi Arabia 
Study Subjects Sample size 
Vitamin D 
deficient* 
Vitamin D** 
sufficient 
(Kaddam et 
al., 2017) 
Saudi school students 
(50.4% males, 49.6% 
females) aged 6-19 and 
Saudi school employees 
(50.9% males, 49.1% 
females) aged 20-62  
In Central, Western and 
Eastern regions- different 
cities 
4000 
students and  
2075 
employees 
95.4% 
students 
 
89.1% 
employees 
4.6% *** 
students 
 
10.9%*** 
employees 
(Aljefree et 
al., 2016) 
Coronary heart disease 
patients and control adults 
In Western region- Jeddah 
city 
325 57.5 % 42.5 %*** 
(Abulkhair et 
al., 2016) 
Newly diagnosed breast 
cancer patients aged 42-57 
In Central region- Riyadh 
city  
406  71 % 29 % *** 
(Al-Saleh et 
al., 2015) 
School children aged 15.1 ± 
2.2 
In Central region- Riyadh 
city 
1188 boys  
1038 girls 
79 % boys 
92.5 % girls 
17.2 % boys 
4.7 % girls 
(Ardawi et al., 
2012) 
Men aged 20-74 
In Western region – Jeddah 
city 
834 51.5 % 38.8 % 
(Azhar, 2009) 
Women aged 20-60 
(pregnant and non-
pregnant) 
In Western region- Makkah 
city 
118 78.9 % 17.8 % 
(Siddiqui and 
Kamfar, 2007) 
Girls aged 12-15 
In Western region- Jeddah 
city 
433 40 % 41 % 
(Al Faraj and 
Al Mutairi, 
2003) 
People with chronic low 
back pain aged 15-52 
In Central region- Riyadh 
city 
360 (90% 
women, 10% 
men) 
83% 12% 
(Serenius et 
al., 1984) 
Pregnant women 
In Central region- Riyadh 
city 
119 
25.2% < 
4ng/mL 
and  
36.1% > 4 - 
25 ng/mL 
38.7% ≥ 25 
ng/mL 
 *Deficient at 25(OH)D < 20 ng/mL 
 **Sufficient at  20≤ 25(OH)D > 30 ng/mL 
 *** 25(OH)D > 20 ng/mL 
 1 ng/mL (nanogram per millilitre) = 2.496 nmol/L (nanomole per litre) 
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2.1.7. Guidelines for vitamin D in Saudi Arabia 
In response to the local need to investigate and address the challenge of vitamin D 
deficiency, the local authority developed guidelines targeting Saudi dwellers, 
clinicians, and policy makers. The two main guidelines were the osteoporosis clinical 
practice guidelines on the role of vitamin D, calcium, and exercise in fracture 
prevention in the elderly, which is run by the Saudi Centre for Evidence Based Health 
Care (SCEBHC), Ministry of Health (Saudi Expert Panel., 2014). The second guideline 
is the Prince Mutaib Chair for Biomarkers of Osteoporosis (PMCO), in King Saud 
University, Riyadh, KSA. Local pioneers and international experts worked together to 
generate the guidelines for vitamin D based on the local circumstances not just in 
Saudi Arabia but also throughout the Middle-East (Al-Daghri et al., 2016). Both 
guidelines proved that total 25(OH)D is the gold standard biomarker for vitamin D 
status as has been proved internationally (Holick et al., 2011). The cut-offs points of 
25(OH)D levels are the same as those used in the current study section 2.1.4.  Table 
2-2 illustrates the PMCO list of people at high risk of vitamin D deficiency and those 
who are eligible for screening, which is also similar to the guidelines used 
internationally (Ross et al., 2011; Holick, 2017). 
Table 2-2 The PMCO list of people at a high risk of vitamin D deficiency in Saudi Arabia (Al-Daghri et 
al., 2016)  
 Pregnant and lactating mothers 
 Infants and children 
 Obese or morbidly obese persons 
 People with dark skin tone 
 Elderly individuals 
 People with low sun exposure habits  
Clinical conditions: 
 Patients with malabsorption syndromes 
 Patients diagnosed or suspected with, osteopenia, osteoporosis, ostemalacia, or 
rickets 
 Patients with renal or liver disease 
 Patients with musculoskeletal disease  
 Post bariatric surgery patients 
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Based on the weather in Saudi Arabia, just recently the PMCO generated specific 
recommendations for sun exposure to obtain sufficient amounts of vitamin D and to 
prevent other complications from excessive sun exposure such as sunstroke and skin 
cancer.  The sun exposure recommendations are as follows: 
- During summer, sun exposure should be three to four times a week from 9:00 
to 10:30 am in the morning and from 2:00 to 3:00 pm in the afternoon.  
- During winter, the times should be from 10:00 am to 2:00 pm.  
- At least 20% of the body should be directly exposed to sunlight, especially the 
hands and legs. Direct exposure means without sunscreen and not through 
glass, windows, or an umbrella.  
- People with darker skin tone may need more time for adequate sunlight 
exposure (Saudi Expert Panel., 2014; Al-Daghri et al., 2016).  
The Saudi Ministry of Health recommends a dietary intake of vitamin D for adults up 
to 70 years old for males and females of 600 IU/day (Saudi Expert Panel., 2014;  
Ministry of Health, 2017). In regard to the use of supplements, the PMCO and SCEBHC 
have provided specific guidelines for Saudi dwellers.  People at high risk of vitamin D 
deficiency are advised to take a maintenance dose of vitamin D supplements (table 
2-3). The PMCO established guidelines for treatment doses and the length of the 
treatment for people in different age groups and with different health conditions. In 
addition, vitamin D supplementation is advised for people who have serum 25(OH)D 
levels <20 ng/mL until they reach a sufficient level of 30 ng/mL, and may need a 
maintenance dose afterwards (Saudi Expert Panel., 2014; Al-Daghri et al., 2016).   
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Table 2-3 The PMCO recommendation for vitamin D supplements maintenance dose (Al-Daghri et al., 
2016) 
People recommended to take vitamin D 
supplements 
Recommended maintenance dose 
IU/day 
Premature infants 400-800 
Infants 0-6 months 400 
Infants 6-12 months 400-600 
Children aged 1-10 years 600-1000 
Adolescents aged 11-17 years 600-1000 
Obese children* 1200-2000 
Pregnant/ lactating women 1000-2000 
Elderly patients 1000-2000 
Postmenopausal women 800-1000 
Obese postmenopausal women* 3000-6000 
* Patients who are obese, have morbid obesity, malabsorption syndromes, hepatic, renal 
diseases, or have had post bariatric surgery. 
  
36 
 
2.2. Atherosclerosis 
Atherosclerosis (arteriosclerotic vascular disease) is the most common type of heart 
disease, which makes it the most common cause of death worldwide (Joseph, 2011; 
Lertratanakul et al., 2014). It is a condition that thickens the artery wall due to the 
accumulation of white blood cells and fatty substances (fatty sticks) (Libby, 2006) 
(figure 2-3). Intima and media are the main layers in the human arterial wall. The 
inner side of the wall is the intima; it contains a layer of cells called the endothelium 
and then the internal elastic lamina (George and Johnson, 2010; Adams et al., 2017). 
Between the internal elastic lamina and the external elastic lamina is the media layer 
(Joseph, 2011). The media consist of vascular smooth muscle cells (VSMCs) 
surrounded by the basement membrane (figure 2-3) (George and Johnson, 2010). 
Dysfunction of the endothelial cells causes the formation of plaques or atheroma 
(British Heart Foundation , 2017). Plaques form slowly and consist of: multiple cell 
types, cholesterol, triglycerides, calcium, proteoglycans, and extensive connective 
tissue (Anderson et al., 2012). Consequently, the plaque formation hardens and 
narrows the arteries, which restricts blood flow in the circulatory system (Menezes 
et al., 2014). Moreover, if the plaque ruptures, it will cause a blood clot that can block 
the artery. Depending on the location of the clot in the arterial tree, the organ that 
is supplied by the artery will be damaged. 
Over time, atherosclerosis will lead to one or more of the following conditions: 
- Angina: which is a discomfort or pain in the chest area and that is due to a 
low level of blood and oxygen going to the heart muscle. 
- Heart attack: a condition when the plaque or the blood clot completely blocks 
the artery that supplies the heart.  
- Ischaemic stroke: a state when the block occurs in the arteries supplying the 
brain. 
- Peripheral arterial disease (PAD): a situation which occurs when not enough 
blood reaches the leg muscles (Giovannucci, 2009; BHF, 2017). 
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Figure 2-3 Illustration of a normal artery and one damaged by atherosclerosis (UNIVERSITY OF 
ROCHESTER MEDICAL CENTER, 2018)  
2.2.1. Atherosclerosis risk factors  
Many risk factors can increase an individual’s chances of developing atherosclerosis. 
The unmodifiable risk factors are stated as: advanced age, maleness, and inheritance 
of premature atherosclerotic disease (Beckman et al., 2002) whereas, modifiable risk 
factors are: hypercholesterolemia, hypertension, hyperglycaemia, smoking, and 
obesity (Anderson et al., 2012). Lifestyle can modulate the development and the 
progression of atherosclerosis, including physical inactivity, smoking, poor diet, and 
stress (Doran et al., 2008). 
2.2.2. Assessment of atherosclerosis 
Atherosclerosis is initially an asymptomatic condition until patients show signs of 
angina or any of the other complications of the disease. Otherwise, usually, it can be 
indicated by the presence of risk factors such as hyperglycaemia and hypertension 
and/or inflammatory markers, such as hyperlipidaemia and high C-reactive protein 
(CRP) concentrations, that are associated with the disease (Sibley et al., 2014). 
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Further assessment tests such as: electrocardiogram (ECG), computerised 
tomography (CT) scan, exercise stress tests, and ultrasound as non-invasive 
techniques could be used when patients have signs of atherosclerosis (Libby, 2006). 
Other examples of invasive tests that are used for assessment and treatment of 
atherosclerosis are digital subtraction angiography (DSA) and coronary artery bypass 
grafting (CABG) (Kim et al., 2008). 
Using the above assessment methods, the arteries’ function, resistance, and stiffness 
can be examined. The measurement of the carotid artery is considered the most 
commonly assessed artery for atherosclerosis especially in non-invasive methods 
(Polak et al., 2013; Adams et al., 2017). The artery can be tested for intima media 
thickness (IMT), Inter-adventitial Diameter (IAD), resistive index (RI), and blood flow 
integral (BFI) (Adams et al., 2017; Awad and Abbas, 2017). Other methods can be 
used to measure the resistance or the blood flow of the arteries using the flow speed 
between two arteries such as the carotid-femoral, brachial-ankle, or carotid-radical 
(Libby, 2006). Additional methods can measure blood flow, vessel diameter or artery 
stiffness such as coronary microvascular vasoreactivity, flow-mediated dilation 
(FMD), or pulse wave velocity (PWV) (Kim et al., 2008). PWV is emerging as the gold 
standard for the measurement of arterial stiffness (Collaboration, 2010; Pereira et 
al., 2014). 
2.2.3. Endothelium 
The endothelium is a thin layer of simple cells that line the inner walls of the vessels 
and provide critical homeostatic functions in the cardiovascular system (Giovannucci, 
2009). Endothelial cells are exposed to a variety of blood-borne signals and 
intravascular stressors, which regulate vascular tone, nutrient delivery, platelet 
activity, leukocyte adhesion, and angiogenesis (Libby, 2006; Arrebola-Moreno et al., 
2012). Moreover, the endothelium synthesises important substances, including 
antiproliferative, antithrombotic molecules, nitric oxide (NO) and prostacyclin 
(Joseph, 2011). Specifically, the limitation of NO secretion is the key manifestation of 
endothelial dysfunction, which promotes atherosclerosis (Widlansky et al., 2003).  
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2.2.3.1. Nitric oxide (NO) 
Nitric Oxide is a simple molecule that consists of a single oxygen atom bonded to one 
nitrogen atom (Ignarro, 2009). It has been proven that NO has many essential roles 
in the human body such as being a mediator in cell-to-cell communication (Napoli 
and Ignarro, 2001). In addition to its influence in the vascular system, it has an impact 
on the immune system, enzyme synthesis, autoimmune diabetes, and liver 
inflammation and infection (Ignarro, 2009). 
Nitric oxide is a very important substance in the cardiovascular system. It controls 
vascular relaxation by potently dilating vessels (Bryan et al., 2008). It also prevents 
platelet aggregation, monocyte adhesion to endothelial cells, and abnormal smooth 
muscle cell proliferation (Anderson et al., 2012). The human body can produce NO 
by converting nitrates found in plants, such as beets, spinach, and leafy green 
vegetables (Hord et al., 2009). When these forms of food are chewed and mixed with 
saliva, commensal bacteria convert nitrates into nitrites (Lancaster, 1996). 
Subsequently, in the stomach, gastric juices convert nitrites to NO (Hord et al., 2009), 
which is then absorbed into the bloodstream (Bryan et al., 2008). However, as the 
human body ages, this process becomes less effective, which is one of the reasons 
endothelial dysfunction develops with age (Ignarro, 2009). 
2.2.3.2. Endothelial dysfunction 
Endothelial dysfunction is an early event in atherosclerosis, which is involved in 
plaque progression and the recurrence of atherosclerotic complications (Hadi et al., 
2005). The inadequacy of NO bioavailability is the main indicator of endothelial 
dysfunction, in addition to vasodilators and an increase of endothelium contracting 
factors (Jablonski et al., 2011). Endothelial nitric oxide synthase (eNOS) is an 
endogenous inhibitor that contributes to the development of diabetes mellitus, 
hypertension, renal failure, and other diseases (Joseph, 2011). In addition to 
endothelium vasodilation weakness, endothelial dysfunction also involves 
endothelial activation, which influences all stages of atherosclerosis (Anderson, 
1999). In fact, all of the modifiable and unmodifiable atherosclerosis risk factors are 
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associated with variations in endothelial function (Hadi et al., 2005). Recent studies 
have also associated endothelial dysfunction with elevated C-RP, chronic systemic 
infection, air pollution, and vitamin D deficiency (Alyami et al., 2014; Joseph, 2011; 
Yiu et al., 2011). 
2.3. The role of vitamin D in atherosclerosis 
Over the previous decades, vitamin D has been shown to have preventive and 
disruptive effects against the development of atherosclerosis (Giovannucci, 2009; 
Menezes et al., 2014). Vitamin D has a vascular-protective effect by regulating 
vascular smooth muscle cells (VSMC) against endothelial dysfunction, and by 
managing the inflammatory and immune processes (Doran et al., 2008; Lertratanakul 
et al., 2014; Menezes et al., 2014; Faridi et al., 2017). 
Endothelial cells are found to express the vitamin D receptor (VDR), which has a 
protective effect on the incidence and progression of endothelial dysfunction 
(Menezes et al., 2014). The endothelial cells host 1-α hydroxylase, which converts 
25(OH)D to 1,25(OH)2D, the biologically active form of the vitamin (de Boer et al., 
2009). Moreover, calcitriol is the transcriptional regulator of NO synthase, which is 
the critical vasodilator (Menezes et al., 2014). Consequently, vitamin D deficiency is 
associated with a lack of NO synthesis, which causes endothelial dysfunction (Yiu et 
al., 2011). Similarly, vitamin D has an effect on the phosphatidylinositol 3 kinase 
enzyme in endothelial cells, as the enzyme is also responsible for the synthesis of NO 
(Alyami et al., 2014). It was observed by Aoshima et al. (2012) that, interactions 
between vitamin D and the VDR cause phosphorylation, which leads to eNOS 
activation and an increase in NO formation. Nitric oxide can prevent early 
atherosclerosis development by inhibiting platelets and leukocytes from aggregation 
and adhesion (Jablonski et al., 2011).  
Vitamin D has a role in protecting endothelial cells from oxidative stress, as it can 
oppose superoxide anion generation, which restrains reactive species and 
counteracts apoptosis (Wong et al., 2008). Menezes et al. (2014) has suggested a 
mechanism of 25(OH)D that influences muscular-vascular tone through an influx of 
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calcium into the endothelial cells that causes activation of calcium-dependent 
phospholipids. Furthermore, vitamin D has anti-proliferative effects on VSMC, which 
is a layer of cells in the vascular wall (Jablonski et al., 2011). VSMC produce molecules 
called the ‘extracellular matrix’, which modifies the lipid content and the formation 
of plaques in the vascular wall (Doran et al., 2008). In addition, VSMC contributes 
several inflammatory molecules that help to limit the development of atherosclerosis 
(Doran et al., 2008). The vitamin D response elements interact with gene promoter 
regions, which are genetic sequences related to arterial wall functions such as 
vascular endothelial growth factors, myosin, and type 1 collagen (Nibbelink et al., 
2007).  
2.3.1. Studies on the effects of vitamin D on atherosclerosis and the 
endothelium 
Many studies have investigated the association between vitamin D status and CVD, 
atherosclerosis, and endothelial function (Jablonski et al., 2011; Alyami et al., 2014; 
Aljefree et al., 2017b). Jablonski et al. (2011) observed a significant correlation  
between endothelial function and serum consentration of 25(OH)D in middle aged 
and older adults (50-79 years). Results showed that FMD was lower (P<0.01) when 
the 25(OH)D level < 20 ng/mL versus 25(OH)D level > 20 ng/mL. Additionally, the VDR 
and 1-α hydroxylase were associated positively with FMD (P<0.05). Tarcin et al. 
(2009) also found a positive correlation between 25(OH)D levels and FMD (r=0.45; 
P<0.05) when the participants presented as deficient (25(OH)D concentration < 25 
ng/mL), and after treatment with vitamin D3 supplements.  
Another study monitored participants over 4-5 years, and indicated a significant 
correlation between the development of CVD and low vitamin D (25(OH)D ≤ 15 
ng/mL) P<0.001 (Wong et al., 2008). Kilkkinen et al. (2009) examined the impact of 
vitamin D concentration on the development of, and mortality from, CVD in healthy 
persons over a period of 25 years. The study found that, based on their 25(OH)D 
serum levels, individuals within the upper 20% (20 ng/mL) had less than half the risk 
of death from CVD compared to those with serum levels of 25(OH)D  in the bottom 
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20%. In addition, a large-scale study observed the association between vitamin D 
levels and hypertension, which is one of the atherosclerosis risk factors. This study 
followed 613 men and 1198 women for 12 ± 3 years.  The results indicated an inverse 
association between the risk of hypertension and 25(OH)D concentration (P<0.001) 
(Forman et al., 2007). A study in Scotland (Sugden et al.2008) investigated the impact 
of vitamin D levels on endothelial function in patients with type 2 diabetes. The 
diabetic patients with 25(OH)D serum levels < 20 ng/mL consumed a single dose of 
100 000 IU vitamin D2 and their endothelial function was re-examined after 8 months. 
The supplements significantly improved the participants FMD status by 2.3% 
(P<0.05). Table 2-4 illustrates additional studies that show the impact of vitamin D 
on atherosclerosis and atherosclerosis risk factors.
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Table 2-4 List of previous studies on vitamin D and atherosclerosis and atherosclerosis risk factors 
Study Subjects 
Sample 
size and 
age 
Location Study design 
Main 
measurements 
Results 
(de Boer et 
al., 2009) 
53% of participants with a 
prevalent of CAC1 at 
baseline and the rest were 
healthy controls 
N=1370 
45-84 years 
United 
States of 
America 
Cohort study 
25(OH)D, 
1,52(OH)2D, 
CAC using CT scan 
21% of participants with CAC at baseline 
developed an incidence of CAC and had a 
lower 25(OH)D after 3 years’ follow up 
(Lertratanak
ul et al., 
2014) 
SLE2 Patients participating 
in inception cohort from 8 
countries. Patient follow-
up after 15 months of first 
diagnosis 
N=890 
Adults 
Canada, 
Iceland, 
Korea, 
Spain, 
Switzerland
,United 
Kingdom, 
and United 
States of 
America  
inception 
cohort study 
25(OH)D, 
SLE assessments, 
CVD3 risk factors 
and events 
Patients with lower 25(OH)D at baseline 
had higher incidence of CVD3 risk factors. 
Patients with higher 25(OH)D were less 
likely to have hypertension, 
hyperlipidaemia, CVD events and more 
likely to have lower CRP, systemic lupus 
erythematosus disease activity. 
(Targher et 
al., 2006) 
Type 2 diabetic adults and 
healthy control adults 
N= 780 
(390 
diabetic & 
390 
nondiabeti
c) 
Arzignano, 
Italy 
Randomised 
control trial 
IMT in CCA 
25(OH)D 
Diabetic patients had lower 25(OH)D 
concentrations than non-diabetics 
P<0.001. Diabetic patients with low 
25(OH)D had higher IMT when compared 
with sufficient 25(OH)D patients P<0.001. 
They also had higher CRP concentrations. 
(Faridi et al., 
2017) 
Participants in a high-risk 
community for 
atherosclerosis 
N= 13,039 
Baseline 
age 
57 ± 6 
United 
States of 
America 
Longitudinal 
community-
based study 
25(OH)D and lipid 
profiles were 
measured 3 
times, each time 
Deficient concentrations of 25(OH)D were 
associated with low TC and high HDL 
concentrations. 
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was ~ 3 years 
apart. 
(Reis et al., 
2009) 
Older adults without a 
history or incidence of 
CVD3 
N= 654 
55-96 years 
United 
States of 
America 
Cross-
sectional 
study 
25(OH)D, 
1,25(OH)2D, IMT, 
BP 
There was no association between 
1,25(OH)2D and IMT in total sample. 
In a subgroup of hypertensive there was 
an inverse association between 
1,25(OH)2D and IMT P=0.036 
(Zittermann 
et al., 2009) 
Healthy overweight 
participants with mean 
25(OH)D =12 ng/mL 
receiving vitamin D 
supplements or placebo 
N= 200 
18-70 years 
United 
States of 
America 
A double 
blind study 
25(OH)D, 
1,25(OH)2D, 
 
Significant improvement of vitamin D 
status in supplement group. 
A positive improvement in cardiovascular 
markers. 
(Aljefree et 
al., 2016) 
Participants were CHD4 and 
age-sex matched controls 
N=130 CHD 
& 195 
controls 
20-70 year 
Saudi 
Arabia 
Case-control 
study 
25(OH)D, 
FBG, lipids profile, 
46% of CHD and 3% of controls had 
25(OH)D <20 ng/mL (P=0.001) 
(Al Mheid et 
al., 2011) 
Participants free of any 
acute illness 
N=554 
20-79 years 
Australia  
Community-
based 
asymptomati
c population 
25(OH)D, FMD, 
PWV , RI, lipid 
profiles 
Vitamin D deficiency associated with 
arterial stiffness, endothelial dysfunction 
and CVD risk markers. 
25(OH)D associated with FMD (P=0.03), RI 
(P=<0.001), and PWV, (P=0.04). 
(Taskiran et 
al., 2017) 
Type 1 diabetic patients 
N-93  
20-45 years 
Turkey 
Observationa
l 
25(OH)D, HbA1c, 
IMT, Lipid profile 
78% had 25(OH)D < 20 ng/mL 
No association was observed between 
25(OH)D and IMT 
1- Coronary artery calcification (CAC) 
2- Systemic lupus erythematosus (SLE) 
3- Cardiovascular disease (CVD) 
4- Coronary heart disease (CHD) 
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2.4. Effect of vitamin D on atherosclerosis risk factors 
Studies have suggested a substantial role for vitamin D in modifying many of the 
atherosclerosis risk factors both modifiable and non-modifiable (Lertratanakul et al., 
2014; Menezes et al., 2014; Arora and Rehan, 2015).  
2.4.1. Effect of vitamin D on lipid profiles 
Many studies have demonstrated the impact of vitamin D deficiency in 
dyslipidaemia. Low concentrations of vitamin D have been associated with increasing 
the blood concentrations of TC, LDL, TG and decreasing the concentrations of HDL 
(Giovannucci, 2009; Faridi et al., 2017). Researchers suggest that vitamin D increases 
the absorption of intestinal calcium, which reduces the amount of lipids absorbed in 
the gut, which will reduce serum concentrations of LDL and TG (van den Ouweland 
et al., 2013; Faridi et al., 2017).  
A large cross-sectional, prospective study by Faridi et al., (2017) examined the impact 
of vitamin D on the lipid profiles of 13,039 participants. Measurements were taken 
at baseline and followed up  twice each visit was approximately 3 years apart. 
Vitamin D deficiency was associated with lower TC and higher HDL levels. Another 
double-blind randomised control study by Qadhi, (2016) investigated the impact of 
vitamin D supplements for a period of 16 weeks. The significant impact of the 
supplementations were shown in the changes in the serum LDL (P=0.001) and TC 
(P=0.028).   
2.4.2. Effect of vitamin D on glucose levels and insulin resistance  
There is some evidence correlating vitamin D concentration to the risk and 
development of diabetes (Lee et al., 2008; Witham et al., 2010; Taskiran et al., 2017). 
β-cells, which synthesise and secrete insulin, in the pancreas express the VDR and 
vitamin D activating enzyme, 1α–hydroxylase (Lee et al., 2008; Holick, 2017). Other 
studies have suggested a role for vitamin D in insulin production and glucose 
homeostasis (Talaei et al., 2013;Al-Daghri, 2016). 
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In a double-blind randomised controlled trial, 60 type 2 diabetes patients were given 
vitamin D fortified yogurt daily for 12 weeks. There was a positive, significant change 
in FBG (P=0.016) and in HBA1c (P=0.001) (Neyestani et al., 2012). Another study by 
Talaei et al., (2013) examined the use of vitamin D supplements in 100 type 2 diabetic 
patients for 2 months. The study found a positive impact of using the supplements 
on the participant’s serum insulin (P=0.02) and FBG (P=0.02). 
2.4.3. Effect of vitamin D on blood pressure 
The positive impact of vitamin D concentration on hypertension has been shown in 
many studies (Holick and Chen, 2008; Berry, 2012). Vitamin D deficiency is associated 
with high parathyroid hormone (PTH) concentrations and elevated blood pressure 
(Reis et al., 2009). Experts have suggested that one role of 1,25(OH)2D is to suppress 
renin enzyme expression and VSMC proliferation, which influences blood pressure 
(Forman et al., 2007; Aljefree et al., 2016). The influence of vitamin D on endothelial 
function is the primary controlling tool of blood pressure (Forman et al., 2007; 
Menezes et al., 2014).  
Two prospective cohort studies examined the risk and incidence of hypertension 
associated with the concentration of 25(OH)D over 4-8 years. The studies included 
613 males in the first one and 1198 females in the second one. The relative risk of 
the incidence of hypertension was 6.13 times greater in deficient males compared to 
participants with an adequate concentration of 25(OH)D. In the females study, the 
relative risk was 3.18 times greater (Forman et al., 2007). Another study investigated 
the impact of sun exposure three times a week for three months on patients with 
hypertension. Eventually, their 25(OH)D increased by 180% and both systolic and 
diastolic blood pressure became normal (Holick, 2007). 
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2.4.4. Effect of vitamin D on body weight 
Obesity is considered one of the major risk factors for cardiovascular disease. Many 
studies have found an association between the increase of CVD events in obese 
subjects and have suggested a role for vitamin D deficiency in an increased risk of 
being overweight or obese (Holick, 2007; Konradsen et al., 2008; Zittermann et al., 
2009). A study by Shirazi et al. (2013) indicated that women with an optimal 
concentration of vitamin D in their serum are less likely to be overweight or obese. 
One study calculated that for each 10% increase in BMI there would be a 4.2% 
decrease in vitamin D serum levels (Vimaleswaran et al., 2013).   
One of the explanations for the correlation between vitamin D levels and obesity is 
that vitamin D is a fat-soluble vitamin, adipose tissue, that contains VDR, sequesters 
the vitamin (Holick et al., 2011).  
2.4.5. Effect of vitamin D on aging 
Studies have suggested an association between aging and vitamin D deficiency (Lips, 
2010; Holick et al., 2011). When people reach 70 years of age, the reduction in 7-
dehydrocholesterol in the skin reduces the production of vitamin D by up to 75% 
(Holick, 2007). Furthermore, older adults are a high-risk group for falls and 
osteopathic fracture for many reasons one of which is muscle weakness. Researchers 
suggest that vitamin D deficiency causes muscle weakness (Al-Daghri et al., 2016).  
2.5. Summary  
Vitamin D deficiency is a common problem worldwide, including Saudi Arabia. This 
prevalence of vitamin D deficiency may be linked to wider biological effects. Some 
studies suggest an association between vitamin D deficiency and atherosclerosis. 
Some suggest a direct association and some observed an association with the 
disease’s risk factors. However, there is a gap in the research which this thesis 
attempts to address by identifying the relationships clearly and identifying the 
factors that might have an impact on them, specifically in Saudi Arabia. A better 
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understanding of this potential association is needed, starting from analysing all of 
the sources of the vitamin, and the factors affecting the status of the vitamin, to the 
biomarkers of atherosclerosis disease and its risk factors. A comprehensive diagnosis 
of the disease and its risk factors are needed through blood tests and non-invasive 
modern assessment devices. In order to study the relationship between the disease 
and the vitamin, three different groups, (sub-clinical) healthy, at risk and previously 
diagnosed, should be studied. Data collection models should be created specifically 
to fit the target group considering the climate, culture, and habits. Subjects should 
be free of additional interventions that could affect the study results. Regardless of 
whether an association is discovered, this observational investigation will provide a 
comprehensive dataset that will assist in understanding the relationship between 
vitamin D and atherosclerosis, especially in a country that has ample sunshine such 
as Saudi Arabia. 
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Chapter 3 - Thesis aims and objectives 
3.1. Hypothesis 
The research hypothesis is that an adequate concentration of vitamin D plays a role 
in preventing atherosclerosis and atherosclerosis risk factors in a population of 
middle age adults living in Saudi Arabia.  
3.2. Aims  
- To identify the vitamin D status in three Saudi Arabian populations: 1) a 
healthy population i.e. having no known disease; 2) a population of patients 
considered by independent clinicians to be at risk of developing 
atherosclerosis; 3) a population of patients with diagnosed atherosclerosis.  
- To establish if there are any relationships between the vitamin D status of the 
study groups and the potential development of, or known incidence of, 
atherosclerosis in a sample of Saudi Arabia dwellers. 
- To apply a cross-sectional examination of the impact of a background of 
vitamin D supplement usage on the atherosclerosis status of both healthy and 
clinical populations.  
3.3. Objectives 
- To collect questionnaire data on health, lifestyle factors, sun exposure, 
dietary intake and determine their association with circulating 25(OH)D. 
- To directly assess circulating 25(OH)D and other biochemical parameters in 
the three study groups of interest. 
- To determine if there is a relationship between circulating 25(OH)D levels and 
vascular structural and functional characteristics.  
- To study the association between vitamin D status and the 
development/incidence of atherosclerosis.  
- To examine the strength of associations between circulating 25(OH)D levels 
and quantitative and qualitative markers of cardiovascular health.  
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Chapter 4 - Quantification of the vitamin D status from 
circulating 25(OH)D concentration, vitamin D 
supplements, dietary intake, and sun exposure in a 
sample of Saudi Arabian volunteers  
51 
 
4.1. Introduction 
The gold standard to determine vitamin D status is the serum concentration of 
25(OH)D (Holick et al., 2011). The sources of vitamin D are confined to diet, exposure 
to sunlight, and the use of vitamin D supplements (Ford, 2013). The status of these 
sources and their measurements, in addition to the associations between them, will 
be investigated. The measurements were determined on the pooled study sample 
and in each of the sub-groups; (control group (CG), at-risk group (ARG), and 
participants diagnosed with atherosclerosis group (DAG)) which are called the clinical 
groups, and between the sexes. Analysis based on the clinical groups was an indicator 
of the association between the measurement and the participants’ clinical condition. 
Analysis between sexes determined if there is any gender variation in each of the 
measurements. This chapter will give an introductory overview of the data collection 
phase and the methods used during data collection. 
4.1.1 Chapter aim 
To identify circulating 25(OH)D concentrations and determine any association with 
diet, sun exposure and usage of vitamin D supplements in three populations: 1) a 
healthy population i.e. having no known disease; 2) a population of patients 
considered by independent clinicians to be at risk of developing atherosclerosis; 3) a 
population of patients with diagnosed atherosclerosis. 
4.1.2. Chapter objectives 
1- To determine circulating 25(OH)D concentrations in the pooled study sample 
and in each of the study sub-groups (clinical group, gender, and vitamin D 
supplementation group). 
2- To assess the dietary intake of vitamin D in the pooled sample and in the sub-
groups and to correlate that with circulating 25(OH)D concentrations. 
3- To investigate the exposure to sunlight in the pooled sample and in the sub-
groups and correlate that with circulating 25(OH)D concentrations. 
4- To compare the magnitude of the associations between vitamin D and 
modulators. 
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4.2. General methods 
4.2.1. Ethical approval 
Prior to initiating data collection for the current study, ethical approval was obtained 
from both the Faculty of Research Degrees Committee at Manchester Metropolitan 
University -HOLL151601- and from the Committee of Medical Ethics at Al-Noor 
Specialist Hospital in Saudi Arabia -019337- (Appendices 1 and 2). Both committees 
requested ethics forms to be filled in with details of the methods, equipment, and 
facilities that would be used for the study. Additionally, risk assessment forms for the 
blood sample collection, the use of ultrasound, and the pulse wave velocity device 
were provided.  Information sheets, consent forms, and a copy of the questionnaire 
were submitted for approval. All of the documents were submitted to both 
committees in two languages, namely Arabic and English. 
Ultimately, the study participant information sheet, study participant consent form, 
and questionnaire were translated into Arabic and then checked for accuracy to 
ensure no loss of meaning had occurred during translation, as Arabic is the native 
language used in Saudi Arabia. The final versions of the English and Arabic documents 
are presented in Appendices 3 to 8. All the study measurements and examination 
were performed using the same protocol and the same operator to ensure reliability.  
All the information obtained during this study (hard and soft copies) was kept 
confidential in a locked cabinet placed in a locked office that only the researcher had 
access to. Participants’ names were not associated with the data. All participants 
were assigned a code number instead of their names in the coded documents. Data 
were collected in accordance with the Data Protection Act (1998) guidelines. For the 
blood samples, the code numbers were written on the relevant sample collection 
tubes and the blood samples were kept in a separate secure refrigerator until data 
collection was completed. Storage of samples was in accordance with Saudi Ministry 
of Health guidelines, and in line with the Human Tissue Act and Manchester 
Metropolitan University guidelines. 
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4.2.2. Study design 
The study took place at Al-Noor specialist hospital in Makkah city, Saudi Arabia. 
Details of study participants’ identification and selection are given below. With 
ethical approvals in place, a total of 97 volunteers participated in the study. 
Participants were of both sexes (82 females, and 15 males) aged 35 to 60 years (48.2 
± 8.36) were recruited representing the three health condition being studied. A 
dedicated research room, with a suitable bed, adjacent to an ultrasound unit was 
used for the study. The research room was equipped with an electronic scale, blood 
pressure monitor, and a PC with access to the patient's medical files. The collected 
data included blood samples, anthropometric measurements, ultrasound 
measurements, central pulse wave velocity measurements, and lifestyle 
questionnaires.  
4.2.2.1. Inclusion and exclusion criteria 
The inclusion criterion for all participants was being an adult aged 35 to 60. The 
exclusion criteria for all of the participants were a medical condition that could affect 
vitamin D metabolism, including liver or kidney diseases (as hepatic or renal disease), 
metabolic bone disease (e.g. osteoporosis), cancer, or hypercortisolism. Participants 
were also excluded if they had undergone bypass surgery, were currently pregnant 
or breast-feeding. 
4.2.2.2. Participants and recruitment 
The participants were divided into three groups. The control group (CG) consisted of 
healthy participants [n=33], who had never been diagnosed with any systemic 
disease.  The second group was of patients at risk of developing atherosclerosis (ARG) 
[n=30], i.e. having at least one of the major risk factor diseases (hypertension, 
diabetes, and/or hyperlipidaemia). The third group was of patients with established, 
formally diagnosed atherosclerosis (DAG) [n=34].  
Candidates from all three groups were invited to participate in the study using one 
of three approaches. Most of the cardiovascular patients were invited to participate 
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during their routine visit to the cardiovascular clinic at the hospital, however, not all 
of the participants from this approach were in the DAG as some were in the other 
two groups. With ethical approval in place, the health files of the patients who had 
appointments at Al-Noor Hospital were checked and patients fitting the recruitment 
criteria were approached. Out of 370 outpatients’ files reviewed, 186 met the criteria 
and 38 agreed to participate (Figure 4-1). 
The second recruitment approach was through the local hospital staff and/or 
relatives who had attended the hospital with patients as companions. The subjects 
were asked to participate in the study if they met the inclusion criteria. Twenty 
participants were invited using this approach and 14 agreed to participate in the 
study (Figure 4-1). Participants form this approach were in either the CG or ARG.   
The third recruitment approach was through a text message sent to hospital patients, 
asking them to participate if they fitted the criteria (Appendix 9). Thereafter, if 
patients replied, a visit was arranged for them at the hospital. Out of 72 text 
messages sent, 45 participants replied and were included in the study (Figure 4 1). 
Most of the participants from this approach in the ARG and CG and some were in the 
DAG. 
 
Figure 4-1 Recruitment of the participants for the study data collection at Al-Noor Specialist Hospital 
Total number 
of participants 
recruited
Participated
Invited to 
participate
Files reviewed
n=370
text messages 
n=72
n=45
Outpatients 
n=186
n=38 n=97
Hospital staff 
n=20
n=14 
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4.2.2.2. Process during the participants’ visit  
During the visit, a scheduled process was followed to avoid any confusion or any 
steps being missed. The first step was to invite the participants to join the study. 
Volunteers were provided with details of the study, their personal details and clinical 
status were checked, and, if they conformed to the study inclusion requirements and 
agreed, they were invited to join the study. Participants were issued with an 
information sheet (pre-approved by the ethics board) to read and were asked to sign 
a consent form, if they were happy to take part in the study. If participants could not 
read or had difficulty reading the information sheet, the documents were read out-
loud and explained to them verbally. If a participant was struggling to read and had 
a companion (e.g. friend or family member) with them, the companion was asked to 
read the information sheet on the participant’s behalf and the consent form was then 
signed by the participant. 
Potential participants recruited using the second and third approaches were given 
temporary file numbers if they did not have one at the hospital. Blood sample 
requests, which were required for the study, were printed from the hospital database 
system and given to the participants to use when giving the blood sample. If the 
participant had already fasted for at least 10 hours, a blood sample was taken at the 
hospital laboratory. If they had not fasted, another appointment was arranged to 
collect blood samples. To maximise the number participants returning to the hospital 
from the previously non-fasted participant groups, volunteers were contacted, via 
either text message or a phone call depending on the participant’s preference, a day 
prior to their planned return visit as a further reminder. 
The first step before starting any of the measurements, the participants were 
informed as to what exactly would be done and what they might feel.  Furthermore, 
the participants were asked to inform the operator if they felt uncomfortable at any 
stage of the study. 
After the blood sample had been taken or arranged to be taken, the participants’ 
anthropometric measurements (height, mass, waist and hip circumference) were 
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taken and recorded in the testing room. The testing room was equipped with all of 
the equipment and devices needed for the data collection. All of the measurements 
were recorded concurrently in a notebook. Then, the measurements were re-
recorded in the participant’s questionnaire and the pulse wave analysis device 
(Complior software, v1.9.4, Vincennes, France). The participants were then offered 
sweet dates (individually wrapped) and orange juice (freshly squeezed) if they had 
given a blood sample. The participants were asked to remove any clothing or 
jewellery from their neck and wrists (testing points). After the anthropometric 
measurements were completed, the participants were asked to lie flat on the test 
bed and allowed to rest for 10 minutes. 
After the rest period, the following measurements were taken; blood pressure was 
measured and recorded; then the ultrasound measurements of the carotid artery 
were taken and recorded. Before applying the gel for the ultrasound, the participants 
were informed that the gel might be slightly cold. Clean tissues were positioned in 
order to protect the participants’ clothes. After completion of the test, the gel was 
carefully removed. Finally, the pulse wave velocity test was performed. The pulse 
wave velocity apparatus software recorded all of the measurements. Then, after the 
examination, the measurements were copied to an Excel spreadsheet. All of the 
measurements were repeated at least three times to ensure internal validity.  
During the appointment, the participants were asked to fill in a questionnaire. A 
participant’s companion or the operator could do this if the participant could not do 
this/preferred this support. When they reached the food frequency questionnaire 
(FFQ) section, plastic examples of the food items and cans were shown in different 
sizes and amounts of possible consumption to the participants to simplify 
identification of the amounts consumed (figure 4-2). 
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Figure 4-2 Plastic food samples that were used to help the participant determine the amount of food 
consumed 
Finally, at the end of the meeting, further explanation was provided about vitamin D 
benefits and sources. The participants were informed that the blood test results 
would be ready within 5 working days. The participants were asked if they wanted a 
copy of their blood test result, and how they wanted it to be sent to them. No medical 
information, based on the results obtained, was provided to the participants. 
However, participants were advised to contact their physician if they had any medical 
query about their results. Figure 4-3 illustrate a diagram of the process used during 
the participant’s visit. 
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Figure 4-3 The flow diagram of the participant’s visit plan  
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4.2.3. Questionnaire design 
A questionnaire was designed based on a review of the literature (McCarty, 2008; 
Holick et al., 2011; Hatfield et al., 2014).The questions were formulated based on 
numerous factors: the purpose of the question and, the target population in the 
target country -Saudi Arabia. Most of the questions were Closed-Ended questions in 
order to simplify answering, coding, and analysing. However, to avoid the restriction 
of the Closed-Ended questions there was an option as ‘other’ with an open space for 
aditional answers. The questionnaire was divided into six parts; personal 
information, sun exposure, health information, supplement and medications, FFQ, 
and anthropometric measurements (a copy of a blank questionnaire is shown in 
appendices 7-8) 
The personal information section was designed to allow for the collection of general 
information. This section included questions on age, gender, place of birth, the 
current city of residence, education level, and socioeconomic status (Section 5.2.). 
The second section, on sun exposure, was designed to investigate the participants’ 
sun exposure for the three months prior to this study. Questions were asked about 
the frequency and duration of exposure to direct sunlight, as well as the body part 
exposed to the sun and the usage of any sun protections (Section 4.3.4.). After that 
was the health information section, which covered questions on health status and 
lifestyle. The questions were about smoking, pregnancy and breastfeeding (for 
females only), and diseases that the participant had, if any (Section 5.2.). The health 
condition was categorised relative to the presence of heart disease, hypertension, 
diabetes (type I or type II), or no cardiovascular disease. The category of health 
condition was filled in by the participants and then reviewed from the participant’s 
hospital files, where available. The hospital guidelines for determining the prevalence 
and incidence of any disease followed “The International Classification of Diseases” 
guidelines (Hamburg et al., 2008; Saudi Expert Panel, 2014).  The next section was 
designed to cover detailed questions on the use of food supplements and 
medications (Sections 4.3.3. and 6.2.). The dietary intake of vitamin D section 
included the FFQ table of food items that contain vitamin D to determine the amount, 
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and frequency of consumption of vitamin D from the diet (Section 4.3.2.). The last 
part of the questionnaire was the anthropometric measurement (Section 5.2.7) and 
skin tone section (Section 4.5.3), which was filled in by the researcher. It included 
measurements of height, weight, waist and hip circumference, and a scale of skin 
tone. 
A pilot study was undertaken to examine the validity of a questionnaire before it was 
used in the current study (Appendix 10). The pilot study included N= 12 participants 
(6 males and 6 females) aged 49.9 ± 6.7, who were otherwise not included in the 
current study. Piloting the questionnaire ensured that the questions were clear and 
understandable for the participants, as they were initially intended from their design.  
4.2.4. Blood sample collection 
Fasting blood samples were taken from participants for biochemical assays, after the 
participants had read the information sheet and signed the consent form. Before 
taking the blood sample, the phlebotomist confirmed the participants’ name, date of 
birth, and how long they had been fasting. Participants had not to have had any food 
or drinks except for clear water for at least 10 hours prior to the test. The samples 
were drawn and handled by a trained phlebotomist in an equipped room in the 
hospital laboratory. Ten ml of blood were taken from each participant, divided into 
three aliquots, and sent to three different laboratory departments. A vacutainer plain 
tube was used for the 25(OH)D test in the hormone department; the second sample 
tube was to test for CRP in the immunology and pathology department. Additionally, 
a lithium heparin tube was used to collect blood for the analysis of lipids and fasting 
glucose. To each tube, a sticker was attached which stated the patient’s name, date 
of birth, ID, and request number. Each tube was kept in a plastic bag along with a 
copy of the request sheet and sent to the relevant department. The blood samples 
were either tested within two hours or stored at 2-8 °C and then tested within 7 days. 
Analysis methods were those routinely used by the hospital laboratories for all the 
blood tests. The results were reported on the hospital database system to which the 
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researcher was allowed access. An example of a blood test report is provided in 
Appendix 11.  
4.2.5. Vascular structural and functional characteristics 
Vascular structural and functional characteristics were determined using two 
devices. Measurements of plus wave velocity (PWV) and central pulse pressure (CPP) 
were determined using a non-invasive Complior device (V1.9.4, Alam Medical, 
Vincennes, France). Carotid artery assessment was performed using a colour Doppler 
ultrasound instrument (MyLab 70 ultrasound, Esaote, Genoa, Italy) that included 
carotid intima media thickness (IMT), and carotid artery inter-adventitial diameter 
(IAD). The measurements were used to assess the participants’ arterial stiffness to 
determine atherosclerosis status. Detailed methods are presented in chapter 7 of the 
current thesis. 
4.2.6. Data coding, reduction, and analysis 
All of the data were coded in a numerical form first in Excel 2013, then transferred 
to SPSS (IBM SPSS statistics 24, Inc., Chicago, IL, USA) electronically to minimise 
human error. There were two types of data: categorical and scale. Categorical data 
were coded by giving a number from 1 to the number of values in each tested 
variable. For instance, for gender there were 2 values, “1” for “male” and “2” for 
“female”. The second type of data was scale, thus ratio level data such as circulation 
25(OH)D values, which were recorded by the actual value of the vitamin for each 
participant e.g. “21.36” or “14.00”. Missing values were represented by a blank 
space. 
To eliminate errors that might have occurred during data collection and coding, the 
data were reviewed and checked continuously (i.e. each data entry was reviewed 
twice: once after coding and again after completion of all the data entry). After that, 
data screening was commenced once the coding had been completed. Each of the 
variables was screened for any outliers (outlier labelling role for interquartile range 
(IQR) of 3), missing data, or inconsistent entries. In each case of an error being found, 
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the entry was fixed by going back to the data source such as the questionnaire or the 
program where the data were first recorded. Outliers were easier to identify in the 
box and whiskers plot. SPSS defines an IQR of three by a * shape.  If the entry was 
correct, an individual discussion about the case was undertaken in the discussion 
section. For the sake of completeness, the data were also analysed after having 
removed any outliers and the effects of these are discussed. Confidence interval 
percentage (CI) were set at 95% for all of the data. Statistical significance was set at 
P ≤ 0.05. Table 4-1 illustrates the strength of the relationship for the R2 value.  
Table 4-1 R2 coefficient of correlation strength of the relationship (edited from (Leech et al., 2011))  
Value of R2 Strength of relationship 
-1.0 to -0.25 or 1.0 to 0.25 Strong 
-0.25 to -0.09 or 0.09 to 0.25 Moderate 
-0.09 to -0.1 or 0.1 to 0.09 Weak 
-0.01 to 0.01 None or very weak 
Multiple linear regressions (forced entry method, run until stability was reached) 
were applied to create a model to predict serum 25(OH)D based on the significant 
predictors identified in each chapter. Using the final multiple linear regression stable 
model an equation, was derived to predict 25(OH)D concentrations. The equation 
will be as follow: 
𝑌 = (𝐵𝑋1) + (𝐵𝑋2) + (𝐵𝑋3) + (𝐵𝑋4) + ⋯ . + 𝐶 (±𝑆𝐸𝐸) (Leech et al. , 2011) 
Y is the value of dependent variable (the predicted value of 25(OH)D); B 1,2,… are the 
values of the slope for X (the value of the un-standardised coefficients); X 1,2,… are 
the values of the significant independent variables (value of the predictors); C is the 
intercept (constant); SEE is the standard error of the estimate. The predicted vitamin 
D concentrations will be determined by substituting the values of B, X, C, and SEE in 
the equation based on the values of the predictors in the study.   
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4.3. Chapter Methods 
4.3.1. Measurement of serum 25(OH)D  
Determination of vitamin D concentrations was performed using the 
electrochemiluminescence binding assay on Elecsys 2010 (Cobas e E601 
immunoassay analysers, Indianapolis, IN, USA) (Roche, 2015a). It is a competitive 
electro-chemiluminescent protein-binding assay (CPBA). The CPBA technique is a 
reliable technique for measuring 25(OH)D in serum or plasma (van den Ouweland et 
al., 2013). The assay uses vitamin D binding protein (VDBP) as a capture protein that 
binds 25(OH)D3 and 25(OH)D2. The assay can measure total 25(OH)D in serum or 
plasma.  
The process of analysing 15µl of serum sample was completed using the following 
steps. First, the sample were incubated with pre-treatment reagents (4 mL of 
Dithiothreitol and 4mL of Sodium hydroxide) to release 25(OH) vitamin D from VDBP. 
Then, the pre-treated sample were incubated with ruthenium labelled VDBP that 
forms a complex between the 25(OH)D and the ruthenylated VDBP. After that, 
streptavidin-coated micro-particles and 25(OH)D labelled with biotin were both 
added to the mix. The free sites on the ruthenium labelled VDBP become occupied. 
A complex containing the ruthenium-labelled VDBP and the biotinylated 25(OH)D 
formed and bound to the solid phase via interaction of biotin and streptavidin. The 
reaction mixture was aspirated into the measuring cell and the micro-particles 
magnetically captured on the electrode surface. At this stage, the unbound 
substances were removed with ProCell. Then, a voltage was applied to the electrode, 
inducing chemiluminescent emission, which was measured with a photomultiplier. 
The results were obtained via a calibration curve specifically generated by 2-point 
calibration and a master curve provided via the reagent barcode. The total duration 
of the assay was about 27 minutes. Vitamin D serum concentration thresholds were 
defined as shown in table 4-2 (CV%= 11 to 13) (Lensmeyer et al., 2006 ; Reis et al., 
2009 ; Abdel-Wareth et al., 2013 ; Al-Daghri et al., 2016).
64 
 
Table 4-2 Definition of serum 25(OH)D concentration thresholds (Reis et al., 2009 ; Al-Daghri et al., 
2016) 
25(OH)D concentration ng/ml nmol/L 
Deficient < 20 < 50 
Insufficient 20 ≤ 30 50 ≤ 75 
Adequate 30 < 100 75 < 250 
Toxicity ≥ 100 ≥ 250 
4.3.2. Food frequency questionnaire (FFQ) 
The FFQ table listed food items that contain vitamin D to determine the dietary intake 
of the vitamin (Appendices 7 and 8). Vitamin D intake was assessed using a previously 
validated FFQ (Azhar, 2009; Shirazi et al., 2013; Hatfield et al., 2014; Bushnaq, 2016). 
The FFQ was designed to include 19 food items that naturally contain, or are fortified 
with, vitamin D in Saudi Arabia; in addition to foods that might be consumed by 
people from different ethnicities (Table 4-3) (Holick, 2007; Roe et al., 2015). The FFQ 
table was designed with an option to record the amount consumed from each item 
by cup, grams, can, slice, or spoon. The measurement of the estimated amount 
consumed was illustrated to the participants using samples of the food items (Figure 
4-2). The frequency of consumption of each food item was recorded by choosing 
from nine responses ranging from never to three-times a day for the past three-
months. There was an option for more than three times a day with an open answer 
but none of the participants chose it (Patterson et al., 1999).    
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Table 4-3 Food Items used for the FFQ and the amount of vitamin D in 100 g of each food item. 
Food item Amount of vitamin D 
µg / 100 g 
Amount of vitamin D 
IU / 100 g 
Camel’s liver* 0.3 12 
Calf’s liver 0.3 12 
Lamb’s liver  0.5 20 
Chicken’s liver 0.2 8 
 Wild salmon, fresh 4.7 188 
Salmon, canned** 13.6 544 
Sardines, fresh 4.0 160 
Sardines, canned 3.3 132 
Mackerel, canned 8.5 340 
Tuna, fresh 3.1 124 
Tuna, canned 1.1 44 
Portobello mushrooms, fresh 0.3 12 
Egg yolk 12.8 512 
Fortified milk*** 1 40 
Fortified yogurts*** 1 40 
Fortified butter*** 0.9 36 
Fortified margarine 8.8 352 
Fortified cheese*** 1 40 
Fortified breakfast cereals*** 4.6 184 
* The amount of vitamin D in camel liver was assumed similar to that in calf’s liver. 
** The amount of vitamin D in canned salmon includes skin and some small bones (Roe et al., 2015) 
*** Amount of fortification was recorded based on the products in Saudi Arabia (Almarai, 2017). 
The vitamin D intake for each of the food items was estimated using McCance and 
Widdowson’s composition of foods integrated dataset (Roe et al., 2015) and Nutritics 
software (Nutritics,  Dublin, Ireland). The amount of vitamin D in fortified products 
was recorded based on the products available in Saudi Arabia (Almarai, 2017). To 
determine the average daily vitamin D intake for each participant, the amount of 
vitamin D consumed from each food item in IU (Table 4-3) was multiplied by the 
frequency of consumption of the food item (Table 4-4) (Welch et al., 2005). The 
calculation was automated using a pre-designed Excel model with all the conversion 
factors for the amount of vitamin D in each food item and the daily intake frequency 
to minimise the chance of inputting errors. The total value of dietary intake of vitamin 
D (DI-VitD) in IU/day was recorded and analysed.   
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Table 4-4 Conversion amount of frequent food consumption 
Frequency of use in three months Conversion to daily frequency 
Never  0/90       = 0 
Less than once a month  1.5/90    = 0.0167 
1-3 times a month  6/90       = 0.0667 
Once a week 13/90     = 0.1444 
2-4 times a week 39/90     = 0.4333 
5-6 times a week 71.5/90  = 0.7944 
Once a day  90/90     = 1 
Twice a day  180/90   = 2 
Three or more times a day  270/90   = 3 
4.3.3. Vitamin D supplements 
In order to collect data on the use of vitamin D supplements by participants, the 
questionnaire included a series of relevant questions. The questions required details 
of the commercial name of the brand, dose, and frequency of use. The frequency of 
use was given as daily, weekly, monthly, or less often. An additional question was on 
whether usage was preventative [without a prescription] or therapeutic [prescribed 
by their doctor]. During data coding, the dose and frequency of the supplement 
usage were calculated to give the daily consumption of vitamin D supplements in 
international units (IU), whether it was consumed separately or as part of multi-
supplement regime. During coding, the total intake of vitamin D (TI-VitD) was 
calculated by adding the amount of DI-VitD to the daily dose of vitamin D 
supplements, if any, for each participant.  
4.3.4. Sun exposure measurement 
There is no standard questionnaire for validated sun exposure measurement and 
analysis. However, studies have agreed that a self-reporting sun exposure 
questionnaire is the best indicator for estimating sun exposure (McCarty, 2008; 
Holick et al., 2011). Based on a review of the literature, a questionnaire was designed 
to determine vitamin D synthesis in the body from sunlight for the three months prior 
to this study (Azhar, 2009; Holick et al., 2011; Tuffaha et al., 2015) (Appendices 7 and 
8). When calculating sun exposure data, studies have used different methods 
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depending upon the purpose of the study (Holick, 2009; Ardawi et al., 2011; Bushnaq, 
2016; Aljefree et al., 2017b). A model has been designed for the current study based 
on the sun exposure questions to give a total value of sun exposure for each 
participant. The coding values for sunlight exposure were 1 (none/ limited), 2 (low), 
3 (medium), and 4 (high). Table 4-5 illustrates the procedure for coding answers to 
these questions. 
The first question was about the frequency of exposure to direct sunlight (not 
through glass, window, or parasol). The highest values were given to the most time 
spent exposed, starting from daily. For example, a value of “4” was given to daily 
exposure of sunlight and “1” for none or rarely. The next two questions asked about 
the times of the day when exposure to the sunlight took place during weekdays and 
at weekends. The highest values in the model were given to the noon times and the 
lowest to no exposure. Participants could choose more than one answer for this 
question and the coding in this case was for the highest value because the highest 
value will include a higher value of UVB radiation. For instance, if a participant chose 
exposure time between 7-9 am, which has a coding of “2”, and 1-3 pm ,which has a 
coding of “4”, the final coding for that question will be “4” as it will inclusive both 
amount of UVB radiation. Then there were two more questions about the length of 
sun exposure on weekdays and during the weekend. The highest value was also given 
to the most time. Furthermore, there was a question about the body parts exposed 
to sunlight, and participants were able to provide more than one answer. The coding 
model gave the highest value for the largest skin area exposed directly to the 
sunlight. The follow-up question asked about the use of sun protection (sunscreen or 
head cover). The highest value was given for no use of any sun protection. Skin 
pigmentation was part of the anthropometric measurement section in the 
questionnaire and was added to the sun exposure model. The category of the skin 
pigmentation was determined using the Fitzpatrick scale (Figure 4-4) by looking at 
the participant’s inner arm colour while carrying out the examination during the 
meeting. Then, the observation was recorded. For the sun exposure model, the skin 
pigmentation was coded with the highest value given to lightest skin tone and the 
lowest value to the darkest skin tone (Table 4-5). Finally, all of the given values were 
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added up to provide a single value representing the total sun exposure (TSE) score 
for each participant.  
To define the TSE score the range of minimum and maximum expected values were 
categorised as none/limited, low, medium and high sunlight exposure as well. The 
TSE values were divided equally to 4 groups as illustrated in table 4-6.   
Table 4-5 TSE coding model based on the questions from the questionnaire 
Questions 
None/ 
limited (1) 
Low (2) Medium (3) High (4) 
How often are you 
exposed directly to the 
sun (not through glass, 
window, or parasol)? 
-None 
-Rarely 
- 1-2 times 
a month 
- 3-4 times 
a month 
- 1-2 times a 
week 
- 3-4 times a 
week 
- 5-6 times a 
week 
-Daily 
What time of the day 
are you exposed directly 
to the sun (not through 
glass, window, or 
parasol)? 
-None 
- 7-9 am 
- 5-7 pm 
- 9-11 am 
- 3-5 pm 
- 11 am -1 pm 
- 1-3 pm 
How much time do you 
usually spend outdoors 
in daylight? 
-None - < 10 min - 10-20 min - > 20 min 
What areas of your 
body are often exposed 
to sunlight? 
Non 
-Only face 
-Only 
hands 
-Hands and 
feet 
-Face, hand, 
and feet 
-Face, hands, 
feet, and half 
arms. 
-Face, hand, 
feet, half arms, 
and half legs. 
What kind of sun 
protection do you 
usually use? 
 -Sunscreen 
-Shomak or 
Qutra 
-None 
Skin pigmentation 
-Black 
-Brown 
- Olive -Medium 
-Fair 
-very fair 
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Table 4-6 Classification of TSE model scores  
TSE category TSE values 
Non/limeted 8.0 – 14 
Low 14 < 20 
Medum 20 < 26 
High 26 < 32 
 
4.3.3.1. Sun exposure factors 
For full determination of sun exposure, other factoers such as location and season 
were considered. Geographic location was determined by the city of residence. It was 
an open question and was categorised to one of 3 cities, during the coding phase, 
based on the participant's answers as provided in table 4-7. All of the participants’ 
cities of residence were in the Makkah area. The cities of residence were used to 
indicate the local climate conditions. All of the participants were living in a similar 
climate and latitute in the Makkah area. Additionally, all of the data were obtained 
between the months of May and July in 2016 to ensure that there would be minimal 
seasonal variations between the participants.   
Table 4-7 Distribution of participants’ place of residence and geographical location 
City of residence Frequency Location 
Makkah n=93 21.4° N 
Jeddah n=2 21.5° N 
AL-Qunfudhah n=2 21.4° N 
TOTAL n=97  
Figure 4-4 The Fitzpatrick skin pigmentation classification (MDSkin, 2015) 
70 
 
4.4. Statistical analysis of the data 
Statistical analysis was performed using SPSS v24 (Inc., Chicago, IL, USA). Data were 
tested for normal distribution using the Kolgomorov-Smirnov test. Similarly, the 
homogeneity of variance was assessed using Levene’s test. In the current chapter, 
only data from TSE were normally distributed. Descriptive analysis is presented as 
mean ± standard deviation, median (interquartile range), and mean rank. One-way 
ANOVA, with Bonferroni corrected post-hoc pairwise mean comparisons, was carried 
out where there were three groups to compare (clinical groups). Independent t-test 
was used to compare the mean in two groups (i.e. gender). The rest of the chapter 
measurements were not-normally distributed, and such data was deemed suitable 
for non-parametric tests. Therefore, Kruskal-Wallis pairwise comparisons, with 
appropriate post-hoc Mann-Whitney tests were carried out where there were three 
groups, or simply Mann-Whitney tests for simple pairwise mean comparisons. 
Additionally, where data were continuous rather than grouped, Spearman rho 
correlations were carried out.  Multiple linear regressions (forced entry method, was 
run until stability was reached) were applied to create a model to predict serum 
25(OH)D based on the significant predictors. 
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4.5 Results 
In this section, a descriptive analysis and relationships are presented between serum 
25(OH)D levels and the other markers of vitamin D including vitamin D supplements, 
vitamin D dietary intake, and sun exposure. The total study sample size was 97. Data 
was analysed as a pooled sample and in sub-groups to investigate any variation 
between the groups. First sub-group included, the clinical groups ((control group 
(CG), at risk group (ARG), and diagnosed with atherosclerosis group (DAG)). The 
second sub-group was gender (male, female). Table 4-8 gives a descriptive analysis 
of the chapter variables in the pooled sample and in clinical groups. 
Table 4-8 Descriptive statistics of the chapter variables by clinical groups and in the pooled sample. 
Data were presented as N (%) for categorical variables and mean ± standard deviation for numerical 
variables. * DI-VitD (dietary intake of vitamin D), TI-VitD (total intake of vitamin D), TSE (Total sun 
exposure). 
Variable 
CG 
N=33 
ARG 
N=30 
DAG 
N=34 
Total 
N=97 
Male 5 (15.2%) 3 (10%) 7 (20.6%) 15 (15.5%) 
Female 28 (84.8%) 27 (90%) 27 (79.4%) 82(84.5%) 
Age 
(years) 
41.3 ± 6.6 50.3 ± 6.6 53.1 ± 6.8 48.2 ± 8.4 
25(OH)D 
(ng/mL) 
18.5 ± 10.3 23.9 ± 14.9 18.3 ± 14.6 20.1 ± 13.4 
DI-VitD 
(IU/day) 
239.1 ± 155.6 264 ± 132.5 211.8 ± 101.7 237.3 ±131.9 
TI-VitD 
(IU/day) 
3330 ± 10193.6 3611.4 ± 10431 7396.5 ±16787.6 4842.3 ± 12959.6 
TSE 
Value 
21.2 ± 3.96 20.9 ± 4.47 21.24 ± 4.9 21.14 ± 4.4 
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4.5.1. Serum 25(OH)D results 
4.5.1.1. Descriptive analysis of serum 25(OH)D in the pooled sample and between sub-
groups  
Serum 25(OH)D was measured in 97 participants of whom 15 were males. The 
minimum 25(OH)D concentration was 3.00 ng/mL and the maximum was 58.94 
ng/mL. Table 4-8 illustrates the mean values of 25(OH)D among the clinical groups 
(control group (CG), at risk group (ARG), and diagnosed with atherosclerosis group 
(DAG)) and figure 4-6 shows the distribution of 25(OH) concentrations among the 
clinical groups. Concentrations of 25(OH)D < 20 ng/mL are deficient, 20 ≤ 30 ng/mL 
are insufficient, 30 < 100 ng/mL are adequate, and above 100 ng/mL considered 
toxic. The majority of the participants (51.5%) had vitamin D deficiency (mean ± SD= 
9.88 ± 4.2 ng/mL), 28.9% had insufficient concentrations (23.37 ± 2.57 ng/mL), and 
only 19.6% had adequate concentrations (42.13 ± 9.28 ng/mL) of serum 25(OH)D 
(figure 4-5). There were no outliers in 25(OH)D data at an IQR of 3. Among the 
participants, 30.9 % were taking vitamin D supplements while the rest (69.1%) were 
not. Descriptive statistic of 25(OH)D concentrations among the pooled sample, 
clinical groups, and gender (male and female) with consideration of the consumption 
of vitamin D supplements are all illustrated in table 4-9.  
 
  
Figure 4-5 Distribution of 25(OH)D concentrations (ng/mL) among the participants. 25(OH)D < 20 
ng/mL are deficient, 20 ≤ 30 ng/mL are insufficient, 30 < 100 ng/mL are adequate, and above 100 
ng/mL toxic. Cut off values are shown between the dotted lines. 
 
Insufficient 
Adequate Deficient 
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Figure 4-6 Distribution of 25(OH) concentrations (ng/mL) among the clinical groups. 25(OH)D < 20 
ng/mL are deficient, 20 ≤ 30 ng/mL are insufficient, 30 < 100 ng/mL are adequate.  
Table 4-9 Descriptive statistic of 25(OH)D concentrations (ng/mL) among the pooled sample and 
clinical groups, gender when consuming vitamin D supplements or not. Data are presented as mean ± 
standard deviation, median (interquartile range), and mean rank. 
 
 
Take Vitamin D 
supplements 
N Mean ± SD Median (IQR) 
Mean 
Rank 
CG 
Yes 6 40.27 ± 16.16 41.92 (25.01) 20.17 
No 27 13.37 ± 8.63 11.54 (14.29) 30.57 
Total 33 18.5  ± 10.31 18.64 (16.09) 43.30 
ARG 
Yes 12 32.51 ± 17.99 30.37 (33.16) 15.67 
No 18 18.17 ± 8.94 20.07 (15.54) 41.64 
Total 30 23.91 ± 14.85 21.87 (19.54) 56.68 
DAG 
Yes 12 27.5 ± 9.4 24.46 (14.87) 13 
No 22 13.56 ± 6.96 10.64 (11.20) 31.57 
Total 34 18.26  ± 14.57 12.7 (15.18) 43.30 
Male 
Yes 0 0 0 0 
No 15 15.75 ± 8 15.47(13.29) 36.87 
Total 15 15.75 ± 8 15.47 (13.29) 42.07 
Female 
Yes 30 32.08 ± 14.96 33.41 (20.84) 15.50 
No 52 14.43 ± 8.50 11.78 (13.27) 33.17 
Total 82 20.888 ± 14.10 20.04 (17.73) 50.27 
Vitamin D 
supplements 
Yes 30 32.08 ± 14.96 33.4 (20.84) 72.0 
No 67 14.72 ± 8.35 12.05 (13.17) 38.70 
Total  sample 97 20.09 ± 13.44 18.77 (16.64)  
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4.5.1.2. 25(OH)D concentration and the difference between sub-groups  
To investigate the results further, a series of non-parametric tests were performed.   
Kruskal-Wallis test indicated no significant differences in 25(OH)D concentrations 
between the clinical groups (P=0.161) as shown in the box and whiskers plot (figure 
4-7). In addition, Mann-Whitney test indicated no significant diffrences between 
male and female in terms of their 25(OH)D status (P=0.299). Box and whiskers plots 
in figures 4-7 illustrated no differences between the sexes. A Mann-Whitney test 
performed using the consumption of vitamin D supplements as a grouping variable 
indicated, as expected, a significant difference (U=315, P<0.001) (table 4-9). Box and 
whiskers plots of 25(OH)D and consumption of supplements is illustrated in figure 4-
7 and shows the significant difference.  
  
 
 
Figure 4-7 Box and whiskers plots for 25(OH)D (ng/mL) by clinical, gender, and vitamin D 
supplementation grouping. A figure include the whole sample and B without the outliers. Data shows 
medians, interquartile range, whiskers and outliers. ** Indicates significant between group differences 
(P<0.01). 
** 
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For additional investigation, data were analysed based on the vitamin D supplement 
consumption. Results using a Kruskal-Wallis test indicated no significant differences 
in 25(OH)D concentrations between the clinical groups when taking the supplements 
(P=0.265), nor when not taking supplements (P=0.146). None of the male 
participants were taking vitamin D supplements thus, there was no comparison 
between male and female who were taking supplements. A Mann-Whitney test was 
performed to investigate any gender bias when vitamin D supplements were not 
used, the comparison revealed no significant difference (P=0.518).  
On the other hand, when comparing the data from the clinical groups the results 
were different. A Mann-Whitney test revealed a significant difference between the 
participants who use vitamin D supplements and those who do not within each of 
the clinical groups CG (U=11, P<0.001), ARG (U=56, P= 0.028), and DAG (U=31, 
P<0.0001) (figure 4-8).  
Figure 4-8 Box and whiskers plots for 25(OH)D (ng/mL) in the clinical groups whether consume vitamin 
D supplements or not. Data shows medians, interquartile range, whiskers and outliers. Significant 
differences between groups indicated by (* = P<0.05) and (** = P<0.01). 
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4.5.2. Dietary intake of vitamin D (DI-VitD) and total intake of vitamin D 
from diet and supplements (TI-VitD). 
4.5.2.1. Descriptive analysis of DI-VitD and TI-VitD in the pooled sample and between 
sub-groups. 
The FFQ was filled out by all of 97 participants and analysed for total dietary vitamin 
D intake (section 4.3.2.) and the dose of supplements consumed (section 4.3.3.). The 
average DI-VitD for the pooled sample was 237.27 ± 131.9 IU/day with minimum and 
maximum values of 26.04 and 589 IU/day. Figure 4-9 illustrate the data distribution 
without outliers. Table 4-10 shows descriptive results of dietary intake of vitamin D 
among the pooled sample and in the sub-groups.  
 
Figure 4-9 Distribution of daily dietary intake of vitamin D IU in the pooled sample  
Table 4-10 Descriptive analysis of dietary intake of VitD (IU/day) in the pooled sample and in the sub-
groups.  
 N Mean ± SD Median (IQR) Mean Rank 
CG 33 239.14 ± 155.67 238.80 (225) 47.77 
ARG 30 264.55 ± 132.543 273.00 (201) 55.2 
DAG 34 211.84 ± 101.785 214.10 (164) 44.74 
Male 15 226.76 ± 139.619 172.92 (147) 688.5 
Female 82 239.19 ± 131.261 238.64 (197) 4064.5 
Total 97 237.27 ± 131.911 237.32 (192)  
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Conversely, the TI-VitD values from diet and supplements for the pooled sample was 
4842.29 ± 12959.6 IU/day with minimum and maximum values 26 and 50363 IU/day 
(table 4-11). The data were not normally distributed (figure 4-10). In the pooled 
sample 23 values above 750 IU/day were pointed as outliers at an IQR of 3 (figure 4-
11 (A)). However, these high values were the result of supplement consumption. 
Therefore, figure 4-11 (B) indicates no outliers when data were divided by the 
consumption of supplements. This indicates that these outliers are part of the TI-VitD 
data and should not be removed.  
 
Figure 4-10 Distribution of the total intake of vitamin D from diet and supplements (IU/day) in the 
pooled sample. 
 
 
Figure 4-11 A box and whiskers plot of the total intake of vitamin D from diet and supplements (IU/day) 
(A)  in the pooled sample and (B)  when vitamin D supplements were taken or not. ** Indicates 
significant between group differences (P<0.01).  
 
A B 
** 
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Figure 4-12 Histograms of the TI-VitD levels (IU/day) when vitamin D supplements were taken of not  
 
Table 4-11 Descriptive analysis of TI-VitD (IU/day) in the pooled sample and in the sub-groups. 
 N Mean ± SD Median (IQR) Mean Rank 
CG 33 3330.1 ± 10193.65 290 (391) 46.11 
ARG 30 3611.4 ± 10431.07 332 (1229) 51.38 
DAG 34 7396.2 ± 16787.6 297 (1278) 49.71 
Male 15 226.80 ± 139.67 173 (148) 497 
Female 82 5686.6 ± 13942.2 323 (1161) 4256 
Total 97 4842.29 ± 12959.6 298 (529)  
 
4.5.2.2. DI-VitD and TI-VitD values and the difference between sub-groups  
To investigate the difference between the sub-groups, non-parametric tests were 
performed. There were no significant differences between the clinical groups 
(P=0.318) nor between male and female (P=0.643) in their DI-VitD values as shown 
in the box and whiskers plots in figure 4-13. Similarly, there was no significant 
difference in TI-VitD values between the clinical groups (P=0.74). In contrast, there 
was a significant difference between male and female in TI-VitD values (U=377, 
P=0.018) as shown in the box and whiskers plot (figure 4-14).  
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Figure 4-13 Box and whiskers plots of DI-VitD and TI-VitD (IU/day) by clinical groups, and gender. Data 
shows medians, interquartile range, whiskers and outliers. 
 
  
Figure 4-14 Box and whiskers plots of DI-VitD and TI-VitD (IU/day) by clinical groups, and gender. Data 
shows medians, interquartile range, whiskers and outliers. Outliers were not removed as they 
represents the consumption of vitamin D supplements. ** Indicates significant between group 
differences (P<0.01). 
 
4.5.3.3. Correlations between DI-VitD, TI-VitD values and Serum 25(OH)D in the pooled 
sample  
To examine the relationship between dietary intake of VitD and the 25(OH)D 
concentration, correlation and regression tests were performed. There were 
statically significant negative Spearman correlation between DI-VitD and the 
25(OH)D (rho= -0.195, P=0.028, R2= 0.04). Contrariwise, a positive significant 
Spearman correlation was observed between TI-VitD and the 25(OH)D (rho=0.338, 
P<0.0001, R2= 0.11) (Table 4-12). Figures 4-15 and 4-16 shows a scatter plots 
** 
80 
 
between DI-VitD and, TI-VitD with 25(OH)D concentrations to illustrate the 
relationships. 
Table 4-12 Spearman correlations between 25(OH)D (ng/mL) and dietary intake of vitamin D (IU/day), 
total intake of vitamin D (IU/day) 
 25 (OH)D DI-VitD TI-VitD 
Spearman's 
rho 
25 (OH)D Correlation Coefficient 1.000 -0.195* 0.338** 
Sig. (1-tailed) . 0.028 < 0.000 
N 97 97 97 
DI-VitD  Correlation Coefficient  1.000 0.532** 
Sig. (1-tailed)   < 0.000 
N   97 
TI-VitD Correlation Coefficient   1.000 
Sig. (1-tailed)   . 
N   97 
*. Correlation is significant at the 0.05 level (1-tailed). 
**. Correlation is significant at the 0.01 level (1-tailed). 
 
 
Figure 4-15 X-Y Scatter graph of 25(OH)D ng/mL 
and dietary intake of vitamin D IU/day. 
 
Figure 4-16 X-Y Scatter graph of 25(OH)D ng/mL 
and total intake of vitamin D IU/day. 
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4.5.3. Sun Exposure results 
4.5.3.1. Descriptive analysis of Total sun exposure (TSE) in the pooled sample and 
between sub-groups  
Data on TSE were scale data designed by a sun exposure model (section 4.3.4). The 
maximum value was 30 TSE and the minimum was 12 TSE with a mean ± SD of (21.14 
± 4.44) (Table 4-13). Figure 5-17 shows the TSE distribution of the participants. 
Among the participants, 11.34% had limited TSE, 36.1% had Low TSE, 41.2% had 
medium TSE and only 11.34% had high TSE. Table 4-13 illustrates descriptive results 
of TSE based on the clinical groups and on gender. There were no outliers in the TSE 
data.  
  
Figure 4-17 Distribution of TSE values among the participants in pooled sample. Cut off values are shown 
between the dotted lines. 
 
Table 4-13 Descriptive statistic of TSE among the pooled sample and in the study sub-groups 
 N Mean ± SD Median (IQR) 
CG 33 21.24 ± 3.96 20.00 (8) 
ARG 30 30.93 ± 4.48 20.50 (7) 
DAG 34 21.24 ± 4.94 22.00 (7) 
Male 15 24.53 ± 4.19 25.00 (6) 
Female 82 20.52 ± 4.22 20.00 (6) 
Total 97 21.14 ± 4.44 21.00 (7) 
Non 
Low Medium 
High 
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4.5.3.2. TSE values and the difference between sub-groups  
To investigate the difference in sun exposure between the sub-groups, a series of 
parametric statistical inference tests were performed. One-way ANOVA  revealed no 
significant differences in sun exposure habits between the clinical groups (P=0.953). 
However, there was a significant difference in the sun exposure habits between male 
and female when an independent t-test was performed (T=3.38, P=0.001). Figure 4-
18 are box and whiskers plots of the difference in TSE within the sub-groups.   
  
Figure 4-18 Box and whiskers plots of TSE value among the clinical groups, and gender. Data shows 
medians, interquartile range, whiskers and outliers. . ** Indicates significant between group 
differences (P<0.01). 
 
4.5.3.3. Correlations and Regressions between TSE and Serum 25(OH)D in the pooled 
sample 
To examine the relationship between TSE and 25(OH)D a Spearman correlation test 
was performed and indicate a statically significant correlation (rho= -0.22, P=0.015, 
R2=0.05) (Table 4-14). Figure 4-19 illustrate Scatter diagram between TSE and 
25(OH)D concentration.
** 
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Table 4-14 Spearman correlations between 25(OH)D concentrations (ng/mL) and total sun exposure 
values 
 25 (OH)D TSE value 
Spearman's 
rho 
25 (OH)D Correlation Coefficient 1.000 -0.220* 
Sig. (1-tailed) . 0.015 
N 97 97 
*. Correlation is significant at the 0.05 level (1-tailed). 
 
  
Figure 4-19 X-Y Scatter graph of 25(OH)D concentrations ng/mL and total sun exposure values. 
4.5.4 Comparison of the size of the correlation 
Serum 25(OH)D concentration was significantly correlated to all of chapter 
modulators (see table 4-15).The strength of correlation was  moderate between 
25(OH)D and total intake with vitamin D supplements (TI-VitD) (R2 = 0.11) and the 
correlations were weak between 25(OH)D and dietary intake of vitamin D (DI-VitD) 
(R2 = 0.04) and total sun exposure (R2 = 0.05). 
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Table 4-15 Spearman’s rho correlations between 25(OH)D and the chapter variables 
 25 
(OH)D 
DI-VitD TI-VitD TSE 
Spearman's 
rho 
25 
(OH)D 
Correlation Coefficient 1.000 -0.195* 0.338** -0.220* 
Sig. (1-tailed) . 0.028 < 0.000 0.015 
N 97 97 97 97 
DI-VitD Correlation Coefficient  1.000 0.532** 0.115 
Sig. (1-tailed)  . < 0.000 0.132 
N  97 97 97 
TI-VitD Correlation Coefficient   1.000 -0.210* 
Sig. (1-tailed)   . 0.020 
N   97 97 
TSE Correlation Coefficient    1.000 
Sig. (1-tailed)    . 
N    97 
*. Correlation is significant at the 0.05 level (1-tailed). 
**. Correlation is significant at the 0.01 level (1-tailed). 
 
4.5.5. Regression model  
A multiple linear regression model was performed to create a composite model 
predictor of serum 25(OH)D using all of the significant modulators identified above. 
These significant modulators included consumption of vitamin D supplements, total 
sun exposure (TSE), dietary intake of vitamin D (DI-VitD), and total intake of vitamin 
D (TI-VitD). The model was statistically significant (P< 0.0001) and explains 39.7% of 
the variance of 25(OH)D concentration. The model is statistically powerful due to the 
low shrinkage of R (Adjusted R2= 0.370). However, in further analysis the model was 
unstable because of the present of non-significant contributors (TI-VitD P=0.917, and 
TSE P=0.83) (see table 4-16). Therefore, the model was re-run to attain a stable model 
that incorporated the consumption of vitamin D supplements and DI-VitD to predict 
25(OH)D. The stable model explains 39.6% of the variance in 25(OH)D and is 
statistically significant and has lower shrinkage of R (adjusted R2= 0.383) than the first 
model. The predictors of this model are all significant, consumption of vitamin D 
supplements (P=0.0001) and DI-VD (P=0.019) (Table 4-17). 
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Table 4-16 Unstable model predictor of serum 25(OH)D 
Coefficients a 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
T Sig. 
B Std. Error Beta 
1 (Constant) 53.269 7.198 
 
7.401 <0.000 
Consumption of 
vitamin D 
supplements 
-17.582 2.830 -0.608 -6.213 <0.000 
Dietary intake of 
vitamin D 
-0.020 0.008 -0.193 -2.350 0.021 
Total intake of vitamin 
D 
1.061E-5 0.000 0.010 0.105 0.917 
Total sun exposure  0.055 0.264 0.018 0.207 0.836 
a. Dependent variable: 25(OH)D 
 
Table 4-17 Stable model predictor of serum 25(OH)D 
Coefficients a 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
T Sig. 
B Std. Error Beta 
1 (Constant) 54.433 4.574  11.901 <0.000 
Consumption of 
vitamin D 
supplements 
-17.579 2.320 -0.608 -7.576 <0.000 
Dietary intake of 
vitamin D 
-0.019 0.008 -0.191 -2.380 0.019 
a. Dependent variable: 25(OH)D 
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4.6. Discussion  
4.6.1. Vitamin D status discussion 
The current study has found a relatively high prevalence of vitamin D deficiency 
among adults who live in Saudi Arabia, mainly Makkah city. 51.5% of the participants 
were vitamin D deficient (25(OH)D < 20 ng/mL) with a 25(OH)D mean value of 9.88 ± 
4.2 ng/mL, and 28.9% had an insufficient concentration of vitamin D in their blood 
plasma (25(OH)D 20 ≤ 30 ng/ml) (23.37 ± 2.57 ng/mL). Only 19.6% of the participants 
had adequate concentrations of vitamin D (25(OH)D > 30 ng/ml) (42.13 ± 9.28 
ng/mL). These results confirmed the issue of vitamin D deficiency in Saudi Arabia 
reported in previous research (Al Faraj and Al Mutairi, 2003; Azhar, 2009; Ardawi et 
al., 2012; Tuffaha et al., 2015; Abulkhair et al., 2016; Al-Daghri, 2016; Aljefree et al., 
2016; Qadhi, 2016; Kaddam et al., 2017). These results were also similar to results 
from other studies, especially those performed on a similar age group population in 
the same region (Western region) of Saudi Arabia (Ardawi et al., 2012; Aljefree et al., 
2016). For instance, Ardawi et al., (2012), indicated that 51.5% of males aged 20-60 
years were deficient and 38.8% had insufficient concentrations of 25(OH)D.  Another 
study by Aljefree et al., (2016) studied adult participants (control and patients with 
coronary heart disease) and found that 57.5% of these had 25(OH)D concentrations 
< 20 ng/mL were deficient and the rest exhibited values > 20 ng/mL which they 
considered adequate. Both Ardawi et al., (2012) and Aljefree et al., (2016) had 
comparable samples and results to the present study, which support the findings of 
the present study.  
The consumption of vitamin D supplements has a significant impact on 25(OH)D 
status (Holick et al., 2011; Aljefree et al., 2017a). In the current study, almost a third 
of the participants (i.e. 30.9%) were taking vitamin D supplements and had a mean ± 
SD 32.08 ± 14.96 ng/mL of 25(OH)D which is within the adequate range for vitamin 
D status. The difference in vitamin D status between the group who consume vitamin 
D supplements and those who did not, was significant (U=315, P<0.001), which 
indicates the positive impact of vitamin D supplements on vitamin D status. 
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The significant differences in 25(OH)D concentrations when vitamin D supplements 
were consumed or not, was also observed within the clinical groups; control group 
(CG), at risk group (ARG), and the diagnosed with atherosclerosis group (DAG) (U=11, 
P<001) (U=56, P=0.028) (U=31, P<0.001) respectively. Although these results are all 
significant, it was observed that the CG had the biggest difference between the 
groups who took or did not take vitamin D supplements. There are many 
explanations for these results. The CG was a healthy group whom are free from any 
systemic disease, which can impair the body’s ability to absorb vitamin D (Holick, 
2007). Since the CG were free from those diseases, the effect of supplementation 
was clearly significant. In addition, the CG are younger in age (41.3 ± 6.6 years) 
compared to the other 2 groups (ARG 50.3 ± 6.6 years and DAG 53.3 ± 6.8 years) but 
not significantly, however, aging is one of the factors that affects vitamin D 
absorption and bioavailability in the body (Holick et al., 2011). 
Additionally, the participants who were taking vitamin D supplements represented 
18.1% of the CG, 40% of the ARG, and 35.2% of the DAG.  The explanation for the low 
number of participants taking vitamin D supplements in the CG compared to the 
other 2 groups is that, the participants in the CG were taking vitamin D supplements 
for prevention or treatment because of a low vitamin D status. On the other hand, 
participants in the ARG and DAG were mainly taking the supplements prescribed by 
their physician, in line with the new recommendation in Saudi Arabia, whereby 
vitamin D deficiency in diabetic patients and patients with cardiovascular disease 
should be treated with vitamin D supplements (section 2.1.7.) (Lee et al., 2008; Al-
Daghri et al., 2016). 
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4.6.2. Discussion of vitamin D intake from diet (DI-VitD) and diet with 
supplements (TI-VitD) 
Dietary vitamin D is the second source of vitamin D after sun exposure, however, very 
few foods naturally contain vitamin D as demonstrated in the literature (Holick et al., 
2011; Dalan et al., 2014) Additionally, in Saudi Arabia, food that naturally contains 
the highest amount of vitamin D i.e. Salmon, Mackerel, and Sardines are not 
commonly consumed. The highest amount of dietary vitamin D comes from the 
consumption of eggs and fortified dairy products such as milk and yogurt, as 
discussed in the literature and observed from the current study (Aljefree et al., 
2017b). The mean intake of vitamin D from the diet (DI-VitD) in the current study was 
237.27 ± 131.9 IU/day which represents only 39.5% of the recommended dietary 
intake of vitamin D (600 IU/day) (Ministry of Health, 2017). Many studies concur with 
this issue of low intake of vitamin D rich food in Saudi Arabia (Yousef et al., 2013; 
Kearney et al., 2015). Yousef et al. have observed similar results in 120 breast cancer 
patients and 120 control volunteers in Saudi Arabia. They found that <34% of cancer 
patients and <39% of the control group had a low consumption of oral vitamin D from 
the diet. The low intake of vitamin D from the diet could be one for the reasons of 
vitamin D deficiency in Saudi dwellers. However, there was a negative significant 
correlation between DI-VitD and 25(OH)D concentrations (P<0.05). The strength of 
the correlations was (R2= 0.04) which indicates a weak relationship and it explains 
only 4% of the variance in 25(OH)D concentrations. Additionally, there were no 
gender or clinical variations in DI-VitD in the current study. 
Conversely, when supplement consumption was added to the dietary intake of 
vitamin D to make the total intake of vitamin D (TI-VitD), there was a moderate 
positive correlation with serum 25(OH)D concentrations (P<0.0001) (R2= 0.11) which 
explains 11% of the variance in 25(OH)D concentrations. The higher the values of TI-
VitD the greater concentrations of 25(OH)D, which enhanced the supplement effect 
on vitamin D status. The mean value of TI-VD was 4842.29 ± 12959.6 IU/day. There 
was a statistical variation between males and females in TI-VD as none of the male 
participants were taking vitamin D supplements (U=377, P=0.018). As demonstrated 
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in the literature review, the new recommendations suggest consumption of vitamin 
D supplements for people at risk of vitamin D deficiency and for treatment of vitamin 
D deficiency, which is supported by the results of the current study (Al-Daghri et al., 
2016; Holick, 2017). 
In the TI-VitD data, there were 23 apparent outliers above 750 IU/day out of the total 
number of the participants n=97. In fact, they were not removed from the data 
because they represented 76.6% of the participants who were taking vitamin D 
supplements n=30. The values were reviewed to confirm they were correct entries. 
It was estimated that any DI-VitD analysis without the outliers would skew that data 
towards a greater proportion of one population than was truly representative of our 
sample; as such, this outlier removal was not performed.  
4.6.3. Discussion of sun exposure 
While exposure to sunlight is the main source of vitamin D, especially in a country 
with sunny climate throughout the year like Saudi Arabia, the current study indicated 
that 50.1% of the participants had vitamin D deficiency. Using the sun exposure 
analysis model designed for this study, total sun exposure (TSE) was determined from 
the questionnaire. Among the participants, TSE was limited in 11.3% of participants, 
low in 36.1%, medium in 41.2% and only 11.3% had a high TSE value. As discussed in 
the literature review, many factors limit sun exposure behaviour in Saudi Arabia. The 
excessive high temperature reduces outdoor activities during daytime (Tuffaha et al., 
2015; Aljefree et al., 2017b). The data collection period was between May and July, 
during which time the temperature rose up to 48°C in Makkah and Al-Qunfudhah 
cities and to 40°C in Jeddah city (AccuWeather, 2016). Additionally, 51.5% of the 
participants were unemployed housewives, which meant they did not have to go out 
during the daytime. These housewives were female participants and so that also 
explained the gender-based significant variation in TSE (P< 0.001). Overall, it was 
observed from the current study and other studies that the majority of the Saudi 
dwellers were not fully aware of the importance of sun exposure and the right way 
to obtain it (Al‐Agha et al., 2016; Aljefree et al., 2017b).   
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The outcome of the TSE value was un-expectedly negatively correlated to 25(OH)D 
concentration (rho=-0.22, P<0.01) the relationship was weak and TSE represented 
only 5% of 25 (OH)D variance (R2=0.05). However, similar results were also observed 
from other studies (Binkley et al., 2007; Bushnaq, 2016). Binkley et al. (2007) 
measured serum 25(OH)D in 93 adults in Hawaii (latitude 21° N). A self-reporting sun 
exposure questionnaire was used. They found no correlation between 25(OH)D 
concentration and sun exposure. Similarly, Bushnaq (2016) also found that the 
average of exposed body surface area in populations from the United Kingdom 
(latitude 53.46° N) and Saudi Arabia (latitude 21.41° N) n=79 has a negative effect on 
25(OH)D concentrations. The negative, or no, association between sun exposure and 
25(OH)D could be due to the low concentration of vitamin D as Binkley et al. 
suggested (2007). Additionally, the low exposure to sunlight could be the reason for 
the unpredicted association with 25(OH)D concentration. Moreover, the lack of 
awareness of the right way to expose oneself to the sun to maximise the potential 
for synthesising vitamin D could be the reason for this negative relationship (Aljefree 
et al., 2017a).  
4.6.4. Multiple linear regression model 
The multiple linear regression model suggested that together, consumption of 
vitamin D supplements and dietary intake of vitamin D, create a stable model to 
predict 25(OH)D serum concentration, more so that any model including other 
factors such as TI-VD, and TSE. The model explains 39.6% of the variance in 25(OH)D 
concentrations. 
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4.7. Summary and conclusion  
The current study confirmed the huge problem of vitamin D deficiency in Saudi 
Arabia. Additionally, the study confirmed the positive impact of vitamin D 
supplements on circulating 25(OH)D levels in the pooled sample and in between the 
clinical groups (CG, ARG, DAG). The current study proved the significant association 
between 25(OH)D and the participants’ vitamin D status when vitamin D 
supplements were consumed. The current study designed dietary intake and the sun 
exposer models for the people who live in Saudi Arabia.  
The current study has confirmed that Saudi dwellers are not consuming sufficient 
vitamin D rich food. Additionally, they are not exposing themselves (uncovered skin) 
enough to sunlight in order to synthesise vitamin D. Out of the sources of vitamin D, 
diet and the consumption of vitamin D supplements were good indicators of 
circulating 25(OH)D concentration, but sun exposure was not. In all, this data would 
suggest that for Saudis, at least, this simplifies the formulation of government 
recommendations for lifestyle to maximise the potential for a healthy vitamin D 
status.   
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Chapter 5 - Determination of the effect of life-style 
factors on circulating 25(OH)D levels in a sample of 
Saudi Arabia dwellers 
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5.1. Introduction 
Certain traits and life style factors, such as the socioeconomic status and education 
level, have an impact on the health of individuals (Shirazi et al., 2013).  Many factors 
can adversely affect vitamin D status and confer a risk of vitamin D deficiency. Some 
studies have demonstrated the impacts of these factors (Shirazi et al., 2013; Holick 
and Chen, 2008). The current chapter presents the association between serum 
25(OH)D status and gender, age, education level, occupation, socioeconomic status, 
smoking, BMI body mass index (BMI) and waist-to-hip ratio (WHR).  
5.1.1. Chapter aim 
- To establish whether there are any relationships between circulating 25(OH)D 
concentrations and lifestyle factors in a sample of Saudi Arabia dwellers. 
5.1.2. Chapter objectives 
1- To assess lifestyle factors and determine any differences between the sub-
groups.  
2- To determine any association between the lifestyle factors and circulating 
25(OH)D concentrations. 
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5.2. Methods  
5.2.1. Gender 
Participants were asked to state their sex in the general information section of the 
questionnaire. The answer had two options, male and female. The tendency was to 
have a similar number of participants from each sex in each of the study groups 
(control group (CG), at risk group (ARG), and diagnosed with atherosclerosis group 
(DAG)). However, females were more cooperative and hence a greater number 
participated in the study.  
5.2.2. Age 
In the general information section of the questionnaire, there was a question about 
the date of birth. The inclusion criteria for age was 35 to 60 years old, a range which 
covered middle aged adults and was found to include participants whose statuses 
were within the 3 categories, control, at-risk and confirmed disease. The majority of 
the participants provided their date of birth in a Hijiri date as it is the standard 
calendar used in Saudi Arabia. The date was converted to a Gregorian date using a 
website converter (IslamiCity, 1995-2018). The same converter was used to 
determine all of the participants’ ages to ensure accuracy of the data.  
5.2.3. Education level 
The participants were asked to choose their level of achievement in education. The 
question was part of the general information section of the questionnaire. There 
were six levels of education that the participants could choose from. The seventh 
option was “other”, with an open space for an answer, but none of the participants 
chose it. Table 5-1 describes each level of education and the ideal age of the person 
at each level.  
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Table 5-1 Description of education levels in Saudi Arabia 
Education level Description of the level Ideal age during level 
Illiterate Did not go to school ----- 
Primary 6 levels from year 1 to 6 6 to 11 years 
Secondary 3 levels from year 7 to 9 12 to 14 years 
High school 3 levels from year 10 to 12 15 to 17 years 
Diploma 1 or 2 years at any age after high school 
Bachelor 4 to 6 levels at any age after high school 
Postgraduate Masters or doctoral degree at any age after bachelor 
5.2.4. Occupation 
In the general information section of the questionnaire, participants were asked 
about their job. The question was targeting the nature of the job rather than the job 
itself. The question had seven answers to choose from: education, healthcare, public 
sector, private sector, housewife, retired and other. Education, if they worked in 
school, university, or any sector related to education. Healthcare, if they worked in a 
hospital, clinic, or any related place. Public sector included jobs that are run by the 
government but not in education or healthcare. Private sector represented jobs that 
are run by a private institution or company that were also not under education or 
healthcare. Housewife represented people who did not have a job. Finally, the option 
for “other” was for any other answer with an open space for the answer, but none of 
the participants chose it.  
5.2.5. Socioeconomic status 
Socioeconomic status assessment consisted of two parts: monthly income and 
number of family members benefiting from said income. The questions were 
included in the general information part of the questionnaire. 
The income question was asked according to the monthly family income in Saudi 
Riyals (SR), the currency that is used in Saudi Arabia. Rather than provide a specific 
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value, the question provided five income ranges (Table 5-2) from which a choice 
could be made. Details of the mean value of the ranges of income and the amounts 
in Great British Pounds (GBP) are also shown in table 5-2. 
The number of members in the family, who were benefiting from the income, was an 
open question. Participants were asked to state how many members of the family 
were using the income value which was selected in the previous question. The 
number should also have included the participant. 
Table 5-2 Monthly income in SR and GBP 
Range in SR Equivalent in GBP Mean value SR Mean value GBP 
Less than 5000 Less than 1050 2500 520 
5000 to 10000 1040 to 2080 7500 1560 
10000 to 15000 2080 to 3120 12500 2600 
15000 to 20000 3120 to 4160 17500 3640 
20000 and above 4160 and above 22500 4680 
5.2.6. Smoking status 
Smoking status was determined using four questions in the health information 
section of the questionnaire. The first question asked about the current smoking 
status. The answer to this question was either yes or no. The second question was 
about the history of smoking if the participants were not current smokers. The third 
question was about the participants’ smoking habits, for participants who were 
smokers or used to be smokers. That question had four possible answers: Heavy 
smoker, moderate smoker, light smoker and rare smoker. The last question was also 
for both smokers and those who used to be smokers, regarding the type of smoking 
products used. The participants could choose from four different types of smoking 
products that were cigarettes, electronic cigarettes, hookah and shisha. There was 
an option for “other” with a blank space to write any additional type but none of the 
participants wrote anything on it.
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5.2.7. BMI and WHR  
Anthropometric measurements were performed to establish the participant’s body 
mass index (BMI) and waist-to-hip ratio (WHR). For the BMI the measurements, 
height and mass were taken. Participants’ height (cm) and mass (kg) were measured 
using an electronic scale (Doran Scales, Charles, IL, USA) (Appendix 12). The 
participants stood on the scale without their shoes, purse, wallet, or any additional 
items. The weight was taken for most of the participants when they arrived in a 10-
hour fasted state for the purpose of the blood collection sample. Some of 
participants first arrived not fasted and their anthropometric measurements were 
taken when they had come back for the blood test while they were fasting. For the 
height measurement, the participants were asked to stand straight and position their 
head in the Frankfort plane (Hirani, 2010). The head plate was gently lowered on to 
the top of the head and the height was then measured. Height and weight were used 
to identify the body mass index (BMI). The BMI is calculated as the ratio of body mass 
in kilograms to the height in meters, squared (body mass/height2). BMI is defined in 
table 5-3. 
Table 5-3 Illustration of BMI (kg/m2) categories for adult (Hirani, 2010) 
Category BMI kg/m2 
Underweight < 18.5 
Healthy weight 18.5 - 24.9 
Overweight 25 - 29.9 
Obese > 30 
The waist and hip circumference measurements were taken to provide an indication 
of abdominal fat. A standard tape measure in centimetres (cm) was used without any 
pressure to the body surface over light clothing. The participants were asked to stand 
straight with feet close together, arms down at the sides, and to relax the abdominal 
muscles. The waist was defined as the midpoint between the hip and the last rib cage 
bone. The hip was defined as the widest point over the buttocks. Waist-to-hip ratio 
(WHR) was calculated by dividing the circumferences of waist over hip. The category 
of WHR ranges are displayed in Table 5-4. 
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Table 5-4 Illustration of WHR (cm) categories for males and females (Dalton et al., 2003; Consultation, 
2008) 
Category WHR for males WHR for females 
Normal adipose ≤0.90 ≤ 0.80 
High adipose 0.90 - 0.99 0.80 - 0.84 
Morbidly adipose ≥ 1.00 ≥ 0.85 
5.2.8. Circulation of 25(OH) D 
Concentrations of 25(OH)D were determined using an electrochemiluminescence 
binding assay that uses Elecsys 2010 (Cobas e E601 immunoassay analysers, 
Indianapolis, IN, USA) (Roche, 2015a). Details of the methods used in blood sample 
collection and laboratory analysis of 25(OH)D are presented in chapter 4.  
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5.3. Statistical analysis of the data  
Statistical analysis were performed using SPSS v24 (Inc., Chicago, IL, USA). Descriptive 
and summary statistics are reported as mean ± standard deviation, median 
(interquartile range), and mean rank for continuous variables and count (N) and 
percent for categorical variables. In the current chapter, none of the outcome 
measures were normally distributed, as such data was deemed suitable for non-
parametric statistical tests. Therefore, the Kruskal-Wallis test, with appropriate post-
hoc Mann-Whitney tests were carried out where there were more than three groups, 
or Mann-Whitney tests alone for simple mean pairwise comparisons. Where data 
was continuous rather than grouped, Spearman Rho correlations were carried out. 
Statistical significance was set at p ≤ 0.05. Multiple linear regressions model was 
performed for further investigation to study an effect of variables on 25(OH)D if there 
were any.  
5.4. Results  
In this section determination of the separate, and where appropriate, combined 
impact of life-style factors including gender, age, education level, socioeconomic 
status, smoking status, skin tone, BMI and WHR on 25(OH)D plasma level is 
presented. The overall study sample size was 97. General data descriptive of the 
participants’ life-style factors in each of the study groups CG, ARG, and DAG are 
illustrated in table 5-5.  
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Table 5-5 Distributions of life-style factors among the participants in total and in each of the study 
groups 
Variable 
CG 
N=33 
ARG 
N=30 
DAG 
N=34 
Total 
N=97 
Gender  
Male (% total) 5 (15.2%) 3 (10%) 7 (20.6%) 15 (15.5%) 
Female (% total) 28 (84.8%) 27 (90%) 27 (79.4%) 82(84.5%) 
Age (years) 41.3 ± 6.6* 50.3 ± 6.6* 53.1 ± 6.8* 48.2 ± 8.4* 
Education level  
Illiterate 1 (3 %) 4 (13.3 %) 3 (8.8 %) 8 (8.2 %) 
Primary 3 (9.1 %) 5 (16.7 %) 10 (29.4 %) 18 (18.6 %) 
Secondary 1 (3 %) 10 (33.3 %) 5 (14.7 %) 16 (16.5 %) 
High school 5 (15.2 %) 4 (13.3 %) 2 (5.9 %) 11 (11.3 %) 
Diploma 2 (6.1 %) 1 (3.3 %) 5 (14.7 %) 8 (8.2 %) 
Bachelor 16 (48.5 %) 5 (16.7 %) 6 (17.6%) 27 (27.8 %) 
Postgraduate 5 (15.2 %) 1 (3.3 %) 3 (8.8 %) 9 (9.3 %) 
Occupation  
Education 7 (21.2 %) 5 (16.7 %) 8 (23.5 %) 20 (20.6 %) 
Health care 12 (36.4 %) 1 (3.3 %) 2 (5.9 %) 15 (15.5 %) 
Public sector 3 (9.1 %) 0 (0 %) 0 (0 %) 3 (3.1 %) 
Private sector 0 (0 %) 2 (6.7 %) 3 (8.8 %) 5 (5.2 %) 
Housewife 10 (30.3 %) 22 (73.3 %) 18 (52.9) 50 (51.5 %) 
Retired 1 (3 %) 0 (0 %) 3 (8.8 %) 4 (4.1 %) 
Income by SR  
Less than 5000 5 (15.2 %) 17 (56.7 %) 16 (47.1 %) 38 (39.2 %) 
5000-10000 9 (27.3 %) 3 (10 %) 6 (17.6 %) 18 (18.6 %) 
10000-15000 6 (18.2 %) 5 (16.7 %) 2 (5.9 %) 13 (13.4 %) 
15000-20000 7 (21.2 %) 4 (13.3 %) 3 (8.8 %) 14 (14.4 %) 
>20000 6 (18.2 %) 1 (3.3%) 7 (20.6 %) 14 (14.4 %) 
Number of family 
members 
4.7 ± 2.2 * 4.6 ± 2.5 * 4 ± 2.9 * 4.4 ± 2.6 * 
Smoking status  
Smokers 12 (36.4 %) 1 (3.3 %) 3 (8.8 %) 16 (16.5 %) 
Used to smoke 0 (0 %) 0 (0 %) 4 (11.8 %) 4 (4.1 %) 
Non-smokers 21 (63.6 %) 29 (96.7) 72 (79.4 %) 77 (79.4 %) 
BMI (kg/m2) 30.6 ± 6.9* 32.1 ± 4.6* 33 ± 5.87* 31.9 ± 5.9* 
WHR (cm) 0.85 ± 0.08* 0.95 ± 0.08* 0.93 ± 0.15* 0.91 ± 0.12* 
Categorical data are calculated as count (% total) 
* = Scale data are calculated as mean ± standard deviation (SD) 
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5.4.1. Association between gender and vitamin D level 
Data on gender included male n=15 and female n=82 of a total sample n=97 as 
illustrated in table 5-5 and figure 5-1. To examine the difference between male and 
female in 25(OH)D concentrations a Mann-Whitney test was performed and revealed 
no significant gender effect (P=0.299) as discussed in section 4.5.1.2. and shown in 
table 5-6. A box and whiskers plot of gender and 25(OH)D concentrations was 
illustrated in section 4.5.1.2. figure 4-7.   
 
Figure 5-1 Distribution of gender among the participants. Data shown in relative percentage (to the 
whole sample). 
Table 5-6 Mean rank of 25(OH)D concentrations ng/mL among sexes. 
 Gender N Mean Rank Sum of Ranks 
25 (OH)D Male 15 42.07 631.00 
Female 82 50.27 4122.00 
Total 97   
 
5.4.2. Association between age and 25(OH)D concentrations 
Data on age were scale data. The participants (n=97) ranged in age between 35 to 60 
years with mean 48.22 ± 8.367 years (Table 5-5). Figure 5-2 shows the age 
distribution of the participants. Table 5-5 illustrate the mean of age among the 
pooled sample and the clinical groups. Running a Kruskal-Wallis test, age was 
significantly different between the study groups (χ2 (2) =35.48, P<0.0001) (table 5-7). 
Running a post-hoc Mann-Whitney, the difference was found to be significant 
15%
85%
Gender
Male Female
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between the CG vs DAG (U=135, P<0.0001) and between CG vs ARG (U=163, 
P<0.0001). Figure 5-3 shows a box and whiskers plot of age in the study groups. 
Additionally, there was a significant differences in age between participants who take 
vitamin D supplements and who do not (U=618, P=0.002) as it is shown in the box 
and whiskers plot (figure 5-3). 
 
Figure 5-2Distribution of age among the participants in the pooled sample 
 
 
 
Figure 5-3 A box and whiskers plot of age among the study groups and the consumption of vitamin D 
supplements. Data shows medians, interquartile range, whiskers and outliers. ** Indicates significant 
between group differences (P<0.01).  
 
Table 5-7 Mean ranks of age among the study groups 
 Category N Mean Rank 
age DAG 34 65.56 
ARG 30 55.50 
CG 33 26.03 
Total 97  
** 
** ** 
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Whilst age was statistically correlated to 25(OH)D (rho=0.29, P=0.0001, R2=0.08) as 
illustrated in table 5-8, the strength of this relationship is considered weak (table 4-
1). That analysis indicates that as the participants aged they were more likely to take 
vitamin D supplements and they had better 25(OH)D status. A scatter plot of the 
relationship between 25(OH)D and age is illustrated in figure 5-4.  
 
Table 5-8 Spearman’s rho correlation between 25(OH)D (ng/mL) and age (years) 
 age 
Spearman's rho 25 (OH)D Correlation Coefficient 0.291** 
Sig. (1-tailed) 0.002 
N 97 
**. Correlation is significant at the 0.01 level (1-tailed). 
 
 
Figure 5-4 X-Y Scatter graph of 25(OH)D (ng/mL) and age (years) 
5.4.3. Impact of education level on vitamin D level 
There were seven levels of education in the current study, ranging from illiterate to 
postgraduate (figure 5-5). A Kruskal-Wallis test revealed no main effect of education 
on 25(OH)D levels (P= 0.165). Table 5-9 shows the mean rank of vitamin D on the 
seven levels of education. Figure 5-6 illustrate the box and whiskers plot for 
education level and 25(OH)D. 
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Figure 5-5 Illustration of the percentile per education level. Distribution was non-normal. 
 
Table 5-9 Mean Rank of vitamin D among education level 
 education level N Mean Rank 
25 (OH)D Illiterate 8 71.75 
Primary 18 37.69 
Secondary 16 52.03 
High School 11 42.86 
Diploma 8 53.75 
Bachelor 27 49.83 
Postgraduate 9 46.78 
Total 97  
 
8%
19%
17%
11%
8%
28%
9%
Education levels
Illiterate Primary Secondary High School
Diploma Bachelor Postgraduate
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Figure 5-6 A box and whiskers plot of education level and 25(OH)D concentrations (ng/mL). Data shows 
medians, interquartile range, whiskers and outliers.  
 
5.4.4. Occupation 
Data on occupation included six different jobs as distributed in figure 5-7.  The 
majority of the participants were housewives. Running a Kruskal-Wallis test revealed 
no difference in 25(OH)D status by occupation (P=0.488), mean ranks are illustrated 
in table 5-10. Figure 5-8 illustrate the box and whiskers plot for education level and 
25(OH)D.  
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Figure 5-7 Distribution of participant’s jobs. Distribution is not normal 
 
Table 5-10 Mean rank of 25(OH)D concentrations (ng/mL) by occupation 
 job N Mean Rank 
25 (OH)D Education 20 58.95 
Health 15 45.10 
Public sector 3 30.00 
Private sector 5 49.60 
Housewife 50 47.75 
Retired 4 43.00 
Total 97  
 
21%
15%
3%
5%
52%
4%
Occupation
Education Health Public sector Private sector Houswife Retired
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Figure 5-8 A box and whiskers plot for 25(OH)D concentrations (ng/mL) and occupations. Data shows 
medians, interquartile range, whiskers and outliers. 
5.4.5. Impact of socioeconomic status on 25(OH)D level 
Data on socioeconomic status includes five levels of income and the number of family 
members who are benefiting from the income. Figure 5-9 illustrates the distribution 
of family income among the participants. The number of family members benefiting 
from the income ranged 1 to 13 (minimum to maximum). Also notable, that income 
normalised for the number of family members ranged 3.913 to 4.962. It is interesting 
that there was a significant positive correlation between the number of family 
members and income (rho=0.24, P=0.009) (Table 5-11).  
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Figure 5-9 Distribution of income among the participants. Data shown in relative percentage (to the 
whole sample) 
 
Table 5-11 Spearman’s correlations between 25(OH)D and family mean income, number of family 
members, and normalised income by family size. 
 25 (OH)D Mean 
income 
N of 
family 
members 
income / 
family size 
S
p
e
a
rm
a
n
's
 r
h
o
 
25 (OH)D Correlation Coefficient 1.000 0.016 -0.146 0.062 
Sig. (1-tailed) . 0.439 0.076 0.275 
N 97 97 97 97 
Mean 
income 
Correlation Coefficient  1.000 0.240** 0.814** 
Sig. (1-tailed)  . 0.009 0.000 
N  97 97 97 
number 
of family 
members 
Correlation Coefficient   1.000 -0.321** 
Sig. (1-tailed)   . 0.001 
N   97 097 
Income / 
family 
size 
Correlation Coefficient    1.000 
Sig. (1-tailed)    . 
N    97 
**. Correlation is significant at the 0.01 level (1-tailed). 
39%
19%
13%
15%
14%
Range of Income
less than 5000 5000 to 10000 10000 to 15000 15000 to 20000 20000 and above
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The mean ranks of 25 (OH) D by socio-economic status are presented in table 5-12 
below. A Kruskal-Wallis test revealed no significant difference between overall 
income and 25(OH)D level (P=0.77). Similarly, a Spearman's rho showed no significant 
correlation between income normalised for number of family members and 25(OH)D 
level (P=0.275) (Table 5-11). In other words, there is no statistical difference or 
correlation in 25(OH)D level by socioeconomic status, whether accounted for as a 
total amount or normalised for number of dependant in the household. Figure 5-10 
and figure 5-11 illustrate the box and whiskers plot for income and number of family 
members and 25(OH)D.  
Table 5-12 Mean rank of 25(OH)D by income (SR) 
 income N Mean Rank 
25 (OH)D less than 5000 38 46.88 
5000 to 10000 18 53.36 
10000 to 15000 13 49.23 
15000 to 20000 14 54.61 
20000 and above 14 43.32 
Total 97  
 
  
Figure 5-10 Box and whiskers plot for income (SR) and 25(OH)D concentrations (ng/mL). Data shows 
medians, interquartile range, whiskers and outliers.  
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Figure 5-11 Box and whiskers plot for number of family members and 25(OH)D concentrations (ng/mL). 
Data shows medians, interquartile range, whiskers and outliers.  
 
5.4.6. Impact of Smoking on 25(OH)D level 
There were three questions related to smoking status. The questions enquired about 
current smoking status, previous history of smoking, amount of smoking (i.e. as they 
define the amount of daily smoking events), and type of smoking implement.  
In terms of the current smoking status, there were only 15 smokers, 4 used to be 
smokers and the majority of the participants 78 were non-smokers (Figure 5-12). In 
order to explore the impact of smoking status on 25(OH)D concentrations, a Kruskal 
Wallis was run with three levels (current smokers’ vs previous smokers, who have 
stopped, vs no-smoking history participants). Consequently, analysis showed no main 
effect of smoking status on 25(OH)D level (P=0.721). Mean ranks were presented in 
table 5-13. Figure 5-13 shows a box and whiskers plot of smoking status and 25(OH)D.  
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Figure 5-12 Smoking status among the participant. Distribution is not normal. 
 
 
Figure 5-13 A box and whiskers plot for smoking status and 25(OH)D (ng/mL). Data shows medians, 
interquartile range, whiskers and outliers. 
 
Table 5-13 Mean rank of 25(OH)D among participants smoking status 
 Smoking status N Mean Rank 
25 (OH)D Smoker 15 45.47 
Used to be smoker 4 41.25 
Non-Smoker 78 50.08 
Total 97  
The second question in this category was aimed at both current smokers and 
participants with a history of smoking, asking them to define their smoking quantity 
from four levels. Only 20 participants fitted this category. The mean rank of vitamin 
16%
4%
80%
Smoking status
Smoker Used to be smoker Non-Smoker
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D level are illustrated below (Table 5-14). However, any apparent difference was 
found to not be statistically significant through a Kruskal-Wallis test (P= 0.06). A box 
and whiskers plot of smoking habits and 25(OH)D is shown in figure 5-16. 
Table 5-14 Mean rank of 25(OH)D among smoking habits 
 smoke habits N Mean Rank 
25 (OH)D Heavy smoker 5 9.40 
Moderate smoker 6 13.00 
light smoker 5 5.20 
Rarely smoke 4 14.75 
Total 20  
 
 
Figure 5-14 A box and whiskers plot of smoking habits and 25(OH)D levels (ng/mL). Data shows 
medians, interquartile range, whiskers and outliers. 
The last question in the smoking section related to the type of smoking apparatus 
participants had used, with four possible levels. The mean rank of vitamin D level was 
11.33 for Cigarettes smokers, 10.31 for Hookah smokers, 10.50 for Shisha smokers 
(none of the participants was using/had used electronic cigarettes) (Table 5-15). A 
box and whiskers plot of smoking types and 25(OH)D is illustrated in figure 5-15.  A 
Kruskal-Wallis test showed no main effect of type of smoking implement on 25(OH)D 
level (P=0.964). There was no significant association between smoking and vitamin D 
level in the current study.  
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Table 5-15 Mean rank of 25(OH)D among types of smoking 
 Type smoke N Mean Rank 
25 (OH)D Cigarettes 3 11.33 
Hookah 13 10.31 
Shisha 4 10.50 
Total 20  
 
 
Figure 5-15 A box and whiskers plot of type of smoking and 25(OH)D. Data shows medians, 
interquartile range, whiskers and outliers.  
 
5.4.7. Impact of Anthropometric measurements (BMI & WHR) on 25(OH)D 
Data on anthropometric measurements n=97 included two categories BMI and WHR. 
Calculation of BMI from height and weight is described in detail in section 5.2.7. For 
BMI values < 18.5 are underweight, 18.5-24.9 are healthy weight, 25-29.9 are 
overweight, and >30 kg/m2 are obese (Table 5-3).  The BMI of the entire group (97) 
was 31.93 ± 5.96kg/m2 which falls within the obese range however, segregation of 
the participants according to gender shows that the female participants bias the data 
because their BMI is 32.38 ± 5.86kg/m2 (table 5-5) which indicates obesity whilst the 
male participants, BMI 29.4 ± 6.01kg/m2 are generally classed as overweight (Table 
5-16). The overall minimum BMI value was 18.00 and the maximum was 49.1 kg/m2.  
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Figure 5-16 Distribution of BMI (kg/m2) values and frequency under BMI categories among the 
participants 
Table 5-16 Descriptive analysis of BMI (kg/m2) in the pooled sample and in sub-group 
 N Mean ± SD Median (IQR) Mean Rank 
CG 33 30.61 ± 6.96 30.63 (11.4) 44.42 
ARG 30 32.13 ± 4.61 31.57 (6.4) 49.63 
DAG 34 33.02 ± 5.87 32.02 (7.3) 52.88 
Male 15 29.42 ± 6.01 29.04 (4.9) 34.67 
Female 82 32.38 ± 5.86 32.84 (7.8) 51.62 
Total 97 31.92 ± 5.95 31.84 (7.6)  
 
There was no difference in BMI between the study groups CG, ARG, and DAG when 
running a Kruskal-Wallis test (P=0.46) (Table 5-16). However, there was a significant 
difference between male and female in BMI when running a Mann-Whitney test 
(U=400, P=0.03) (Table 5-16). Box and whiskers plots of BMI among the clinical 
groups and gender are illustrated in figure 5-17 and 5-18. There was no spearman's 
rho correlation between BMI and 25(OH)D (P=0.47) (Table 5-18). Figure 5-19 
represents the scatter diagrams of the lack of any relationship between 25(OH)D and 
BMI. 
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Figure 5-17 A box and whiskers plot for BMI 
(kg/m2) and Gender. Data shows medians, 
interquartile range, whiskers and outliers. * 
Indicates significant difference between groups 
(P<0.05). 
 
Figure 5-18 A  box and whiskers plot for BMI 
(kg/m2) and study groups. Data shows medians, 
interquartile range, whiskers and outliers. 
 
 
Figure 5-19 X-Y Scatter graph of 25(OH)D (ng/mL) against BMI (kg/m2). 
The second category of anthropometric measurements was WHR. Results were 
calculated from the measurement of waist and hip circumference as was explained 
in section 5.2.7. Results were considered to show normal body adipose if the WHR 
≤0.90 for males and ≤ 0.80 for females, high adipose between 0.90-0.99 for males 
and 0.80-0.84 for females, morbidly adipose ≥1.00 for males and ≥0.85 for females 
(Table 5-4 and Figure 5-20). The mean WHR for males was 0.947 ± 0.069 cm, which 
indicates high body adipose levels. The female participants’ mean WHR was 0.903 ± 
0.112 cm, which is considered morbidly adipose (table 5-17). Mann-Whitney test 
revealed a significant difference between male and female in WHR (U=412, P=0.043) 
as shown in the box and whiskers plot in (Figure 5-21). Moreover, the Kruskal-Wallis 
* 
116 
 
test indicates a significant difference in WHR between the clinical groups (χ2 (2) 
=19.38, P<0.0001). Post-hoc Mann-Whitney tests showed that the significant 
difference were between CG vs ARG (U=169, P<0.0001) and CG vs DAG (U=344, 
P=0.006) as shown in the box and whiskers plot in figure 5-22.  
  
Figure 5-20 Distribution of WHR values (cm) and frequency under WHR categories among the 
participants 
  
Table 5-17 Descriptive analysis of WHR (cm) in the pooled sample and in sub-group 
 N Mean ± SD Median (IQR) Mean Rank 
CG 33 0.852 ± 0.085 0.849 (0.12) 32.55 
ARG 30 0.951 ± 0.083 0.937 (0.08) 63.15 
DAG 34 0.939 ± 0.150 0.922 (0.15) 52.49 
Male 15 0.947 ± 0.069 0.925 (0.11) 62.53 
Female 82 0.907 ± 0.126 0.892 (0.13) 46.52 
Total 97 0.913 ± 0.119 0.906 (0.12)  
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Figure 5-21 A box and whiskers plot for WHR and 
Gender. Data shows medians, interquartile 
range, whiskers and outliers. * Indicates 
significant between group differences (P<0.05). 
 
Figure 5-22 A box and whiskers plot for WHR 
and study groups. Data shows medians, 
interquartile range, whiskers and outliers. ** 
Indicates significant between group differences 
(P<0.01). 
A spearman’s rho correlation indicate no significant relation between WHR and 
25(OH)D. A simple scatter plot between WHR and 25(OH)D illustrates the lack of 
relationship between the two variables in the pooled sample (Figure 5-23) For 
additional investigation, the correlation between WHR and age was tested and 
found to be significant (rho=0.29, P=0.002) table 5-18.   
Table 5-18 Spearman’s correlations between 25(OH)D (ng/mL), BMI (kg/m2), and WHR (cm) 
 25 (OH)D BMI WHR 
Spearman
's rho 
25 
(OH)D 
Correlation 
Coefficient 
1.000 0.017 0.134 
Sig. (1-tailed) . 0.434 0.095 
N 97 97 97 
BMI Correlation 
Coefficient 
 1.000 -0.026 
Sig. (1-tailed)  . 0.402 
N  97 97 
WHR Correlation 
Coefficient 
  1.000 
Sig. (1-tailed)   . 
N   97 
* ** 
** 
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Figure 5-23 X-Y Scatter graph of 25(OH)D (ng/mL) and WHR (mm). 
 
5.4.8 The chapter correlation and regression model 
Serum 25(OH)D concentration was only significantly correlated with age out of all of 
the potential modulating life style factors (table 5-20). The strength of the 
correlation, R2, was 0.08, which is considered weak. Table 5-20 represent all of the 
chapter non-parametric correlations between all the chapter variables.  
To create a composite model predictor of serum 25(OH)D levels, a multiple linear 
regression model was performed. The stable model in chapter 4 of the current study 
incorporated the use of vitamin D supplements and dietary intake of vitamin D (DI-
VitD). Since age was the only modulator that was significantly correlated to 25(OH)D 
in this chapter, a model was designed which included those three modulators (Table 
5-19). The model was statistically significant (P<0.0001) and explains 40.1% of the 
variance of 25(OH)D concentrations. The model was statistically powerful due to the 
low shrinkage of R (Adjusted R2= 0.382). However, in further analysis the model was 
unstable because age was a non-significant contributor (age P=0.389). Age will 
therefore not be added to the final regression model in chapter 8 of the study. 
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Table 5-19 Unstable model predictor of serum 25(OH)D 
Coefficientsa 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
B Std. 
Error 
Beta 
1 (Constant) 47.732 8.999  5.304 0.000 
Take vitamin D 
supplements 
-16.928 2.443 -0.585 -
6.930 
0.000 
Dietary vitamin D 
intake IU 
-0.020 0.008 -0.193 -
2.406 
0.018 
age 0.117 0.136 0.073 0.865 0.389 
a. Dependent Variable: 25 (OH)D 
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Table 5-20 Spearman’s correlation and analysis of the chapter measurements 
 25 
(OH)D 
Gender age education 
level 
Mean 
Income 
family 
membe
rs 
Income
/ family 
size 
BMI WHR 
Sp
ea
rm
an
's
 r
h
o
 
2
5
 (
O
H
)D
 
Correlation Coefficient 1.000 0.106 0.291** -0.031 0.016 -0.146 0.062 0.017 0.134 
Sig. (1-tailed) . 0.151 0.002 0.382 0.439 0.076 0.275 0.434 0.095 
N 97 97 97 97 97 97 97 97 97 
G
en
d
er
 Correlation Coefficient  1.000 0.008 -0.101 -0.014 -0.144 0.050 0.219* -0.207* 
Sig. (1-tailed)  . 0.470 0.162 0.447 0.080 0.315 0.016 0.021 
N  97 97 97 97 97 97 97 97 
ag
e
 Correlation Coefficient   1.000 -0.296
** -0.175* -0.209* -0.092 -0.010 0.295** 
Sig. (1-tailed)   . 0.002 0.044 0.020 0.184 0.462 0.002 
N   97 97 97 97 97 97 97 
ed
u
ca
ti
o
n
 
le
ve
l Correlation Coefficient    1.000 0.622
** 0.205* 0.474** -0.106 -0.124 
Sig. (1-tailed)    . 0.000 0.022 0.000 0.150 0.114 
N    97 97 97 97 97 97 
M
ea
n
 
In
co
m
e
 Correlation Coefficient     1.000 0.240** 0.814** -0.110 -0.160 
Sig. (1-tailed)     . 0.009 0.000 0.141 0.059 
N     97 97 97 97 97 
n
u
m
b
er
 o
f 
fa
m
ily
 
m
e
m
b
er
s Correlation Coefficient      1.000 -0.321
** -0.215* -0.074 
Sig. (1-tailed)      . 0.001 0.017 0.236 
N 
 
     97 97 97 97 
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N
o
rm
al
is
e
d
 in
co
m
e 
b
y 
fa
m
ily
 
si
ze
 Correlation Coefficient       1.000 -0.013 -0.074 
Sig. (1-tailed)       . 0.451 0.235 
N       97 97 97 
B
M
I 
Correlation Coefficient        1.000 -0.026 
Sig. (1-tailed)        . 0.402 
N        97 97 
W
H
R
 Correlation Coefficient         1.000 
Sig. (1-tailed)         . 
N         97 
*. Correlation is significant at the 0.05 level (1-tailed). 
**. Correlation is significant at the 0.01 level (1-tailed). 
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5.5. Discussion 
This chapter is a general descriptive chapter of the lifestyle factors that could have 
an effect on vitamin D and atherosclerosis status. The factors proposed initially 
included gender, age, education level, occupation, socioeconomic status, smoking, 
BMI, and WHR.    
The majority of the participants in the current study were female n=82 compared to 
15 males. The initial target was to have the same number of participants of each sex 
however, males were not as cooperative in participating in the study as females. It 
was observed that men were not comfortable to participate in the study because the 
researcher conducting the data collection was female. Additionally, the majority of 
the male participants were invited through the first recruitment approach, which was 
during their routine visit to the cardiovascular clinic at the hospital. Few were 
approached as they were local hospital staff and/or relatives who had attended the 
hospital with patients as companions. None of the male participants who 
participated in the study were recruited through the third recruitment approach, 
which was a text message sent to hospital patients, asking them to participate if they 
fitted the criteria. There was no difference between the sexes in 25(OH)D 
concentration. Studies have suggested that there is no physical difference between 
sexes in synthesising vitamin D (Giovannucci, 2009; Holick et al., 2011).  
One of the main factors that is commonly associated with vitamin D status is age 
(Holick et al., 2011). In the current study, there was a positive correlation between 
age and 25(OH)D concentrations (rho=0.291, P=0.002), which conflicts with what has 
been proposed in the literature (Arain et al., 2015). This correlation was no longer 
apparent when only the participants who were not taking vitamin D supplements 
were considered (P=0.055). Participants who were taking vitamin D supplements 
(52.07 ± 7.67 years) tended to be significantly older than those who were not taking 
them (46.49 ± 8.14 years) (U=618, P<0.01). Additionally, those participant were 
mainly from the ARG and DAG who were mostly recommended to take vitamin D 
supplements by their physician, which make them tend to have higher values of 
25(OH)D. The reverse association between age and 25(OH)D levels when vitamin D 
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supplements were consumed was also observed in previous studies which lends to 
further support to the current study’s findings (Lertratanakul et al., 2014; Degerud, 
2016).  
The participants were from all educational backgrounds, economic status, and doing 
different jobs. All of these potential covariates showed no effect on circulating 
25(OH)D concentrations in the current study. Additionally, smoking habits were 
examined as a status, frequency of smoking, and the method of smoking used. None 
of these showed a relationship with 25(OH)D concentrations ether. Previous studies 
have had similar observations whereby there was no association between these 
lifestyle factors and vitamin D status (Ardawi et al., 2011; Shirazi et al., 2013), 
opposed to other studies that did observe such associations (Azhar, 2009; Kilkkinen 
et al., 2009). In the study by Kilkkinen et al. (2009) high concentrations of 25(OH)D 
were associated with older, and highly educated participants, whereas heavy 
smoking was associated with low concentrations of 25(OH)D. The associations were 
obvious with vitamin D status probably because of the large number of participants 
(n=6219) which gave greater accuracy to their results. Moreover, the study by Azhar 
observed associations only between type of job and smoking status with 25(OH)D 
levels. However, the study also had slightly larger number of participants (n=118) 
than the current study and they were all healthy participants. The health condition 
of participants definitely had an impact on the results, which could be one of the 
explanations for the absence of an association between these factors and 25(OH)D 
concentration in the current study.   
Anthropometric measurements indicated that the majority of the participants 
(63.9%) were obese (25.8%) were overweight (8.1%) had healthy weight and the rest 
were under weight. According to the BMI measurements. Similarly, the WHR 
indicated that (57.7%) of the participants were morbidly adipose and (22.7%) were 
high adipose and the rest were normal adipose. These data highlight the huge issue 
of obesity among the Saudi dwellers as addressed in the literature review (Ardawi et 
al., 2012; Aljefree et al., 2016). In the current study, significant correlations between 
anthropometric measurements and 25(OH)D concentration were not observed. Also, 
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worryingly, obesity and vitamin D deficiency were both apparent in the study. 
Vitamin D tends to be deposited in the adipose tissues in the body which decreases 
the bioavailability of the vitamin (Holick and Chen, 2008; Ardawi et al., 2011).  
Anthropometric measurements showed significant differences between sexes and 
clinical groups. Female participants had significantly higher BMI than males (P<0.05). 
Conversely, females had a significantly lower WHR than males (P<0.05) which 
indicates less abdominal obesity in the female than in the males. On the other hand, 
the WHR variation was obvious between the clinical groups (P<0.0001). The control 
group (CG) had the lowest WHR, then the diagnosed with atherosclerosis group 
(DAG) (U=344, P<0.01), and then the at-risk group (ARG) (U=169, P<0.0001). This 
indicates an association between abdominal obesity and the incidence and 
development of atherosclerosis.  
5.5.1. Multiple linear regression model 
The multiple linear regression model suggested that age is a non-significant 
contributor (P=0.389) when added to the stable model from chapter 4. Therefore, 
the stable model from chapter 4 that includes the usage of vitamin D supplements 
and dietary intake of vitamin D, is the stable model, so far, for predicting 25(OH)D 
serum concentration.  
5.6. Summary and conclusion  
None of the lifestyle factors examined in the current study was associated with 
circulating 25(OH)D concentration. Only age was, in fact, positively associated with 
25(OH)D concentration. However, this effect was a result of increased vitamin D 
supplement use with greater age.  Obesity was prevalent in the current study sample 
of Saudi dwellers and was associated with the participants’ clinical conditions. In 
conclusion, the current study suggests that gender, education level, occupation, 
socioeconomic status, smoking, BMI, and WHR are not indicators of vitamin D status. 
In addition, age also was not a good indicator of vitamin D status after accounting for 
vitamin D supplement usage.  
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Chapter 6 - Association between circulating 25(OH)D 
levels and other blood markers of health 
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6.1. Introduction  
A review of the literature indicates a potential relationship between vitamin D status, 
atherosclerosis risk factors, such as having hyperglycaemia and/or hyperlipidaemia, 
and inflammatory markers such as high concentrations of C-reactive protein (CRP) 
(Menezes et al., 2014; Faridi et al., 2017). Within this chapter, an investigation of 
these associations is presented. Experimental work includes the measurement and 
analysis of markers such as C-reactive protein (CRP), fasting blood glucose (FBG), 
total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), 
and triglycerides (TG) as indicators of the markers discussed above. The relationships 
between these markers were investigated in the pooled study sample, and in each of 
the clinical groups (control group (CG), at-risk group (ARG), and participants 
diagnosed with atherosclerosis group (DAG)). The consumption of vitamin D 
supplements was considered when investigating the relationships. Other factors 
such as gender, consumption of related medications, and diseases were also taken 
into account in the analysis.  
6.1.1. Chapter aim  
The chapter aims to investigate the association between vitamin D status and the 
biochemical parameters.  
6.1.2. Chapter objectives: 
1- To assess each of the biochemical parameters (CRP, FBG, and lipids) in the 
pooled sample and in each of the study sub-groups. 
2- To investigate any association between the parameters monitored and the 
concentration of 25(OH)D in the pooled sample and in each of the study sub-
groups, considering general factors influencing the parameters. 
3- To elucidate any observable relationship between the monitored parameters. 
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6.2. Methods  
6.2.1. Measurement of high sensitivity C-reactive protein (CRP) 
CRP is a protein produced by the liver. It is present in human serum, and increases 
after most forms of tissue injury, bacterial and viral infections, inflammation and 
malignant neoplasia (van Wissen et al., 2002). In the current study, measurement of 
CRP in serum was carried out using an in vitro diagnostic reagent (Siemens BN II / BN 
ProSpect® system, Marburg, Germany) (Siemens, 2014). Polystyrene particles coated 
with monoclonal antibodies (goat IgG) specific to human CRP are aggregated when 
mixed with samples containing CRP. These aggregates scatter a beam of light passed 
through the sample. The intensity of the scattered light is proportional to the 
concentration of the relevant protein in the sample. The result is evaluated by 
comparison with a standard of known concentration (CV%= 3.1 to 5.8) (van Wissen 
et al., 2002; Siemens, 2014). Normal concentrations of CRP for adults are presented 
in table 6-1 (Ministry of Health Portal. 2016).  
Table 6-1 Normal ranges of blood parameters concentrations (Ministry of Health Portal. 2016) 
Test Normal Range unit 
High-sensitivity C-Reactive Protein (CRP) 0.0001 - 0.3 mg/dL 
Glucose (FBG) 70 -115 mg/dL 
Lipid Profile   
Cholesterol, Total (TC) 50 -200 mg/dL 
Triglycerides (TG) 30 -200 mg/dL 
HDL Cholesterol (HDL) 35 - 55 mg/dL 
LDL Cholesterol (LDL) 0.01< -150 mg/dL 
 
6.2.2. Measurement of fasting blood glucose (FBG) 
Fasting blood glucose concentration was determined using the hexokinase enzymatic 
reference method using a Roche Cobas c 501 analyser (Indianapolis, IN, USA) (Roche, 
2014b). Using 2µl of the participants’ serum sample, the hexokinase catalyses the 
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phosphorylation of glucose to glucose-6-phosphate by ATP. Then, glucose-6-
phosphate dehydrogenase oxidises glucose-6-phosphate in the presence of NADP to 
gluconate-6-phosphate. No other carbohydrate is oxidised. The rate of NADPH 
formation during the reaction is directly proportional to the glucose concentration 
and is measured by an automatic fluorescence analyser (CV%= 0.7 to 1.2) (Roche, 
2014b). The normal FBG concentrations for adults are shown in table 6-1(Ministry of 
Health Portal. 2016). 
6.2.3. Lipid profile 
Enzymatic methods were used to measure lipids including high-density lipoprotein 
(HDL-C), low-density lipoprotein (LDL-C), triglycerides (TG), and total cholesterol (TC). 
Optimal concentrations of lipids in adults are shown in table 6-1 (Ministry of Health 
Portal. 2016).  
6.2.3.1. Measurement of HDL and LDL cholesterol 
HDL and LDL cholesterol were measured using the Roche enzymatic colorimetric 
assay system (Roche c 501, Indianapolis, IN, USA). The concentrations of HDL-C and 
LDL-C were determined enzymatically using cholesterol esterase and cholesterol 
oxidase. Cholesterol esters are hydrolysed into free cholesterol and fatty acids by 
cholesterol esterase. In the presence of oxygen, cholesterol is oxidised by cholesterol 
oxidase to 4-cholestenone and hydrogen peroxide. In the presence of peroxidase, 
the generated hydrogen peroxide reacts with 4-amino-antipyrine and HSDA to form 
a purple-blue product. The colour intensity is directly proportional to the cholesterol 
concentration and was measured photometrically using the Cobas analyser e501. A 
volume of 2.5µl of serum was used to measure HDL-C and 2µl of serum for LDL-C. 
The control intervals for HDL-C were set as 23.7-32.5 mg/dL for the lower limit and 
53.2-73.6 mg/dL for the upper limit using PreciControl ClinChem Multi 1 and 2 (CV%= 
0.4 to 1.0). The control intervals for LDL-C were set as 44.6-61.4 mg/dL for the lower 
limit and 80.3-110.7 mg/dL for the upper limit, using PreciControl Multi 1 and 2 
respectively CV%= 0.9 to 2.1) (Roche, 2013a; Roche, 2014a) 
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6.2.3.2. Measurement of total cholesterol (TC) 
A Roche assay was used to measure TC (Roche c 501, Indianapolis, IN, USA). 
Cholesterol esters are cleaved by the action of cholesterol esterase to yield free 
cholesterol and fatty acids following the same method that was used when 
measuring HDL and LDL cholesterol. The colour intensity is directly proportional to 
the TC concentration. TC was determined by measuring the increase in absorbance 
using the Cobas e501 analyser. A volume of 2µl of serum was used and the control 
intervals set as 74.1-90.5 mg/dL for the lower limit and 155-191 mg/dL for the upper 
limit using PreciControl ClinChem Multi 1 and 2 (CV%= 0.8 to 1.9) (Roche, 2013b). 
6.2.3.3. Measurement of triglycerides (TG)   
TG were measured using a Roche assay (Roche c 501, Indianapolis, IN, USA) that uses 
a lipoprotein lipase for the rapid and complete hydrolysis of triglycerides to glycerol 
followed by oxidation to dihydroxyacetone phosphate and hydrogen peroxide. The 
hydrogen peroxide produced then reacts with 4-aminophenazone and 4-
chlorophenol under the catalytic action of peroxidase to form a red compound. The 
colour intensity of the red dye formed is directly proportional to the triglyceride 
concentration and can be measured automatically by the analyser. A sample size of 
2 µl was used and the control intervals set as 93-113 mg/dL for the lower limit and 
184-224 mg/dL for the upper limit using PreciControl ClinChem Multi 1 and 2 (CV%= 
1.6 to 1.9) (Roche, 2015b). 
6.2.4. Measurement of serum 25 (OH) D  
Measurement of 25(OH)D was accomplished using an electrochemiluminescence 
binding assay. Details of the measurements are provided in section 4.3.1. of the 
current study.  
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6.3. Statistical analysis of the data 
Statistical analysis was performed using SPSS v24 (Inc., Chicago, IL, USA). Data were 
tested for normal distribution using the Kolgomorov-Smirnov test. In addition, 
homogeneity of variance was assessed using the Levene’s test. Descriptive analysis 
are presented as mean ± standard deviation, median (interquartile range), and mean 
rank. In the current chapter, none of the outcome measures was normally 
distributed. As such, the data was deemed suitable for analysis using non-parametric 
tests. Therefore, categorical data were analysed using a Kruskal-Wallis test and/or a 
Mann-Whitney U test (as appropriate for the number of comparisons) to examine 
the mean differences between the groups. Thus, the Kruskal-Wallis test with 
appropriate post-hoc Mann-Whitney tests, were carried out to test the data for mean 
differences between more than two groups. The Mann-Whitney test was performed 
for simple pairwise comparisons. Box and whiskers plots were used to illustrate 
medians, interquartile range, whiskers, outliers, and indicate significant between 
group differences.  
On the other hand, where data was continuous rather than grouped, a Spearman rho 
correlation analysis was carried out to examine associations. Furthermore, 
multinomial logistic regression was applied to further describe a comprehensive 
model predictor of 25(OH)D using the specified blood markers when significant 
association was observed. Throughout, statistical significance was set at p ≤ 0.05.  
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6.4. Results 
In this section blood markers of health including:-  C-reactive protein (CRP) , fasting 
blood glucose (FBG), total cholesterol (TC), high-density lipoprotein (HDL), low-
density lipoprotein (LDL), and triglycerides (TG) are explored. The overall study 
sample size was 97. As in the previous chapters, data were analysed as a pooled 
sample and as sub-groups. The first sub-group was, the clinical groups (control group 
(CG), at risk group (ARG), and diagnosed with atherosclerosis group (DAG)). The 
second sub-group was gender (male, female). The third sub-group was the 
consumption of vitamin D supplements groups (consume vitamin D supplements, do 
not consume vitamin D supplements). Some blood parameters can be directly 
affected by other factors, such as the use of hypoglycaemic agents or statins. Data is 
presented based on the usage of those factors . Table 6-2 shows statistical mean and 
standard deviation of the study blood markers within each of the clinical groups and 
the pooled study sample. 
Table 6-2 Descriptive statistic of the chapter parameters in each of the clinical groups and in the pooled 
sample. Data were presented as mean ± standard deviation. Parameters are 25-hydroxi vitamin D 
(24(OH)D), C-reactive protein (CRP) , fasting blood glucose (FBG), total cholesterol (TC), high-density 
lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides (TG) 
Biochemical 
parameters 
CG 
N=33 
ARG 
N=30 
DAG 
N=34 
Total 
N=97 
25(OH)D 
(ng/mL) 
18.50 ± 10.31 23.91 ± 14.85 18.26 ± 14.57 20.09 ± 13.44 
CRP 
(mg/dL) 
0.479 ± 0.804 0.837 ± 0.804 0.626 ± 1.520 0.641 ± 1.052 
FBG 
(mg/dL) 
89.73 ± 9.139 177.60 ± 68.93 133.71 ± 51.73 132.11 ± 60.25 
TC 
(mg/dL) 
196.76 ± 31.66 183.27 ± 42.60 182.88 ± 44.01 187.72 ± 39.88 
HDL 
(mg/dL) 
48.00 ± 12.80 44.23 ± 11.83 48.35 ± 16.87 46.71 ±13.06 
LDL 
(mg/dL) 
129.48 ± 27.85 109.70 ±38.44 107.35 ± 35.52 115.60 ± 35.21 
TG 
(mg/dL) 
108.70 ± 62.83 182.37 ± 114.02 161.03 ± 88.81 149.82 ± 94.40 
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6.4.1. Analysis of C-reactive protein (CRP) 
6.4.1.1. Descriptive analysis of CRP in the pooled sample and between sub-groups  
Measurement of CRP provided continuous data for the 97 participants. The minimum 
value was 0.0001 mg/dL and the maximum value was 8.55 mg/dL. 41.2% of the 
participants had normal concentrations of CRP (mean ± SD) (0.007 ± 0.047 mg/dL), 
whereas the rest 58.8% had high concentrations (1.086 ± 1.186 mg/dL). Normal 
values of CRP are ≥0.0001 and ≤0.3 mg/dL (table 6-1). Table 6-3 illustrates descriptive 
analysis of CRP based on the clinical groups and on gender. There were three outlier 
values above 2.00 mg/dL (i.e. 2.87, 4.00, 8.55 mg/dl). Table 6-4 shows CRP values 
without outliers n= 94. Figure 6-1 shows the distribution of the sample without CRP 
outliers. The results were reviewed for validation. None of the participants who had 
outliers’ values in CRP had outliers in the rest of the blood markers. This appear to 
indicate that these outliers are simply related to the CRP data and have no common 
feature.   
  
Figure 6-1 Histograms of CRP (mg/dL) frequent among the whole sample and in clinical groups. A figure 
include the whole sample and B without the outliers. Normal range is shown between the dotted lines. 
Normal 
High levels 
B A 
Normal  
High levels 
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Figure 6-2 Distribution of CRP concentration among the study clinical groups 
 
Table 6-3 Descriptive statistic for CRP (mg/dL) among the pooled sample, clinical groups and gender 
 N Mean ± SD Median (IQR) Mean Rank 
CG 33 0.479 ± 0.533 0.389 (0.99) 41.75 
ARG 30 0.837 ± 0.804 0.542 (0.97) 60.27 
DAG 34 0.626 ± 1.52 0.000 (0.73) 41.75 
Male 15 0.444 ± 0.518 0.356 (0.96) 44.73 
Female 82 0.677 ± 1.121 0.423 (1.003) 49.78 
Total 97 0.641 ± 1.052 0.418 (0.97)  
 
Table 6-4 Descriptive statistic for CRP without outliers (mg/dl) among the pooled sample, clinical 
groups and gender 
 N Mean ± SD Median (IQR) Mean Rank 
CG 33 0.47 ± 0.53 0.38 (0.99) 46.23 
ARG 29 0.73 ± 0.52 0.51 (0.89) 59.03 
DAG 32 0.31 ± 0.41 0.00 (0.69) 38.36 
Male 15 0.44 ± 0.52 0.356 (0.96) 44.73 
Female 79 0.51 ± 0.53 0.41 (0.94) 48.03 
Total 94 0.49 ± 0.52 0.41 (0.94)  
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6.4.1.2. CRP concentration and the differences between sub-groups  
To investigate the differences between the sub-groups in their CRP concentrations a 
series of statistical tests were performed. A Kruskal-Wallis test indicates a significant 
difference in CRP among the clinical groups (χ2 (2) =7.89, P=0.019)). A post Hoc 
analysis revealed this main effect to be due to the differences between CG vs ARG 
(U=346, P=0.037) and, ARG vs DAG (U=321, P=0.009). Even after removing the three 
apparent outliers (χ2 (2) =9.53, P=0.009) the significant difference remained between 
CG vs ARG (U=346, P=0.057), and ARG vs DAG (U=262, P=0.003).  Figures 6-3 A and B 
shows the box and whiskers plot of CRP among the clinical groups, which revealed 
significant difference in the total sample and without the outliers. Additionally, to 
determine if there was a difference between the sexes in CRP status a Mann-Whitney 
test was performed and revealed no significant difference (P=0.509) even when after 
removing the outliers (P=0.657).  
  
Figure 6-3 A box and whiskers plot of CRP (mg/dL) among the clinical groups. Data shows medians, 
interquartile range, whiskers and outliers. A figure include the whole sample and B without the outliers 
Significant differences between groups indicated by (* = P<0.05) and (** = P<0.01). 
6.4.1.3. Correlations between CRP and 25(OH)D in the pooled sample and in sub-groups 
To examine the continuous relationship between CRP and the blood markers 
concentrations Spearman’s correlation tests were performed. There was no 
significant correlation between CRP and 25(OH)D (P=0.388) nor when outliers were 
removed (P= 0.458) (table 6-5). Scatter plots illustrate these relationships (or lack 
thereof) in figure 6-4 A and B, in the total sample and without the outliers. However, 
there was a statistically significant correlation between 25(OH)D and CRP in the ARG 
* 
* ** 
** 
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in the vitamin D supplements users only (rho=-0.666, P=0.009) (table 6-20). The 
remaining blood markers exhibited, there were statistically significant Spearman 
correlations between CRP and FBG (rho=0.046, P=0.046), and between CRP and TG 
concentration (rho=0.026, P=0.026) (table 6-19).  
Table 6-5 Spearman’s correlation between 25(OH)D ng/mL and CRP mg/dl with and without outliers  
 25 (OH)D 
Spearman's rho 25 (OH)D Correlation Coefficient 1.000 
Sig. (1-tailed) . 
N 97 
C reactive protein Correlation Coefficient 0.029 
Sig. (1-tailed) 0.388 
N 97 
CRP without outliers Correlation Coefficient 0.011 
Sig. (1-tailed) 0.458 
N 94 
 
  
Figure 6-4 X-Y Scatter graph of 25(OH)D (ng/mL) and CRP (mg/dL). A represent the total sample and B 
without outliers. 
6.4.2. Analysis of fasting blood glucose (FBG) 
6.4.2.1. Descriptive analysis of FBG in the pooled sample and between sub-groups  
Fasting blood glucose was measured in all 97 participants. The minimum 
concentration was 60 mg/dL and the maximum was 350 mg/dL. Normal 
B A 
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concentrations of FBG are between 70-115 mg/dL (table 6-1). The majority of the 
participants (55.7%) had normal FBG levels (mean ± SD) (93.70 ± 8.5), 43.3% high FBG 
levels (184.5 ± 63.5), and only 1% had low FBG levels (60 ± 0). Figure 6-5 illustrates 
the FBG concentrations among the clinical groups. Descriptive statistic of FBG 
concentrations in sub-groups among the participants under treatments 
(hypoglycaemic agent) are shown in table 6-6. In addition, tables 6-7 and 6-8 shows 
descriptive statistics and FBG concentration among the study clinical group and 
diabetic participants.   
  
Figure 6-5 Histograms of FBG concentrations (mg/dL) in the whole sample and among the clinical 
groups. The dotted line shows the cut off values for FBG.  
High Low 
Normal 
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Table 6-6 Descriptive statistic and mean ranks of FBG levels (mg/dL) among the clinical groups and sex 
considering the participants under medication 
 
Take 
hypoglycaemic 
agent 
N Mean ± SD Median (IQR) Mean Rank 
CG 
Yes 0 0 0 0 
No 33 89.73 ± 9.139 90 (12) 21.14 
Total 33 89.73 ± 9.139 90 (12) 22.29 
ARG 
Yes 26 189.88 ± 64.83 172.50 (115) 22.69 
No 4 92.75 ± 2.87 91.50 (5) 24.63 
Total 30 176.93 ± 68.93 156.0 (119) 70.43 
DAG 
Yes 14 157.79 ± 63.15 136 (87) 16.43 
No 20 116.85 ± 34.54 103 (30) 42.85 
Total 34 133.71 ± 51.73 118.50 (49) 22.29 
Male 
Yes 4 180 ± 90.35 166.50 (170) 18.25 
No 11 110.27 ± 41.99 97 (15) 36.68 
Total 15 128.93 ± 63.52 101.00 (35) 47.03 
Female 
Yes 36 179.97 ± 67.12 158 (96) 20.75 
No 46 96.87 ± 18.55 93 (12) 27.64 
Total 82 132.70 ± 60.01 105.50 (59) 49.36 
Total  97 132.67 ± 62.029 104.00 (58)  
 
Table 6-7 Descriptive statistic of the FBG concentration (mg/dL) among the clinical groups 
FBG levels 
CG ARG DAG 
N Mean ± SD N Mean ± SD N Mean ± SD 
Low 1(3%) 60 ± 0 0 0 0 0 
Normal 32 (97%) 90 ± 7.53 6 (20%) 98.17 ± 8.77 16 (47.1%) 98.13 ± 8.18 
High 0 0 24 (80%) 197.5 ± 64.5 18 (52.9%) 167.2 ± 59.6 
FG concentration are Low <70 mg/dL, Normal 70≤115 mg/dL, high >115 mg/dL 
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Table 6-8 Descriptive statistic of FBG concentrations (mg/dL) among diabetic participants  
Diabetic 
status 
CG ARG DAG 
N Mean ± SD N Mean ± SD N Mean ± SD 
Diabetic 0 0 26 (86.7%) 190.6 ± 66.3 14 (41.2%) 160.2 ± 69.9 
Non-
diabetic 
33 (100%) 89.7 ± 9.1 4 (13.3%) 92.7 ± 2.9 20 (58.8%) 116.8 ± 34.5 
 
6.4.2.2. FBG concentration and the difference between sub-groups  
The difference in FBG concentrations within the sub-groups has been tested. Analysis 
showed significant differences in FBG between the clinical groups CG, ARG, and DAG 
using a Kruskal-Wallis test (χ2 (2) = 49.25, P<0.001), mean ranks are illustrated in table 
6-6. The significant difference were between CG, ARG (U=53, P<0.0001), CG, DAG 
(U=121.5, P<0.0001) and ARG, DAG (U=309, P=0.007). However, a Mann-Whitney 
test on FBG by sex revealed no significant difference (P=0.768). On the other hand, a 
Mann-Whitney test revealed significant differences in FBG between the participants 
who are taking a hypoglycaemic agent and who do not (U=176.5, P<0.0001). Box and 
whiskers plots are illustrated in figure 6-6 and show the significant differences in FBG 
levels between the clinical groups and between the participants who take 
hypoglycaemic agent and who do not, In addition to the gender bias box and whiskers 
plot.  
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Figure 6-6 A box and whiskers plot of FBG (mg/dL) among the clinical groups, gender, and consumption 
of hypoglycaemic agent. Data shows medians, interquartile range, whiskers and outliers. ** Indicates 
significant between group differences (P<0.01) 
 
For further analysis, data were sorted by consumption of hypoglycaemic medication. 
Obviously, none of the participants in the control group was under diabetic 
treatments nor had high FBG levels as it is shown in table 6-6. On the other hand, the 
other two groups had diabetic patients who were using hypoglycaemic medication. 
A Kruskal-Wallis test determined non-significant difference between the clinical 
groups taking hypoglycaemic medication (P=0.106) as it is shown in the box and 
whiskers plots in figure 6-7. There was however a significant difference within the 
clinical groups not taking diabetic medication (χ2 (2) =21.64, P<0.001) between CG vs 
DAG (U=84.50 P<0.0001), and ARG vs DAG (U=8.50, P=0.015).  
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Figure 6-7 Box and whiskers plots for FBG among clinical groups who consume diabetic medications 
and who do not. Data shows medians, interquartile range, whiskers and outliers. ** Indicates 
significant between group differences (P<0.01) 
 
6.4.2.3. Correlations between FBG and 25(OH)D in addition to the rest of the blood 
markers  
Correlation between FBG and 25(OH)D was performed to investigate any 
relationship. Spearman correlations revealed no significant correlation between FBG 
and 25(OH)D (table 6-9). For additional information on the relationship between 
25(OH)D and FBG, a scatter diagram is presented for 25(OH)D against FBG (figure 6-
8). However, FBG levels were significantly correlated with CRP (rho=0.172, P=.046), 
HDL (rho=0.221, P=.015), and TG (rho=0.541 P<0.0001) (table 6-19).  
Table 6-9 Spearman’s correlation between 25(OH)D (ng/mL) and FBG (mg/dl) concentrations 
 25 (OH)D FBG 
Spearman's 
rho 
25 (OH)D Correlation Coefficient 1.000 .027 
Sig. (1-tailed) . .398 
N 97 97 
 
** 
** 
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Figure 6-8 X-Y Scatter graph of 25(OH)D against FBG 
 
Analysis of lipid profile 
6.4.3. Analysis of total cholesterol (TC) 
6.4.3.1. Descriptive analysis of TC in the pooled sample and between sub-groups  
Total cholesterol was measured in all 97 participants. The normal concentrations of 
TC are between 50 to 200 mg/dL (table 6-1). The majority of the participants 60.8% 
had normal levels of TC (162.1 ± 24.5), and 39.2% had high TC concentrations (227.5 
± 22.8). The minimum value was 105 mg/dL and the maximum was 295 mg/dL. 
Distribution of TC results among the participants in the clinical groups and in both 
genders is shown in table 6-10. In addition, all of the descriptive results are shown 
when dividing the sample according to usage of Statins.  
  
Figure 6-9 Illustration of HDL (mg/dL) status among the whole participants and a histogram of TC 
levels among the clinical groups. Cut off values are shown between the dotted lines. 
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Table 6-10 Distribution of TC (mg/dL) among the clinical groups and gender when consume Statin 
medication or not 
 Taking Statins N Mean Median Mean rank 
CG Yes 0 0 0 0 
 No 33 196.76 ± 31.66 202 (47) 42.52 
 Total 33 196.76 ± 31.66 202 (47) 56.35 
ARG Yes 10 163.50 ± 37.56 156.50 (63) 9.60 
 No 20 193.15 ± 42.350 185.50 (48) 38.63 
 Total 30 183.27 ± 42.6 177.50 (48) 45.25 
DAG Yes 10 180.50 ± 50.403 172.50 (99) 11.40 
 No 24 183.88 ± 42.205 183.50 (78) 34.48 
 Total 34 182.88 ± 44.01 178 (83) 45.18 
Male Yes 4 152.50 ± 21.01 146.00 (38) 8.88 
 No 11 197.09 ± 58.82 185 (116) 10.91 
 Total 15 185.20 ± 54.61 172 (97) 43.80 
Female Yes 16 176.88 ± 47.45 172.50 (90) 38.95 
 No 66 190.92 ± 33.86 191.50 (46) 39.01 
 Total 82 188.18 ± 36.99 188.50 (51) 49.95 
Total  97 187.72 ± 39.88 185 (54)  
 
6.4.3.2. TC concentration and the difference between sub-groups  
To investigate the difference between the sub-groups, a series of non-parametric 
tests were performed. A Kruskal-Wallis test was performed and revealed no 
statistical significant difference in TC between the three clinical groups (P=0.182). 
Consequently, a Mann-Whitney test indicated no significant difference in TC 
concentrations between genders (P=0.436). Mean ranks are shown in table 6-6. 
However, a Mann-Whitney test indicated a significant difference in the whole sample 
between participants who take Statin and those who do not (U=534, P=0.035). Box 
and whiskers plots of the difference within the clinical groups, gender, and the usage 
of Statin medication in TC concentrations are presented in figure 6-10. 
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Figure 6-10 Box and whiskers plots for TC levels (mg/dL) within clinical groups, gender, and usage of 
Statin medication. Data shows medians, interquartile range, whiskers and outliers.* Indicates 
significant between group differences (P<0.05)  
 
6.4.3.3. Correlation between TC and 25(OH)D concentrations in addition to the other 
blood parameters 
Further analysis of the association between TC and 25(OH)D was performed. 
Spearman rho correlation revealed no significant correlation between 25(OH)D 
status and TC status (P=0.392) (table 6-11). A scatter plot is presenting the 
association between 25(OH)D and TC levels in the total sample figure 6-11. However, 
there were significant correlations between TC and HDL (rho=0.215, P=0.017), LDL 
(rho=0.893, P<0.0001), and TG (rho=0.211, P=0.019) (table 6-19).   
* 
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Table 6-11 Spearman’s correlation between 25(OH)D (ng/mL) and TC (mg/dl) concentrations 
 25 (OH)D Total Cholesterol 
Spearman's rho 25 (OH)D Correlation Coefficient 1.000 0.028 
Sig. (1-tailed) . 0.392 
N 97 97 
 
 
Figure 6-11 X-Y Scatter Graph of 25(OH)D (ng/ml) and TC (mg/dL) concentrations 
 
6.4.4. Analysis of HDL cholesterol 
6.4.4.1. Descriptive analysis of HDL in the pooled sample and between sub-groups  
High-density lipoprotein cholesterol was measured in all 97 participants. Normal 
values of HDL concentrations for the age of the study group are 35 to 55 mg/dL (table 
6-1). In the current study, the minimum value was 20 mg/dL and the maximum was 
114 mg/dL. The majority of the participants had normal concentrations 62.9% (44.93 
± 6.1), 20.6% had high concentrations (67.1 ± 13), and only 16.5% had low HDL 
concentrations (29.4 ± 4) (figure 6-12).  
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Figure 6-12 Illustration of HDL concentrations (mg/dL) among the whole participants and the clinical 
groups. Normal concentrations are shown between the dotted lines.  
 
Table 6-12 Descriptive and mean ranks of HDL concentrations (mg/dL) among the clinical groups and 
gender 
 N Mean ± SD Median (IQR) Mean Rank 
CG 33 48 ± 12.8 49 (19) 52.30 
ARG 30 44.23 ± 11.83 44 (12) 44.60 
DAG 34 48.35 ± 16.87 45 (19) 49.68 
Male 15 39.67 ± 9.83 39 (17) 33.97 
Female 82 48.29 ± 14.37 47 (16) 51.75 
Total 97 46.96 ± 14.08 45 (16)  
 
6.4.4.2. HDL concentration and the difference between sub-groups  
Analysis of the differences between sub-groups in HDL concentrations was 
performed using Kruskal-Wallis and Mann-Whitney tests. The Kruskal-Wallis test 
revealed no significant difference in HDL level between the clinical groups (P=0.546). 
However, the Mann-Whitney test indicated a significant difference in HDL 
concentrations between male and female (U=389.5, P=0.024). Mean ranks are shown 
in table (6-7). Box and whiskers plots in (figure 6-13) shows the differences in HDL 
concentrations among the clinical groups and gender.  
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Figure 6-13 Box and whiskers plots for HDL level (mg/dL) among the clinical groups and gender. Data 
shows medians, interquartile range, whiskers and outliers.* Indicates significant between group 
differences (P<0.05)  
 
6.4.4.3. Correlations between TC and 25(OH)D and the other blood parameters 
Additional analysis was performed to investigate relations between HDL and other 
blood markers. A Spearman rho test indicated no significant correlation between 
25(OH)D status and HDL concentration in the total sample (P=0.181) (table 6-13). 
Further analysis using a scatter plot showed the lack of impact between 25(OH)D and 
HDL in the pooled sample (figure 6-14). However, there were significant correlations 
between HDL and FBG (rho= -0.221, P=0.015), TC (rho= 0.893, P<0.0001), TG (rho= -
0.474, P<0.0001) (table 6-19).  
Table 6-13 Spearman’s correlation between 25(OH)D (ng/mL) and HDL (mg/dl) concentrations 
 25 (OH)D HDL 
Spearman's rho 25 (OH)D Correlation Coefficient 1.000 0.094 
Sig. (1-tailed) . 0.181 
N 97 97 
 
* 
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Figure 6-14 X-Y Scatter graph of 25(OH)D (ng/ml) against HDL (mg/dL) concentrations 
 
6.4.5. Analysis of LDL cholesterol 
6.4.5.1. Descriptive analysis of LDL in the pooled sample and between sub-groups  
Low-density lipoprotein was measured in all 97 participants. Normal concentrations 
of LDL level for the target group are ≥ 0.001 and ≤ 150 mg/dL (table 6-1) .The majority 
of the participants had normal concentrations of LDL 81% (mean ± SD) (103.67 ± 
25.89) whereas, 18.6% had high levels of LDL (168.0 ± 18.96) (figure 6-15). The 
minimum value of LDL was 46 mg/dL and the maximum was 220 mg/dL. Descriptive 
analysis of LDL levels among the clinical groups, gender in total sample and when 
consuming Statin medication are illustrated in (table 6-14).  
 
 
 
Figure 6-15 LDL levels (mg/dL) among the whole sample and between the clinical groups. Cut off values 
are shown between the dotted lines.  
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Table 6-14 Distribution of participants LDL levels (mg/dL) among the study groups and gender when 
consume Statin medication or not 
 Taking Statins N Mean ± SD Median (IQR) Mean Rank 
CG Yes 0    
 No 33 129.48 ± 27.85 132 (38.5) 48.08 
 Total 33 129.48 ± 27.85 132 (38.5) 61.58 
ARG Yes 10 103.64 ± 32.89 94.5 (61.1) 9.70 
 No 20 112.74 ± 41.41 98.50 (43.1) 34.23 
 Total 30 109.7 ± 38.44 97.50 (49.8) 24.62 
DAG Yes 10 115.8 ± 45.15 113 (78.8) 11.30 
 No 24 103.83 ± 31.13 97.50 (49.8) 30.50 
 Total 34 107.35 ± 35.52 100.50 (48.5) 42.43 
Male Yes 4 101.8 ± 20.07 103 (38.6) 9.88 
 No 11 127.45 ± 52.57 117 (87) 10.66 
 Total 15 120.6 ± 46.89 113 (73.8) 49.20 
Female Yes 16 111.70 ± 42.66 10 (77.5) 41.55 
 No 66 115.42 ± 30.47 113.50 (47.3) 38.58 
 Total 82 114.69 ± 32.93 112.50 (48.3) 48.96 
Total  97 115.6 ± 35.21 113 (53)  
 
6.4.5.2. LDL concentration and the difference between sub-groups  
To investigate the difference within the sub-groups in LDL concentrations a series of 
non-parametric tests were performed. Analysis of the LDL levels indicated a 
significant statistical difference between the clinical groups (χ2 (2) =9.988 P=0.007) 
using Kruskal-Wallis test. The difference were between CG vs ARG (U=295.5, 
P=0.006), and CG vs DAG (U=345.5, P=0.007). However, a Mann-Whitney test 
revealed no significant statistical difference (P=0.976) between male and female. 
Additionally, a Mann-Whitney indicated no significant difference in LDL 
concentration when Statins were taken or not (P=0.545). Box and whiskers plots of 
the difference between the sub-groups in LDL concentration are shown in figure 6-
16. 
149 
 
  
 
 
Figure 6-16 Box and whiskers plots for LDL (mg/dL) in clinical groups, gender, usage of Statin. Data 
shows medians, interquartile range, whiskers and outliers. ** Indicates significant between group 
differences (P<0.01) 
 
6.4.5.3. Correlations between LDL and 25(OH)D and the other blood parameters 
Further investigations of the relationship between LDL concentration and the other 
blood parameters were performed. A Spearman rho test revealed no significant 
correlation between LDL and 25(OH)D concentrations (P=0.386) (table 6-15). A 
simple scatter plot between LDL and 25(OH)D illustrates the lack of relationship 
between the two variables in the pooled sample (figure 6-17).  On the other hand, 
there was a significant correlation between LDL and TC (rho=0.893, P<0.0001) (table 
6-19).   
** 
** 
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Table 6-15 Spearman’s correlation between 25(OH)D (ng/mL) and TC (mg/dl) concentrations 
 25 (OH)D LDL 
Spearman's rho 25 (OH)D Correlation Coefficient 1.000 0.030 
Sig. (1-tailed) . 0.386 
N 97 97 
 
 
Figure 6-17 X-Y Scatter graph of 25(OH)D (ng/mL) and LDL (mg/dL) 
 
6.4.6. Analysis of Triglycerides (TG)   
6.4.6.1. Descriptive analysis of TC in the pooled sample and between sub-groups  
Triglycerides were measured in all 97 participants. Normal concentrations of TG are 
between 30-200 mg/dL. In the current study, the minimum concentration of TG was 
35 mg/dL and the maximum was 605 mg/dL. Seventy seven percent of the 
participants had normal TG values (mean± SD) (111.40 ± 39.55) and the rest 20.6% 
had high values (297.75 ± 98.75) (figure 6-18). Descriptive analysis of TG results are 
shown in table 6-16. There were four values of TG above 340 mg/dl considered 
outliers. Table 6-17 shows TG values without outliers. Figure 6-18 shows the 
distribution of the sample without TG outliers. The results were reviewed for 
validation. None of participants who had outliers’ values in TG had outliers when the 
rest of the blood markers were analysed. This appears to indicate that these outliers 
are simply related to the TG data and have no common feature.   
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Figure 6-18 Distribution of Triglycerides concentrations (mg/dL) in the total sample and without 
outliers. Cut off concentrations are shown between the dotted lines. 
 
Table 6-16 Distribution of Triglycerides among the participants within the clinical groups and gender 
 N Mean ± SD Median (IQR) Mean Rank 
CG 33 108.7 ± 62.83 91 (65) 33.79 
ARG 30 182.37 ± 114.02 157 (97) 60.27 
DAG 34 161.03 ± 88.81 137 (111) 53.82 
Male 15 145.40 ± 82.58 123 (69) 49.07 
Female 82 150.63 ± 96.84 122.50 (106) 48.99 
Total 97 149.82 ± 94.4 123 (92)  
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Table 6-17 Distribution of TG without outliers among the participants within the clinical groups and 
gender 
 N Mean ± SD Median (IQR) Mean Rank 
CG 33 108.7 ± 62.83 91 (65) 33.79 
ARG 28 157.46 ± 62.55 149.50 (92) 57.68 
DAG 32 147.72 ± 72.7 129.5 (91) 51.28 
Male 14 129.3 ± 56.45 121 (58) 642 
Female 79 138.1 ± 71.19 120 (87) 3729 
Total 93 136.8 ± 68.97 120 (81)  
 
6.4.6.2. TG concentration and the difference between sub-groups  
To investigate the difference in TG levels between the sub-groups a series of non-
parametric tests were performed. A Kruskal-Wallis test revealed a statistically 
significant main effect in clinical groups on TG levels (χ2 (2) =15.448, P<0.0001). The 
significant differences were between CG vs ARG (U=227, P<0.0001) and CG vs DAG 
(U=327, P=0.003). When the test performed without the outliers similar results were 
observed (χ2 (2) =13.09, P=0.001) in that the differences were also between CG vs 
ARG (U=227, P=0.001), and CG vs DAG (U=327, P=0.008) (figure 6-19). However, a 
Mann-Witney test indicated no significant difference in TG concentrations between 
male and female neither with (P=0.992) nor without the outliers (P=0.864). In 
addition, there was no difference in TG levels whether Statin was taken or not 
(P=0.711).  Box and whiskers plots of TG concentrations between the study groups 
and gender are shown in figure 6-20.  
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Figure 6-19 Box and whiskers plots of TG (mg/dL) in clinical groups in the total sample and without 
outliers. Data shows medians, interquartile range, whiskers and outliers. ** Indicates significant 
between group differences (P<0.01). 
 
  
Figure 6-20 Box and whiskers plots of TG (mg/dL) and gender. Data shows medians, interquartile 
range, whiskers and outliers. 
 
6.4.6.3. Correlations between LDL and 25(OH)D in addition to the other blood 
parameters 
For further investigation of the relationship between triglycerides concentrations 
and the other blood health markers, a sequence of non-parametric statistical tests 
were performed. A Spearman’s rho indicated no significant correlation between 
25(OH)D and TG concentrations either with (P=0.499) nor without outliers (P=0.497) 
(table 6-18). Figure 6-21 presents the scatter diagrams showing the lack of any 
relationship between 25(OH)D and TG.  However, there was a significant negative 
correlation between 25(OH)D and TG, in the ARG in participants not taking vitamin D 
supplements (rho= -0.587, P=0.005). Similar results were obtained with TG without 
** 
** ** 
** 
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outliers (rho= -0.585, P=0.009) (table 6-20). Moreover, there were statistically 
significant correlations between TG and FBG (rho=0.541 P<0.0001), CRP (rho=0.198 
P=0.026), TC (rho=0.211 P=019), and HDL (rho=-0.474 P<0.0001) (table 6-19). 
Table 6-18 Spearman’s correlation between 25(OH)D (ng/mL), TG and TG without outliers (mg/dl) 
concentrations 
 25 (OH)D TG TG without 
outliers 
Spearman's 
rho 
25(OH)D Correlation Coefficient 1.000 0.000 0.001 
Sig. (1-tailed) . 0.499 0.497 
N 97 97 93 
 
  
Figure 6-21 X-Y Scatter graph of 25(OH)D (ng/mL) against Triglycerides (mg/dL) in total sample and 
without outliers. 
 
6.4.7. Correlations between 25(OH)D and other blood parameters, and 
multiple linear regression model  
A number of Spearman correlations were performed to investigate the relationship 
between 25(OH)D concentration and the rest of the blood markers. The test revealed 
no significant correlations between 25(OH)D concentration and the blood markers in 
the pooled sample (table 6-19). Thus, a multiple linear regression model was not 
appropriate to predict 25(OH)D from the blood health markers of interest in this 
chapter. 
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Table 6-19 Spearman’s rho correlations between all of the chapter blood parameterises in the pooled population  
 25 (OH)D CRP CRP 
without 
outliers 
FBG TC HDL LDL TG TG 
without 
outliers 
S
p
e
a
rm
a
n
's
 r
h
o
 
25 (OH)D Correlation Coefficient 1.000 0.029 0.011 0.027 0.028 0.094 0.030 0.000 0.001 
Sig. (1-tailed) . 0.388 0.458 0.398 0.392 0.181 0.386 0.499 0.497 
N 97 97 94 97 97 97 97 97 93 
CRP Correlation Coefficient  1.000 1.000** 0.172* -0.126 -0.140 -0.143 0.198* 0.209* 
Sig. (1-tailed)  . . 0.046 0.109 0.085 0.082 0.026 0.022 
N  97 94 97 97 97 97 97 93 
CRP No 
outliers 
Correlation Coefficient   1.000 0.221* -0.084 -0.109 -0.111 0.181* 0.187* 
Sig. (1-tailed)   . 0.016 0.210 0.148 0.144 0.040 0.039 
N   94 94 94 94 94 94 90 
FBG Correlation Coefficient    1.000 -0.003 -0.221* -0.148 0.541** 0.501** 
Sig. (1-tailed)    . 0.487 0.015 0.074 0.000 0.000 
N    97 97 97 97 97 93 
TC Correlation Coefficient     1.000 0.215* 0.893** 0.211* 0.153 
Sig. (1-tailed)     . 0.017 0.000 0.019 0.072 
N     97 97 97 97 93 
HDL Correlation Coefficient      1.000 0.078 -0.474** -0.433** 
Sig. (1-tailed)      . 0.225 0.000 0.000 
N      97 97 97 93 
LDL Correlation Coefficient       1.000 0.063 0.054 
Sig. (1-tailed)       . 0.270 0.305 
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N       97 97 93 
TG Correlation Coefficient        1.000 1.000** 
Sig. (1-tailed)        . . 
N        97 93 
TG without 
outliers 
Correlation Coefficient         1.000 
Sig. (1-tailed)         . 
N         93 
**. Correlation is significant at the 0.01 level (1-tailed). 
*. Correlation is significant at the 0.05 level (1-tailed). 
  
157 
 
Table 6-20 Spearman’s rho correlations between 25(OH)D  and each of the blood parameterises within the clinical groups considering the consumption of vitamin D 
supplements  
Take vitamin D 
supplements 
Category CRP CRP No 
outliers 
FBG TC HDL LDL TG TG No 
outliers 
Yes DAG 
2
5
 (
O
H
)D
 
 
Correlation Coefficient -0.280 -0.426 -0.182 -0.168 -0.263 -0.063 -0.028 -0.245 
Sig. (1-tailed) 0.189 0.096 0.286 0.301 0.204 0.423 0.466 0.233 
N 12 11 12 12 12 12 12 11 
ARG Correlation Coefficient -0.666** -0.765** -0.266 -0.035 0.014 0.035 -0.063 -0.063 
Sig. (1-tailed) 0.009 0.003 0.201 0.457 0.483 0.457 0.423 0.423 
N 12 11 12 12 12 12 12 12 
CG Correlation Coefficient -0.348 -0.348 -0.086 0.086 -0.029 0.371 0.667 0.667 
Sig. (1-tailed) 0.250 0.250 0.436 0.436 0.479 0.234 0.074 0.074 
N 6 6 6 6 6 6 6 6 
No DAG 
2
5
 (
O
H
)D
 
 
Correlation Coefficient -0.277 -0.155 0.194 0.282 -0.015 0.153 0.275 0.262 
Sig. (1-tailed) 0.106 0.252 0.193 0.102 0.474 0.248 0.108 0.125 
N 22 21 22 22 22 22 22 21 
ARG Correlation Coefficient 0.128 0.128 -0.206 -0.253 0.369 -0.259 -0.587** -0.585** 
Sig. (1-tailed) 0.307 0.307 0.207 0.156 0.066 0.150 0.005 0.009 
N 18 18 18 18 18 18 18 16 
CG Correlation Coefficient 0.035 0.035 -0.047 0.106 0.041 0.175 -0.168 -0.168 
Sig. (1-tailed) 0.431 0.431 0.407 0.300 0.420 0.192 0.201 0.201 
N 27 27 27 27 27 27 27 27 
*. Correlation is significant at the 0.05 level (1-tailed). 
**. Correlation is significant at the 0.01 level (1-tailed). 
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6.5. Discussion 
The current study hypothised an association between 25(OH)D concentrations and 
the indicators of blood health that are deemed to be markers or risk factors for 
atherosclerosis. The hypothesis was rejected in this chapter, as there was no 
association observed between the desired variables in the pooled sample. A detailed 
discussion of the results and the peer-reviewed previous studies are presented in this 
section. 
6.5.1. Discussion of CRP and vitamin D status  
C-reactive protein is considered to be an important marker of cardiovascular disease 
and atherosclerosis (Sibley et al., 2014). In the present study, 41.2% of the 
participants had normal values of CRP (0.007 ± 0.047 mg/dl) and the rest had high 
concentrations (1.086 ± 1.186 mg/dl). There was a significant difference in CRP 
concentrations between the clinical groups (CG, ARG, DAG) P<0.001. It appears that 
the ARG had a mean rank of 60.27 mg/dL whilst the other two groups had the same 
mean rank of 41.75 mg/dL of CRP. The ARG were at risk of developing atherosclerosis 
and they were not currently undergoing any treatments for the disease, which 
explains the high concentrations of CRP (0.837 ± 0.804 mg/dl). This was unlike the 
DAG patients who were being treated for atherosclerosis (0.626 ± 1.52 mg/dl) and 
the CG who were free of atherosclerosis and its risk factors (0.479 ± 0.533).  
In the current study, no statistically significant correlation was found between 
25(OH)D and CRP in the pooled sample. However, there was a statistically significant 
correlation between 25(OH)D and CRP in the ARG when taking vitamin D 
supplements (rho=0.666, P<0.05). In this group (ARG), 40% of the participants were 
using supplements. This result indicates the positive impact of vitamin D 
supplementation in preventing the causes that leads to high production of CRP, 
which is one of the inflammatory markers of atherosclerosis (Targher et al., 2006; 
Lertratanakul et al., 2014). 
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These results are similar to findings by Lertratanakul et al. (2014) who studied the 
association between 25(OH)D deficiency and the increased risk of cardiovascular 
disease and its risk factors in the general population. Lertratanakul et al. (2014) found 
that participants with adequate 25(OH)D concentrations (31-91 ng/mL) had normal 
CRP concentrations <0.300 mg/dL. On the other hand, in the present study, the ARG 
had 86.7 % diabetic participants and that could be one of the reasons for the 
noticeable correlation with CRP. Targher et al., (2006) studied type 2 diabetic adults 
and found that those diabetic patients who were vitamin D deficient (11.2±2.8 
ng/mL) had significantly (P<0.001) higher levels of CRP (0.498 ± 0.65mg/dL). The 
potential biological explanation for the inverse association between CRP and 
25(OH)D could be because of the protective effect of vitamin D against inflammation 
and inflammation is one of the reasons that CRP is produced by the liver (van Wissen 
et al., 2002; Giovannucci, 2009). These findings confirm results from the current 
study of the inverse association between 25(OH)D and CRP in participants at risk of 
developing atherosclerosis. 
 6.5.2. Discussion of FBG and vitamin D status  
Fasting blood glucose is one of the key indicators of diabetes, which is a risk factor 
for further ill health including cardiovascular disease and atherosclerosis (Beckman 
et al., 2002; Witham et al., 2010). In the current study, high FBG concentrations were 
prevalent in the ARG and DAG but not in the CG P<0.001. In addition, 40% of the 
participants were diabetic and they were taking hypoglycaemic agents. The ARG 
included the highest number of diabetic participants, 86.7%, of any group in the 
current study.  However, hyperglycaemia was observed in most of the diabetic 
participants in the current study, 43% of participants had FBG levels > 115 mg/dL 
even with the consumption of hyperglycaemic agents. This could be because their 
condition was poorly controlled or they had other diseases, which is an issue that 
needs to be considered (Beckman et al., 2002; Talaei et al., 2013).  
The current study has found no significant relationship between 25(OH)D and FBG 
concentrations in the pooled sample or in the sub-groups regardless of whether 
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vitamin D supplements were taken nor not. This finding is supported by other studies 
such as (Jorde and Figenschau, 2009; Qadhi, 2016). In the study by Qadhi (2017), the 
impact of vitamin D supplementation in diabetic participants was tested for 16 
weeks. There was a significant improvement in the HbA1c (P<0.001) but there was 
no significant impact on FBG concentration. HBA1c was a more accurate predictor 
than FBG for mean glucose concentration in serum for the previous three months 
(Qadhi, 2016). Additionally, Jorde and Figenschau (2009) also tested vitamin D 
supplementation in diabetic patients and found no association between 25(OH)D and 
FBG. Those studies and the current study observed no association between vitamin 
D status and FBG. However, high concentrations of FBG and diabetes are considered 
major risk factors for atherosclerosis (Beckman et al., 2002; Menezes et al., 2014) 
and some other studies have found an association between FBG and 25(OH)D in 
atherosclerosis risk factor participants. For instance, a study by Talaei et al. (2013) 
found a significant association between FBG and 25(OH)D in diabetic patients after 
treatment of vitamin D deficiency by vitamin D supplements for eight weeks (P<.05). 
Another recent study by Aljefree et al. (2016) examined participants with coronary 
heart disease and considered the measurement of FBG as one of the markers of the 
disease. They found a significant association between the markers and the 
prevalence of vitamin D deficiency (P<0.001). The association between FBG and 
25(OH)D needs further examination to confirm whether such an association exists.  
6.5.3. Discussion of lipids profiles and vitamin D status 
In the current study, lipid profiles included total cholesterol (TC), high-density 
lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides (TG). The majority 
of the participants had normal values of TC, HDL, LDL, and TG; 59%, 61%, 79%, and 
77% respectively. In total, 39.2% of the participants had hyperlipidaemia (that is, the 
highest lipid concentrations in the current study). The results were certainly affected 
by other factors such as the use of Statin medications. All of the lipid measurements 
in the current study were significantly associated with each other (P<0.05).  
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There was no significant correlation between 25(OH)D concentrations and any of the 
lipids profile measurements in the pooled sample. These results were similar to 
observations by Gepner et al. (2012). They performed a double-blind, placebo-
controlled trial to examine the impact of vitamin D supplementations on 
cardiovascular risk. They did not observe any significant correlation between 
25(OH)D and lipids (TC, HDL, LDL, and TG) either in the placebo, or the supplement 
group. Another study tested the association between 25(OH)D and lipid profile 
measurements in vitamin D deficient participants (Tarcin et al., 2009). They also 
observed no significant association between 25(OH)D concentration and any of the 
measured lipids.  
The association between 25(OH)D and lipids is not consistent; some studies observe 
associations and some do not. The current study observed an inverse correlation 
between 25(OH)D and TG in the ARG when vitamin D supplements were not 
consumed (P<0.01). Similar results were observed in a longitudinal community-based 
study by Faridi et al., (2017) in which participants at a high risk of developing 
atherosclerosis were tested for 25(OH)D and lipid profiles. The measurements were 
taken at baseline and twice more within 5 years. The study found that vitamin D 
deficiency was associated with lower HDL and higher TC, but it was not associated 
with TG and LDL. However, in another study (Qadhi, 2016) the impact of vitamin D 
supplementation for 16 weeks was examined in diabetic participants. Significant 
improvement in TC (P<0.05) and LDL (P<0.001) was observed, but no association was 
found with HDL and TG. Conversely, another study by Lertratanakul et al. (2014) did 
observe associations between 25(OH)D concentrations and all of the lipid profile 
measurements (P<0.001) (Lertratanakul et al., 2014). This indicates that the 
association between 25(OH)D concentration and hyperlipidaemia could be affected 
by other factors such as (medications and diseases). These factors could be the 
explanation of the un-clear association between 25(OH)D and lipids in the current 
study.    
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6.6. Summary and conclusion  
The current study confirmed the significant differences in blood markers of 
cardiovascular disease between the study’s clinical groups. The control group had 
normal concentrations of CRP, FBG, and lipid profiles when compared with the at-
risk group and the diagnosed with atherosclerosis group. Additionally, the use of 
hypoglycaemic agents, statins and vitamin D supplements had an impact on the 
blood markers. However, 25(OH)D concentrations did not correlate with any of the 
other measured blood-health markers in the pooled sample.  
The use of vitamin D supplements had an impact on the results only in the ARG. 
Correlations were observed between 25(OH)D and CRP in the ARG when using 
vitamin D supplements. In addition, there was an association between 25(OH)D and 
TG in the ARG who were not using vitamin D supplements. The majority of the 
participants (86.7%) in the ARG were diabetic patients and many studies have 
observed an association between vitamin D status and diabetes (Targher et al., 2006; 
Faridi et al., 2017), which probably provides an explanation for the correlation seen 
in this group between taking supplements and blood markers. 
In conclusion, the use of vitamin D supplements tends to be a factor that affects the 
association between blood markers of cardiovascular disease and 25(OH)D 
concentration only in the group at-risk of developing atherosclerosis. Further 
investigation may be needed to clarify the impact of 25(OH)D concentration on blood 
markers of cardiovascular disease and atherosclerosis risk factors.
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Chapter 7 - Association between circulating 25(OH)D 
levels and vascular structural and functional 
characteristics 
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7.1. Introduction  
The details of the association between 25(OH)D concentrations and atherosclerosis 
incidence and risk factors are still under investigation (Menezes et al., 2014; 
Adamczak, 2017). Assessment of atherosclerosis can be performed by testing 
vascular structural and functional characteristics. The status of carotid-radial pulse 
wave velocity (PWV), central blood pressure (cBP), peripheral blood pressure (pBP) 
carotid intima-media thickness (IMT), carotid artery inter-adventitial diameter (IAD), 
and other markers were therefore assessed. The measurements were determined on 
the pooled study sample and in each of the sub-groups, clinical groups (control group 
(CG), at-risk group (ARG), and participants diagnosed with atherosclerosis group 
(DAG)), and between the sexes. Analysis based on the clinical groups was considered 
an indicator of the association between the measurement and the participants’ 
clinical condition. Analysis between the sexes determined any male vs female 
variation in each of the measurements. The associations between these vascular 
structural and functional characteristics and 25(OH)D status were investigated to 
determine any association between these markers of health.  
7.1.1. Chapter aim 
- To determine if there is a relationship between circulating 25(OH)D levels and 
vascular structural and functional characteristics.  
7.1.2. Chapter objectives 
1- To assess each of the vascular structural and functional characteristics (PWV, 
cBP, pBP, IMT, and IAD) in the pooled sample and in each of the study’s sub-
groups. 
2- To investigate any association between the measurements monitored and the 
concentration of 25(OH)D in the pooled sample and in each of the study’s sub-
groups. 
3- To elucidate any observable relationship between the monitored 
measurements. 
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7.2. Methods 
7.2.1. Measurements of arterial stiffness using pulse wave velocity (PWV) 
and central blood pressure (cBP) measurement  
PWV and cBP were performed using a non-invasive pulse-wave velocity device 
(Complior, Alam Medical, Vincennes, France) and software (V1.9.4, Alam Medical, 
Vincennes, France). These were provided for the purpose of the study by Manchester 
Metropolitan University. Following training in the use of the equipment, and 
systematic assessment of the intra-day reliability of the results obtained, the study 
proper was resumed. The reliability pilot study was performed on 11 different 
participants (age 35 -51 years; seven females and four males; seven CG, three ARG, 
and one DAG) who were otherwise not included in the current study.  Coefficient of 
variation (CV) [CV= standard deviation/mean) was below 5% on 3-5 repetitive tests 
for all outcome variables. 
PWV and cBP assessments were performed in a quiet room where the temperature 
was controlled at 23° C (Ikonomidis et al., 2013). Prior to testing, the participants lay 
in a supine position, without a pillow or reclining seatback, on the examination bed 
for 10 minutes to allow for fluid equilibrium.  Then, the relevant sensors were placed 
on the key anatomical sites, previously marked on the participant’s skin at the neck 
and the wrist (for the carotid and radial arteries respectively). The correct positions 
to place the sensors were defined by palpation using the index and middle fingers to 
feel a pulse signal (Sztrymf et al., 2013).  
The Complior software (v1.9.4, Vincennes, France) had a login username and 
password that were known only to the researcher. The programme asked for the 
participant's gender, identification name or ID (the current study used ID). Peripheral 
systolic blood pressure (pSBP) and diastolic blood pressure (DBP) would then be 
entered, prior to the measurement, which was taken using an automated electronic 
sphygmomanometer (CARESCAPE V100 Monitor, GE Healthcare, St. Louis, USA) 
(Appendix 12). Total body height (in centimetres) and mass (in kilogrammes), were 
assessed using a stadiometer (Doran Scales, Charles, IL, USA) and an electronic scale 
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(Doran Scales, Charles, IL, USA), respectively and these data were also inputted. The 
distance between the carotid and radial arteries was measured (in metres) and then 
inputted. After that, the sensors were positioned on the respective arteries at the 
pre-selected locations. The red sensor was used for the carotid artery using the neck, 
hands-free holder. The blue sensor was used for the radial artery using the wrist, 
hands-free holder. During the measurements, the participant’s arm was not allowed 
to come in contact with the body, and the legs were kept sufficiently apart to avoid 
any possible damping of the signal (figure 7-2) (Sztrymf et al., 2013). The Complior 
screen displayed the pulse waves in the monitored arteries.  
 
Figure 7-1 The pulse wave analysis test being performed on a participant 
The PWV was calculated by the Complier software as the distance between the two 
measured points divided by the transit time between the waves (m/s) (figure 7-2). 
Once 10 valid pulses had been obtained, the acquisition could be processed, 
preferably only when the signal of quality score was above 80% (Complior analyser 
operator's manual, 2016). 
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Figure 7-2 Illustration of the method used to measure PWV but in the current study the arteries used 
were carotid- brachial- edited from the (Complior analyse operator's manual, 2016) 
 
The central blood pressure (cBP) is the pressure in the main large arteries (aorta and 
carotid). cBP is a better indicator of blood pressure than the standard peripheral 
blood pressure and it is more related to cardiovascular events (Pini et al., 2008; 
Sztrymf et al., 2013). It can be determined by measuring the central systolic blood 
pressure (cSBP). The diastolic blood pressure is the same by definition in the carotid 
and peripheral arteries (Pereira et al., 2014; Complior analyse operator's manual, 
2016).  
The test was repeated 2 to 3 times for validation. For accurate and fast results, the 
participant needed to be relaxed. Out of the 97 participants on the study it was not 
possible to obtain readings using the Complior software (v1.9.4, Vincennes, France) 
from six (6) patients. It is believed that this was due to the volunteers failing to relax 
because they were in a rush to leave or distracted by someone waiting for them. In 
each of the six cases, the researcher was unable to relieve the stress of the 
participants despite the attempts to do so. Thus, results from only 91 participants 
were included in the study from the pulse-wave velocity device. 
The software displayed the result and saved it under the participant’s profile. The 
data from the highest quality score recording (i.e. the one closest to 100% signal 
strength) was used in the study. An additional copy of the results was saved in an 
Excel file as a backup (Pereira et al., 2014; Complior analyse operator's manual, 
2016). Figure 7-3 illustrate an example of the result and analysis sheet details of the 
pulse wave analysis software, Complior.    
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Figure 7-3 Examples of the result and analysis sheet details of the pulse wave analysis software, 
Complior 
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7.2.2. Carotid artery ultrasound measurements  
Carotid artery examinations were used to assess participants’ arterial structure 
status. The examination was performed using an ultrasound (MyLab 70, Esaote, 
Genoa, Italy) that had a brightness mode as well as colour Doppler facilities. A high 
frequency, 10 MHz, linear array transducer was used for the examination. The 
participant had to be lying down flat with their head in a straight position (figure 7-
4). The right side of the common carotid artery (CCA) was visualised first in the 
coronal view and then the probe is twisted along the sagittal plane. As a safety 
precaution, the colour Doppler mode was used for only up to 10 seconds maximum 
to ensure the right position on the CCA (Corretti et al., 2002). The angle of insonation 
was at 60° to eliminate the error in velocity measurements (Roman et al., 2006). 
Measurements of the carotid intima media thickness (IMT), carotid artery inter-
adventitial diameter (IAD), heart rate (HR), resistance index (RI) and blood flow 
integral (BFI (total average velocity (TAV) + blood flow (BF)) were taken. Before 
starting data collection, intense training on the use of the ultrasound was performed. 
Risk assessment forms were written and signed. A pilot study was undertaken to 
assess the reliability of the results was performed on 11 different participants (see 
details above in section 7.2.1).  The coefficient of variation (CV) [CV= standard 
deviation/mean) was < 5 % on three repeated readings of each parameters. 
 
Figure 7-4 The ultrasound test being performed on a participant 
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7.2.2.1. Carotid intima media thickness (IMT) 
To measure IMT, a clear ultrasound image had to be taken. The image had to show 
the carotid node (as an anatomical reference and standardised position point) and 
had to be taken at the end of the systolic phase, which is when the artery had its 
largest diameter. Measurements were taken in three different positions along the 
vessel, 10.00 Millimetres (mm) away from the carotid node. The distance from the 
lumen-intima interface to the media-adventitial interface is the measurement of IMT 
as shown in figure 7-5. IMT is considered normal <0.75 mm; at risk of atherosclerosis 
between the 0.75 mm and 1.00 mm; and as having atherosclerosis at > 1.00 mm 
(Polak et al., 2013; Taskiran et al., 2017).  
7.2.2.2. Carotid artery inter-adventitial diameter (IAD)  
The carotid artery diameter is the measurement of the inter-adventitial diameter 
(IAD). IAD is defined as the distance between the medial-adventitial interfaces on the 
near wall to the medial-adventitial interface on the far wall on the CCA as shown in 
figure 7-5 (Roman et al., 2006; Lloyd et al., 2012). The measurements were 
performed on a scan image at three different points 10 mm away from the node. The 
ultrasound images were taken during the systolic phase. 
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Figure 7-5 Illustration of IMT and IAD measurements on a participant’s CCA ultrasound image 
 
7.2.2.3. Additional vascular measurements  
Resistive Index (RI) 
Resistive index is the measurement between the peak of the systolic velocity wave 
and the trough of the diastolic velocity wave as illustrated in figure 7-6. After 
recording at least ten clear waveforms, the measurement was taken on three 
different waves along the waveform. The average of the three measurements was 
recorded for each participant.  
Blood flow integral (BFI) 
Blood flow integral is the total average velocity (TAV) + blood flow (BF). The 
measurement was taken on three different waves along the waveforms. The 
measurement can be taken by measuring the velocity wave from the peak of the 
systolic velocity wave to the trough of the diastolic velocity wave, as illustrated in 
figure 7-6.  
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Heart Rate (HR) 
Heart rate was measured using two methods in the current study. The first one was 
by using an electronic sphygmomanometer (CARESCAPE V100 Monitor, GE 
Healthcare, St. Louis, USA), which gives an automatic reading. The second method 
was through using the Doppler ultrasound in the CCA. At least ten clear waveforms 
were recorded. The measurement between two systolic velocity waves is the 
measure of heart rate as shown in figure 7-6. At least three measurements were 
taken, and the averages were counted to indicate the heart rate. A coefficient of 
variation of 95% was confirmed between the two methods, and then the average 
was calculated.  
 
Figure 7-6 Illustration of HR, RI, and BFI measurements on a participant’s CCA ultrasound image  
 
7.2.3. Measurement of Serum 25 (OH) D  
Measurement of 25(OH)D was accomplished using an electrochemiluminescence 
binding assay. Details of the measurement are provided in section 4.3.1. of the 
current study.   
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7.3. Statistical analysis of the data  
Statistical analysis was performed using SPSS v24 (Inc., Chicago, IL, USA). Data were 
tested for normal distribution using the Kolgomorov-Smirnov test. Similarly, 
homogeneity of variance was assessed using the Levene’s test. Descriptive analysis 
is presented as mean ± standard deviation, median (interquartile range), and mean 
rank. In the current chapter, only data from IAD were normally distributed. One-way 
ANOVA, with Bonferroni corrected post-hoc pairwise mean comparisons, were 
carried out where there were 3 groups to compare (clinical groups). Independent t-
test was used to compare two groups (i.e. gender). The rest of the chapter 
measurements were not normally distributed, as such data was deemed suitable for 
non-parametric statistical tests. Therefore, Kruskal-Wallis tests, with appropriate 
post-hoc Mann-Whitney tests were carried out where there were three groups, or 
simply Mann-Whitney tests for simple pairwise mean comparisons. Wilcoxon Signed 
test was carried out to compare the difference in SBP in peripheral and central 
arteries. Confidence Interval percentage (CI) was set at 95% for all of the data. Box 
and whiskers plots were used to illustrate medians, interquartile range, whiskers, 
outliers, and indicates significant between group differences.  
Additionally, where data was continuous rather than grouped, Spearman Rho 
correlations were carried out.  Multiple linear regression model was applied to try 
and ascertain whether 25(OH)D levels can be predicted from a composite of all the 
significant confounders if any. Statistical significance was set at p ≤ 0.05.  
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7.4. Results 
In this section, descriptive analysis of the vascular structural and functional 
characteristics were performed. Additionally, the relationships between 25(OH)D 
concentrations and the monitored characteristics were examined. It was not possible 
to obtain measurements  using the pulse wave analysis device and the peripheral 
blood pressure monitor from six participants who were not able to relax for the 
procedure.  Thus the total complete set samples (PWV, cSBP, pSBP, and DBP) was 
derived from 91 participants. It was possible to obtain ultrasound measurements 
(IMT, IAD, RI, TAV, BF) from all 97 participants. Data were analysed as a pooled 
sample and as sub-groups. First sub-group was the clinical groups ((control group 
(CG), at-risk group (ARG), and diagnosed with atherosclerosis group (DAG)). The 
second sub-group was gender (male, female). Table 7-1 shows the statistical mean 
and standard deviation of the chapter measurements within each of the clinical 
groups and the pooled study sample. 
Table 7-1 Descriptive analysis of the chapter parameters in each of the clinical groups and in the pooled 
sample. Data were presented as mean ± standard deviation. Parameters included carotid-radial pulse 
wave velocity (PWV), central systolic blood pressure (cSBP), Peripheral systolic blood pressure (pSBP), 
Diastolic blood pressure (DBP )-represent both peripheral and central-,  Carotid intima-media thickness 
(IMT), Carotid artery inter-adventitial diameter (IAD), Resistive index (RI), total average velocity (TAV) 
& blood flow (BF), and Heart rate (HR).  
Measurements CG ARG DAG Total sample 
PWV (m/s) 7.35 ± 4.81 9.87 ± 5.39 8.58 ± 3.58 8.57 ± 4.66 
cSBP  (mmHg) 105.4 ± 10.24 119.82 ± 18.9 125.64 ± 19.2 117.2 ± 18.62 
pSBP (mmHg) 123.0 ± 15.5 133.17 ± 12.57 139.88 ± 18.26 132.06 ± 17.12 
DBP  (mmHg) 68.76 ± 11.15 73.0 ± 9.06 75.76 ± 9.74 72.53 ± 10.37 
IMT (mm) 0.508 ± 0.121 0.603 ± 0.161 0.749 ± 0.261 0.622 ± 0.215 
IAD (mm) 6.306 ± 0.602 6.64 ± 0.756 6.94 ± 0.914 6.63 ± 0.807 
RI (cm/s) 0.745 ± 0.053 0.734 ± 0.062 0.783 ± 0.203 0.755 ± 0.129 
TAV (cm/s) 19.366 ± 6.817 16.703 ± 6.01 16.072 ± 6.843 17.388 ± 6.678 
BF (ml/min) 348.5 ± 121.3 335.8 ± 123.7 346.9 ± 146.6 344.03 ± 130.2 
HR (bpm) 70.16 ± 10.2 78.9 ± 11.04 73.85 ± 14.77 74.16 ± 12.6 
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7.4.1. Analysis arterial stiffness by pulse wave velocity (PWV)  
7.4.1.1. Descriptive analysis of PWV in the pooled sample and between sub-groups  
The carotid-radial measurements were performed in 91 participants with an average 
quality of the PWV measurement of 83.8 ± 14.19 %. Descriptive analysis of PWV 
analysis among the pooled sample and in sub-groups are shown in table 7-2. The 
minimum PWV value was 2.1 m/s and the maximum was 26.2 m/s. figures 7-7 
illustrate the distribution of PWV in the pooled sample. 
 
Figure 7-7 Distribution of carotid-radial PWV among the pooled sample 
 
Table 7-2 Descriptive statistic of CR PWV (m/s) in the pooled sample and in Sub-groups 
 N Mean ± SD Median (IQR) Mean rank 
CG 30 7.35 ± 4.8 7.1 (7.6) 37.68 
ARG 28 9.56 ± 5.39 10.9 (8) 53.59 
DAG 33 8.58 ± 3.58 9.3 (5.8) 47.12 
Male 15 9.88 ± 5.43 10.5 (8.4) 53.60 
Female 76 8.31 ± 4.496 9.2 (7.9) 44.50 
Total 91 8.57 ± 4.66 9.3 (7.9)  
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7.4.1.2. PWV and the difference between sub-groups  
To investigate the differences between the sub-groups in their PWV, a series of 
statistical tests were performed. A Kruskal-Wallis test indicates no significant 
difference in PWV among the clinical groups CG, ARG, and DAG (P=0.069). Similarly, 
there was no variation in PWV between sex (P=0.223). Box and whiskers plots are 
illustrated in figure 7-8 show no significant variation  
  
Figure 7-8 A box and whiskers plot of PWV (m/s) among the clinical groups. Data shows medians, 
interquartile range, whiskers and outliers. 
 
7.4.1.3. Correlations between PWV and 25(OH)D and the rest of the vascular structural 
and functional characteristics. 
To examine the relationship between PWV and 25(OH)D concentrations Spearman 
correlation was performed and indicated no significant correlation (P=0.201) (table 
7-3). Additionally, simple linear X-Y scatter plots were used to illustrate the lack of 
association between 25(OH)D status and PWV (figure 7-9). 
Table 7-3 Spearman correlations between 25(OH)D (ng/mL) and PWV (m/s) 
 25 (OH)D CR PWV 
Spearman's rho 25 
(OH)D 
Correlation Coefficient 1.000 -0.089 
Sig. (1-tailed) . 0.201 
N 97 91 
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Figure 7-9 X-Y scatter plot between PWV and 25(OH)D ng/mL. 
 
7.4.2. Analysis of peripheral and central blood pressure  
7.4.2.1. Descriptive analysis of peripheral and central blood pressure in the pooled 
sample and between sub-groups  
The pulse wave analysis software takes measurements of the central blood pressure 
as the central systolic blood pressure (cSBP). The average observation in the study 
sample was (mean ± SD) 132.06 ± 17.12 mmHg (table 7-5). The average diastolic 
blood pressure (DBP) was 72.53 ± 10.37 mmHg, which is the same in Peripheral and 
central assessments (table 7-1). The average peripheral systolic blood pressure 
(pSBP) was 132.06 ± 17.12 mmHg measured by the electronic sphygmomanometer 
(CARESCAPE V100 Monitor, GE Healthcare, St. Louis, USA) (table 7-4). The 
measurements were performed in 91 participants. Figures 7-10 illustrate distribution 
and descriptive statistic of pSBP and cSBP in the pooled sample. 
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Figure 7-10 Distribution of pSBP and cSBP among the pooled sample 
Table 7-4 Descriptive statistic of pSBP in the pooled sample and in Sub-groups  
pSBP N Mean ± SD Median (IQR) Mean Rank 
CG 30 121.4 ± 12.65 121.2 (20) 29.35 
ARG 28 133.6 ± 12.9 130 (15) 49.88 
DAG 33 139.2 ± 18.07 137 (18) 57.85 
Male 15 129.6 ± 10.369 130.2 (18) 45.97 
Female 76 131.97 ± 17.5 131 (18) 46.01 
Total  91 131.59 ± 16.58 131 (18)  
 
Table 7-5 Descriptive statistic of cSBP in the pooled sample and in Sub-groups 
cSBP N Mean ± SD Median (IQR) Mean Rank 
CG 30 105.4 ± 10.24 106 (15) 28.50 
ARG 28 119.8 ± 18.9 117.5 (22) 50.70 
DAG 33 125.6 ± 19.2 123 (31) 57.92 
Male 15 115.6 ± 16.2 116 (20) 47.10 
Female 76 117.5 ± 19.140 112 (24) 45.78 
Total  91 117.18 ± 18.62 113 (22)  
 
7.4.2.2. pSBP, cSBP and the difference between sub-groups  
To investigate the results further, a series of non-parametric tests were performed. 
The Kruskal-Wallis test indicates a significant difference between the clinical groups 
in pSBP (χ2 (2) = 19.28, P<0.0001). The differences were significant between CG, ARG 
(U=263, P=0.001) and CG, DAG (U=247.5, P<0.0001). However, there was no variation 
in pSBP between sexes (P=0.996). Box and whiskers plots of the pSBP between the 
clinical groups and sex are illustrated in (figure 7-11). 
On the other hand, there was a significant difference between the clinical groups in 
cSBP (χ2 (2) = 20.79, P<0.0001). The differences were significant between CG, ARG 
(U=207.5, P=0.001) and CG, DAG (U= 182.5, P<0.0001). Additionally, there was no 
difference between sexes in cSPB (P=0.860). Box and whiskers plots of the cSBP 
between the clinical groups and sex are illustrated in (figure 7-12).  
179 
 
  
Figure 7-11 Box and whiskers plots of pSBP, (mmHg) among the clinical groups and sexes. Data shows 
medians, interquartile range, whiskers and outliers. ** Indicates significant between group differences 
(P<0.01) 
 
 
 
Figure 7-12 Box and whiskers plots of cSBP, (mmHg) among the clinical groups and sexes. Data shows 
medians, interquartile range, whiskers and outliers. ** Indicates significant between group differences 
(P<0.01) 
For further investigation in the difference between peripheral SBP and central SBP a 
Wilcoxon Signed Rank test was performed. There was a significant difference 
between the pSBP and cSBP in the pooled sample (Z= -6.836, P< 0.0001). The test 
was performed again, after splitting the sample by the clinical groups, to further mine 
the data. The significant differences between pSBP and cSBP occurred within the CG 
(Z= -4.705, p< 0.0001), ARG (Z= -3.372, P< 0.0001), and DAG (Z= -4.003, P< 0.0001). 
Box and whiskers plots are shown in (figure 7-13).  
** 
** 
** 
** 
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Figure 7-13 Box and whiskers plot of pSBP and cSBP (mmHg) within the clinical groups. Data shows 
medians, interquartile range, whiskers and outliers. ** Indicates significant between group differences 
(P<0.01) 
 
7.4.2.3. Correlations between pSBP, cSBP and 25(OH)D and the rest of the vascular 
structural and functional characteristics. 
There was no significant Spearman’s association between pSBP, cSBP and 25(OH)D 
in the pooled sample (table 7-6). Interestingly however, pSBP was significantly 
correlated to IMT (rho=0.390, P<0.0001) and IAD (rho= 0.279, P=0.003). cSBP was 
significantly correlated to IMT (rho=0.327, P=0.001) and IAD (rho=0.340, P<0.0001) 
(table 7-11). Scatter plot of 25(OH)D against pSBP and against cSBP are illustrated in 
figure 7-14. 
When the sample was separated by the clinical groups and consumption of vitamin 
D supplements, a strong negative significant Spearman’s correlation was observed 
between 25(OH)D and pSBP only in the DAG when taking vitamin D supplements 
(rho= -0.642, P=0.017, R2=0.41). Conversely, cSBP was moderately correlated with 
25(OH)D Also in the DAG when vitamin D supplements are not taken (rho= 0.360, 
P=0.050, R2=0.31) (table 7-12).   
** ** 
** 
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Table 7-6 Spearman correlations between 25(OH)D (ng/mL) and pSBP, cSBP (mmHg) 
 25 (OH)D pSBP cSBP 
Sp
ea
rm
an
's
 r
h
o
 
25 
(OH)D 
Correlation Coefficient 1.000 -0.028 0.139 
Sig. (1-tailed) . 0.393 0.095 
N 97 97 91 
pSBP Correlation Coefficient  1.000 0.690** 
Sig. (1-tailed)  . 0.000 
N  97 91 
cSBP Correlation Coefficient   1.000 
Sig. (1-tailed)   . 
N   91 
*. Correlation is significant at the 0.05 level (1-tailed). 
**. Correlation is significant at the 0.01 level (1-tailed). 
 
 
 
Figure 7-14 X-Y scatter plots between pSBP, cSBP (mmHg)  and 25(OH)D ng/mL. 
 
7.4.3 Analysis of carotid artery intima-media thickness (IMT) using 
ultrasound 
7.4.3.1. Descriptive analysis of IMT in the Pooled sample and between sub-groups 
Measurement of carotid artery intima-media thickness provided continuous data for 
97 participants using MyLab 70 ultrasound (Esaote, Genoa, Italy). The minimum IMT 
in the current study was 0.32 mm and the maximum was 1.43 mm. Descriptive 
analysis of IMT values among the pooled sample and in sub-groups are presented in 
table 7-7. Distribution of IMT values among the pooled sample are represented in 
(figure 7-15). IMT is considered normal <0.75mm; at risk of atherosclerosis between 
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the 0.75mm and 1.00 mm; and atherosclerosis patients at > 1.00 mm (Polak et al., 
2013; Taskiran et al., 2017). Based on the IMT measurements 83.5% of the 
participants had normal values of IMT (0.547 ± 0.1 mm), 9.3% were at risk (0.85 ± 
0.06 mm), and 7.2% were atherosclerosis patients (1.19±0.16 mm) (figure 7-15)  
  
Figure 7-15 Distribution of IMT values (mm) among the whole sample and categorised based on the 
IMT values. The dotted lines illustrate the cut off values for IMT.  
 
Table 7-7 Descriptive analysis of IMT (mm) among the pooled sample and in sub-groups. 
 N Mean ± SD Median (IQR) Mean Rank 
CG 33 0.508 ± 0.12 0.49 (0.19) 32.68 
ARG 30 0.603 ± 0.16 0.57 (0.19) 49.35 
DAG 34 0.749 ± 0.26 0.658 (0.32) 64.53 
Male 15 0.64 ± 0.23 0.59 (0.39) 51.87 
Female 82 0.61 ± 0.21 0.57 (0.21) 48.48 
Total 97 0.622 ± 0.215 0.58 (0.21)  
 
7.4.3.2. IMT values and the difference between sub-groups  
The difference in IMT values within the sub-groups has been tested. Analysis showed 
significant differences in IMT between the study clinical groups CG, ARG, and DAG 
using a Kruskal-Wallis test (χ2 (2) = 21.456, P<0.0001). The significant differences 
were between CG, ARG (U=304, P=0.009), CG, DAG (U=213.5, P<0.0001), and ARG, 
DAG (U= 329.5, P=0.015). However, a Mann-Whitney test on IMT by sex revealed no 
significant difference (P=0.668). Box and whiskers plots are illustrated in figure 7-16 
High values Normal values 
At-risk values 
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shows the significant differences in FBG levels between the clinical groups and shows 
no sex bias.  
  
Figure 7-16 A box and whiskers plot of IMT (mm) among the clinical groups and gender. Data shows 
medians, interquartile range, whiskers and outliers. Significant differences between groups indicated 
by (* = P<0.05) and (** = P<0.01). 
 
7.4.3.3. Correlations between IMT and 25(OH)D and the rest of the vascular structural 
and functional characteristics. 
No significant correlation was observed between 25(OH)D and IMT (P=0.414) (table 
7-8). Similarly, there was no effect of 25(OH)D concentration on IMT levels (P=0.87) 
as illustrated in the simple X-Y scatter graph line in figure 7-17. However, IMT was 
significantly correlated to pSBP (rho=0.390, P<0.0001), cSBP (rho= 0.327, P=0.001), 
and IAD (rho=0.431, P<0.0001) (table 7-10). 
When the sample was separated by the clinical groups and consumption of vitamin 
D supplements, a moderate negative significant Spearman’s correlation was 
observed between 25(OH)D and IMT only in the CG when vitamin D supplements are 
not taken (rho= -0.358, P=0.033, R2=0.13) (table 7-12).  
Table 7-8 Spearman correlations between 25(OH)D (ng/mL) and IMT (mm) 
 25 (OH)D IMT 
Spearman's 
rho 
25 (OH)D Correlation Coefficient 1.000 -0.022 
Sig. (1-tailed) . 0.414 
N 97 97 
** 
** 
* 
184 
 
 
 
Figure 7-17 Simple X-Y scatter plot between IMT (mm) and 25(OH)D ng/mL 
 
7.4.4. Analysis of carotid artery inter-adventitial Diameter (IAD) using 
ultrasound 
7.4.4.1. Descriptive analysis of IAD in the Pooled sample and between sub-groups 
IAD was measured in all 97 participants 6.63 ± 0.807 mm. The minimum value of IAD 
was 5.17 mm and the maximum was 8.73 mm. Figure 7-18 shows the distribution of 
IAD among the participants. Descriptive analysis of IAD levels among the clinical 
groups, gender in the total sample and are illustrated in (table 7-8) 
 
Figure 7-18 Distribution of IAD values (mm) among the whole sample  
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Table 7-9 Descriptive analysis of IAD (mm) among the pooled sample and in sub-groups. 
 N Mean ± SD Median 
CG 33 6.30 ± 0.6 6.13 (1) 
ARG 30 6.64 ± 0.756 6.58 (1.01) 
DAG 34 6.94 ± 0.91 6.93 (1.21) 
Male 15 7.03 ± 0.92 6.86 (1.33) 
Female 82 6.56 ± 0.766 6.5 (1.15) 
Total  97 6.63 ± 0.807 6.56 (1.20) 
 
7.4.4.2. IAD values and the difference between sub-groups  
To investigate the difference between the sub-groups in IAD a series of parametric 
statistical tests were performed. One-way ANOVA revealed significant mean 
differences between the clinical groups [F (2, 94) = 5.68, P=0.005]. The post-hoc test 
indicates that the mean difference was only between CG and DAG (df= -0.63, 
P=0.003). Additionally, there was a significant difference between males and females 
in their IAD values when independent t-test was performed (T=0.47, P=0.036). Figure 
7-19 illustrates box and whiskers plots of the difference in IAD within the sub-groups.   
  
Figure 7-19 Box and whiskers plots for IAD values (mm) within clinical groups and gender. Data shows 
medians, interquartile range, whiskers and outliers. Significant differences between groups indicated 
by (* = P<0.05) and (** = P<0.01). 
** 
* 
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7.4.4.3. Correlations between IAD and 25(OH)D and the rest of the vascular structural 
and functional characteristics. 
No significant correlation was observed between 25(OH)D and IAD (P=0.164) (table 
7-10). Similarly, there was no effect of 25(OH)D concentration on IAD levels (P=0.258) 
as illustrated in the X-Y scatter graph line in figure 7-20. Conversely, IAD were 
significantly correlated to pSBP (rho=0.279, P=0.003), cSBP (rho=0.340, P<0.0001), 
and IMT (rho=0.431, P<0.0001) (table 7-10).  
Table 7-10 Spearman correlations between 25(OH)D (ng/mL) and IAD (mm) 
 25 (OH)D IAD 
Spearman's rho 25 (OH)D Correlation Coefficient 1.000 -0.100 
Sig. (1-tailed) . 0.164 
N 97 97 
 
 
Figure 7-20 Simple X-Y scatter graph between IAD (mm) and 25(OH)D ng/mL 
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7.4.5. Additional vascular measurements RI, TVA, BF, and HR 
A preview of the mean ± SD of RI, TVA, BF and HR in the pooled sample and in each 
of the clinical groups is illustrated in table 7-1. The primary analysis of those 
measurements has shown similar results to results from the main indicator of 
vascular function measurement IMT and IAD. In addition, Spearman’s correlation 
shows no significant correlation between 25(OH)D concentration and those vascular 
measurements. Thus, further detailed analysis was not performed. 
7.4.6. Correlations between 25(OH)D and the study vascular structural and 
functional characteristics, and multiple linear regression model 
Spearman correlations were performed to investigate the relationship between 
25(OH)D concentration the vascular structural and functional characteristics. The 
test revealed no significant correlations between 25(OH)D concentration and any of 
the measurements in the chapter (table 7-11). Given the lack of significant 
association between vascular structure/ function and 25(OH)D, the multiple linear 
regression model was not performed in this chapter. 
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Table 7-11 Spearman’s rho between the vascular structural and functional characteristics and 25(OH)D levels.  
 25 
(OH)D 
CR 
PWV 
pSBP DBP cSBP IMT IAD RI TVA BF HR 
Sp
ea
rm
an
's
 r
h
o
 
25 
(OH)D 
Correlation Coefficient 1.000 -0.089 -0.028 -0.083 0.139 -0.022 -0.100 -0.119 -0.028 -0.106 -0.006 
Sig. (1-tailed) . 0.201 0.397 0.217 0.095 0.414 0.164 0.124 0.392 0.150 0.478 
N 97 91 91 91 91 97 97 97 97 97 97 
CR 
PWV 
Correlation Coefficient  1.000 0.027 0.056 -0.080 -0.067 0.103 0.065 -0.087 -0.039 0.118 
Sig. (1-tailed)  . 0.401 0.299 0.226 0.264 0.167 0.271 0.207 0.356 0.134 
N   91 91 91 91 91 91 91 91 91 
pSBP Correlation Coefficient   1.000 0.513** 0.690** 0.393** 0.268** 0.043 -0.238* -0.142 0.214* 
Sig. (1-tailed)   . 0.000 0.000 0.000 0.005 0.344 0.011 0.090 0.021 
N   91 91 91 91 91 91 91 91 91 
DBP Correlation Coefficient    1.000 0.416** 0.129 0.128 -0.172 -0.072 -0.081 0.272** 
Sig. (1-tailed)    . 0.000 0.111 0.114 0.052 0.250 0.221 0.004 
N    91 91 91 91 91 91 91 91 
cSBP Correlation Coefficient     1.000 0.327** 0.340** -0.100 -0.096 0.075 0.098 
Sig. (1-tailed)     . 0.001 0.000 0.173 0.183 0.238 0.178 
N     91 91 91 91 91 91 91 
IMT Correlation Coefficient      1.000 0.431** 0.278** -
0.275** 
-0.053 0.006 
Sig. (1-tailed)      . 0.000 0.003 0.003 0.303 0.475 
N      97 97 97 97 97 97 
IAD Correlation Coefficient       1.000 0.101 -
0.259** 
0.254** -0.101 
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Sig. (1-tailed)       . 0.163 0.005 0.006 0.163 
N       97 97 97 97 97 
RI Correlation Coefficient        1.000 -
0.397** 
-
0.354** 
-0.075 
Sig. (1-tailed)        . 0.000 0.000 0.233 
N        97 97 97 97 
TVA Correlation Coefficient         1.000 0.785** 0.028 
Sig. (1-tailed)         . 0.000 0.392 
N         97 97 97 
BF Correlation Coefficient          1.000 0.004 
Sig. (1-tailed)          . 0.485 
N          97 97 
HR Correlation Coefficient           1.000 
Sig. (1-tailed)           . 
N           97 
**. Correlation is significant at the 0.01 level (1-tailed). 
*. Correlation is significant at the 0.05 level (1-tailed). 
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Table 7-12 Spearman’s rho corelations between the vascular structural and functional characteristics and 25(OH)D levels in consideration of the consumption of vitamin D 
supplements among the clinical groups 
Take VitD 
supplem
ents 
Category CR 
PWV 
pSBP DBP cSBP IMT IAD RI TVA BF HR 
Yes DAG 
2
5
 (
O
H
)D
 
 
Correlation Coefficient 0.264 -0.642* -0.521 -0.284 0.042 -0.289 0.294 0.322 0.203 0.049 
Sig. (1-tailed) 0.216 0.017 0.050 0.199 0.448 0.181 0.177 0.154 0.264 0.440 
N 11 11 11 11 12 12 12 12 12 12 
ARG Correlation Coefficient -0.049 0.326 0.283 0.428 0.070 -0.021 0.042 0.301 0.007 0.308 
Sig. (1-tailed) 0.440 0.151 0.187 0.083 0.414 0.474 0.448 0.171 0.491 0.165 
N 12 12 12 12 12 12 12 12 12 12 
CG Correlation Coefficient 0.551 -0.086 -0.029 0.000 -0.371 0.377 -0.371 -0.371 -0.429 -0.143 
Sig. (1-tailed) 0.129 0.436 0.479 0.500 0.234 0.231 0.234 0.234 0.198 0.394 
N 6 6 6 6 6 6 6 6 6 6 
No DAG 
2
5
 (
O
H
)D
 
 
Correlation Coefficient -0.211 0.057 0.113 0.360* 0.360 0.069 -0.437* 0.339 0.238 -0.071 
Sig. (1-tailed) 0.173 0.401 0.308 0.050 0.050 0.379 0.021 0.061 0.143 0.377 
N 22 22 22 22 22 22 22 22 22 22 
ARG Correlation Coefficient -0.206 0.150 -0.108 0.192 -0.342 -0.338 -0.061 -0.350 -0.494* -0.047 
Sig. (1-tailed) 0.222 0.289 0.346 0.238 0.082 0.085 0.405 0.077 0.019 0.426 
N 16 16 16 16 18 18 18 18 18 18 
CG Correlation Coefficient 0.018 -0.070 -0.239 0.044 -0.358* -0.040 0.078 -0.021 -0.149 0.075 
Sig. (1-tailed) 0.466 0.373 0.130 0.419 0.033 0.421 0.350 0.458 0.230 0.354 
N 24 24 24 24 27 27 27 27 27 27 
*. Correlation is significant at the 0.05 level (1-tailed). 
**. Correlation is significant at the 0.01 level (1-tailed). 
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7.5. Discussion 
7.5.1 Discussion of Arterial stiffness using pulse wave velocity (PWV)  
PWV was performed between the carotid-radial arteries. The average for signal 
quality reached in this study was 83.8%, which is above 80% (the desired signal) 
(Pereira et al., 2014; Complior analyse operator's manual, 2016). PWV has been 
proposed to be an independent indicator for atherosclerosis (Collaboration, 2010; 
Pereira et al., 2014). However, the current study did not find significant differences 
between the clinical groups for PWV. Mean values for PWV were 7.35 ± 4.81 for the 
CG, 9.87 ± 5.39 for the ARG, and 8.58 ± 3.58 m/s for the DAG. Additionally, there was 
no significant correlation observed between 25(OH)D concentration and PWV 
measurements. The current data are similar to observations by Arora and Rehan 
(2015), who also tested the association between 25(OH)D and cardiovascular disease 
risk and observed no significant association between 25(OH)D and PWV (P=0.93). 
However, the findings of the current study are unlike another study by Al Mheid et 
al., (2011), who examined the relationship between 25(OH)D and PWV measurement 
and found that low 25(OH)D concentrations were inversely associated with PWV 
values (adjusted R2=0.42, P=0.04).  
The gold standard for PWV measurement is the carotid-femoral arterial 
measurement. However, in the current study, the carotid-radial arteries were used 
as the participants were from a conservative society that is not comfortable 
participating in a study if the thigh area is one of the points where the sensor is to be 
placed. The use of carotid-to-radial arteries instead of the carotid-to-femoral arteries 
could be an explanation for the absence of difference between the clinical groups 
and the absence of a correlation with 25(OH)D. Another issue that could affect the 
PWV results is the signal quality. Despite numerous attempts to improve the signal 
quality by insuring the position of the sensors, encouraging the participants to relax, 
removing the source of stress if it is possible, and explaining any worries they have 
from the examination. Out of all of the participants, 27.5% had PWV measurements 
exhibited a below 80% signal quality. 
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7.5.2. Discussion peripheral and central blood pressure  
Hypertension is considered to be one of the major risk factors for atherosclerosis and 
cardiovascular disease (Hamburg et al., 2008; Sibley et al., 2014). In the current study, 
that association was clearly evident. Both peripheral and central blood pressure were 
significantly different between the study groups (P<0.0001). The control group (CG) 
had the lowest pSBP and cSBP (123.0 ± 15.5 and 105.4 ± 10.24 mmHg respectively) 
compared to the at-risk group (ARG) (133.17 ± 12.57 and 119.82 ± 18.9 mmHg 
respectively) and the diagnosed with atherosclerosis group (DAG) (139.88 ± 18.26 
and 125.64 ± 19.2 mmHg respectively). The difference was significant (P<0.001) in 
both pSBP and cSBP between the CG and ARG. Additionally, the difference was 
similarly significant (P<0.0001) in both pSBP and cSBP between the CG and DAG. The 
current study indicates that both pSBP and cSBP are associated with the incidence 
and progression of atherosclerosis and cardiovascular disease. In addition, both pSBP 
and cSBP were positively correlated with the other markers of atherosclerosis, IMT 
(P<0.0001, P<0.001 respectively) and IAD (P<0.01, P<0.0001 respectively). 
Conversely, both pSBP and cSBP did not show correlations with 25(OH)D 
concentration in the pooled sample. This is similar to observations in a study by 
Gepner et al. (2012) who examined the association between 25(OH)D and 
cardiovascular risk factors in a randomised, double-blind, placebo-controlled study. 
They did not observe any correlation between pSBP and 25(OH)D (P=0.976) nor 
between cSBP and 25(OH)D (P=0.66) in neither the supplemented nor the non-
supplemented groups. Since the current study is an observational study, the absence 
of the correlations between the factors can be expected. 
On the other hand, other correlations were observed only in the DAG. The pSBP was 
correlated with 25(OH)D in the DAG only in the group who took vitamin D 
supplements (P<0.05). Additionally, when vitamin D supplements were not 
consumed, there was a significant correlation between cSBP and 25(OH)D in the DAG 
(P<0.05) as well. There are many studies that have observed associations between 
blood pressure and 25(OH)D concentration (Forman et al., 2007; Reis et al., 2009; A. 
Zittermann, 2014). Since there are conflicting results between these studies, more 
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research is needed to confirm the relationship between blood pressure and 25(OH)D 
concentration.  
7.5.3. Discussion of carotid artery intima-media thickness (IMT) 
IMT is an important risk marker of atherosclerosis (Constantinescu et al., 2012; 
Simova, 2015). A common artery IMT thicker than above 1.00 mm is an indicator of 
atherosclerosis and endothelial dysfunction (Flammer et al., 2012; Awad and Abbas, 
2017). In the current study, the measurements were performed using a colour 
Doppler ultrasound (MyLab 70, Esaote, Genoa, Italy) in a quiet, temperature 
controlled room as illustrated in section 7.2.2. of the thesis. The results on N= 97 
participant show that there were significant differences in IMT measurement 
between the clinical groups, as expected. The differences were between the CG and 
ARG (U=304, P=0.009), the CG and DAG (U=213.5, P<0.0001), and the ARG and DAG 
(U= 329.5, P=0.015). The CG had the lowest IMT values 0.508 ± 0.121 mm, then the 
ARG 0.603 ± 0.161 mm, and the highest IMT values were in the DAG 0.749 ± 0.261 
mm. Additionally, IMT was significantly correlated with the other vascular structural 
and functional characteristics pSBP (P<0.0001), cSBP (P=0.001), and IAD (P<0.0001). 
These observations confirmed the clinical condition of the participants. 
However, IMT was not significantly correlated to 25(OH)D concentration in the 
pooled sample, which supports what has previously been observed in other studies 
by Taskiran et al. (2017) and Reis et al. (2009). Taskiran et al. (2017) tested the 
relationship between IMT and 25(OH)D concentration in 93 diabetes sufferers in an 
observational study and found no association. Reis et al. (2009) tested the association 
between IMT and 1,25(OH)2D in older adults without a history or incidence of 
cardiovascular disease. The study was cross-sectional and did not observe any 
significant correlation in the pooled sample. However, they observed an association 
in a sub-group of hypertensive patients (P=0.036); for each 1 SD increase in 
1,25(OH)2D, the IMT decreased by 0.050 mm. Additionally, Targher et al. (2006) 
found a negative correlation between 25(OH)D and IMT in diabetic patients, but did 
not observe any association in healthy participants. In contrast to a sub-group of 
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healthy participants (CG) in the current study, where there was a significant 
correlation between 25(OH)D and IMT (P<0.05) in the group that did not take vitamin 
D supplements. These results from all the studies discussed show that the 
relationship between vitamin D status and intima-media thickness could be affected 
by many factors and it is not a direct association.  
7.5.4. Discussion of carotid artery inter-adventitial diameter (IAD) 
The common carotid artery inter-adventitial diameter (IAD) is another risk marker for 
atherosclerosis (British Heart Foundation, 2017). Tt is an arterial structure 
measurement that was assessed using an ultrasound (MyLab 70, Esaote, Genoa, 
Italy) of the carotid artery section 7.2.2. A larger IAD is associated with a higher risk 
and incidence of cardiovascular diseases (Krejza et al., 2006; Lloyd et al., 2012). In the 
current study there was a significant difference in IAD measurements between the 
control group (CG) and the diagnosed with atherosclerosis group (DAG) (P<0.01). This 
indicates that atherosclerosis patients have a larger IAD compared to healthy people. 
The CG had an IAD measurement of 6.306 ± 0.602 mm which was the lowest 
compared to the other clinical groups, 6.64 ± 0.756 mm in the ARG and 6.94 ± 0.914 
mm in the DAG, as expected. Additionally, there was an expected significant gender 
variation (P<0.05). Males had a larger IAD than females, 7.03 ± 0.92mm, and 6.56 ± 
0.807 mm respectively. Males naturally have larger arteries than females (British 
Heart foundation, 2017). Furthermore, the IAD was significantly correlated with the 
other vascular structural and functional characteristics, pSBP (P=0.003), cSBP 
(P<0.0001), and IMT (P<0.0001). This indicates that there is an association between 
IAD and the clinical status of the participants. 
As with the other vascular structural and functional characteristics in this study, IAD 
was not significantly correlated with 25(OH)D concentration. Additionally, to our 
knowledge, no study has previously examined the association between 25(OH)D and 
common carotid artery inter-adventitial diameter (IAD).  
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7.6. Summary and conclusion  
In the current study, with the exception of the PWV outcome measures, all of the 
vascular structural and functional characteristics (pSBP, cSBP, IMT, and IAD) were 
good indicators of the participants’ cardiovascular health condition. The parameters 
were significantly different between the study clinical groups. In addition, they were 
significantly correlated with each other. However, none of the measurements was 
significantly correlated with circulating 25(OH)D concentrations in the pooled 
sample. In the sub-groups some correlations were observed, but these were 
influenced by the consumption of vitamin D supplements. A consensus on the 
presence or absence of correlations, bearing in mind both our data and previous 
research, has yet to be reached.  
In conclusion, the study indicates that pSBP, cSBP, IMT, and IAD are good indicators 
of atherosclerosis risk factors and incidence. Nevertheless, the parameters were not 
correlated to 25(OH)D concentrations. The relationship between vitamin D status 
and atherosclerosis risk factors and incidence needs further investigation.   
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Chapter 8 - General discussion, final conclusion, study 
limitations and future work 
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8.1. General discussion 
The current study has investigated the association between vitamin D status and 
atherosclerosis risk factors and incidence in a sample of Saudi Arabia dwellers. The 
current study agreed with many other studies that found a relatively high prevalence 
of vitamin D deficiency among adults living in Saudi Arabia (Al Faraj and Al Mutairi, 
2003; Ardawi et al., 2012; Aljefree et al., 2017a). The results show that 51.5% of the 
participants were vitamin D deficient (25(OH)D < 20 ng/mL) with a mean value of 
9.88 ± 4.2 ng/mL, and 28.9% had an insufficient concentration of vitamin D in their 
blood plasma (25(OH)D 20 ≤ 30 ng/mL) (23.37 ± 2.57 ng/mL). Only 19.6% of the 
participants had adequate concentrations of vitamin D (25(OH)D > 30 ng/mL) (42.13 
± 9.28 ng/mL). 25(OH)D status was significantly correlated with the use of vitamin D 
supplements, dietary intake of vitamin D (DI-VitD), total intake of vitamin D (TI-VitD), 
exposure to sunlight, and age in the pooled sample of the study.  
The associations between 25(OH)D concentrations and all of the sources of the 
vitamin (vitamin D supplements, diet, and sun exposure) were indicators of the 
importance of all of these sources in obtaining optimal concentrations of vitamin D 
(Lehmann and Meurer, 2010; Holick et al., 2011). Further analysis of the data in this 
thesis indicates that only vitamin D supplementation and diet are reliable predictors 
of the vitamin status, as suggested by the multiple linear regression model. 
The final multiple linear regression stable model that predicts serum 25(OH)D 
concentration for the current study is the model that incorporated only the 
consumption of vitamin D supplements and dietary intake of vitamin D (DI-VitD) (out 
of a possible 27 potential modulators investigated). The stable model explains 39.6% 
of the variance in 25(OH)D and is statistically significant and has low shrinkage of R 
(adjusted R2= 0.383), thereby indicating good statistical power. The predictors of this 
model are all significant, consumption of vitamin D supplements (P=0.0001) and DI-
VitD (P=0.019) (Table 4-17). Thus, in summary, 25(OH)D blood concentration can be 
predicted as was discussed in section 4.2.6 using the following equation:  
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𝒀 = (𝑩𝟏 ∗ −𝟎. 𝟎𝟏𝟗) + (𝑩𝟐 ∗ −𝟏𝟕. 𝟓𝟕𝟗) + 𝟓𝟒. 𝟒𝟑𝟑 ± 𝟏𝟎. 𝟓𝟓 
Y= 25(OH)D concentrations (ng/mL) 
B1= DI-VitD in IU 
B2= 1 if using vitamin D supplements or 2 if not using vitamin D supplements 
On the other hand, observation of the data in consideration of the use of vitamin D 
supplements and the clinical groups (control group (CG), at-risk group (ARG), and the 
diagnosed with atherosclerosis group (DAG)) provided interesting insights in the 
inter-relationship between atherosclerosis markers. When vitamin D supplements 
were used, 25(OH)D levels were associated with CRP only in the ARG, and pSBP in 
the DAG group. In contrast, in participants who were not using vitamin D 
supplements, 25(OH)D concentrations were correlated to TG in the ARG, cSBP in the 
DAG, and IMT, in the CG. On the other hand, the participants’ health status, as 
represented by the study’s clinical groups were significantly different in terms of age, 
WHR, CRP, FBG, LDL, TG, pSBP, cSBP, IMT, and IAD measurements. This indicates an 
association between those markers and the incidence and development of 
atherosclerosis. 
Previous studies have not agreed on a consistent outcome that illustrates the 
relationship between 25(OH)D and atherosclerosis risk factors and markers. In a 
study by Al Mheid et al. (2011) on healthy participants, 25(OH)D was associated only 
with the LDL levels from the lipids profile test and with PWV and FMD from the 
arterial measurements. No association was observed with the rest of the blood 
profile measurements. Another double-blind study examined the impact of vitamin 
D supplementations on cardiovascular disease markers in healthy participants 
(Zittermann et al., 2009). The study observed a significant difference between the 
placebo and supplement groups on TG and inflammation markers of cardiovascular 
disease, but there was no association with body weight and the rest of the blood 
profile measurements. The inconsistent association could be because of the 
substantial number of factors that affect the association such as the form of 
measured vitamin D, the participants’ health condition, and the study design.   
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Furthermore, in the studies that focus on of the cardiovascular disease risk factors, 
such as diabetes or hypertension, there were always associations between vitamin D 
status and cardiovascular disease (Targher et al., 2006; Zittermann et al., 2009; Yiu 
et al., 2011) that could be because when the damage is there, the difference can be 
easily distinguished. The association between vitamin D and these major risk factors 
of disease have been observed by many previous studies (Talaei et al., 2013; Al-
Daghri, 2016; Qadhi, 2016); as such, vitamin D status is considered as providing a 
valid and reliable early warning system in the prevention of these risk-factor diseases 
such as diabetes, hypertension, and hyperlipidaemia. 
Moreover, it has been observed that in order for the association between vitamin D 
status and cardiovascular disease to be observed, longitudinal (as opposed to the 
cross-sectional design in the present study and/or in the majority of the published 
literature) studies need to be performed. Indeed, the studies that were longitudinal 
observed the change before and after giving vitamin D supplements, thereby 
reporting a significant impact of vitamin D on cardiovascular health markers (Reis et 
al., 2009; A. Zittermann, 2014; Aljefree et al., 2016). In support of the longitudinal 
design’s importance, whilst even in observational studies such as the one by Degerud 
(2016), the association between 25(OH)D and atherosclerosis progression was not 
observed after one year of follow-up. After 12 years of follow up, there was an 
inverse association between low 25(OH)D and cardiovascular mortality.  
The issue of vitamin D deficiency is still occurring in Saudi Arabia in addition to the 
increasing number of atherosclerosis disease cases and deaths. Some healthcare 
professionals are aware of the situation, but decisive action is needed to control the 
prevalence of vitamin D deficiency in Saudi Arabia.
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8.1.1. Contribution of the thesis 
The current study is the first, to our knowledge, to evaluate the effects of vitamin D 
from a multitude of sources and to hence systematically examine the association 
between serum 25(OH)D and atherosclerotic disease and its risk factors in Saudi 
Arabia. The present study developed a model to measure sun exposure based on the 
weather, cultural and social factors in Saudi Arabia, with consideration of the 
guidelines by the PMCO. In addition, the current study developed a dietary vitamin 
D FFQ, based on the diet used by Saudi people, and an analysis program to determine 
total intake of vitamin D. Moreover, the study developed an equation to assess 
vitamin D status from dietary intake and use of vitamin D supplements. The current 
study additionally used a novel assessment method of markers of atherosclerosis 
which could be used in studies that examine the impact of any potential dietary 
habits in atherosclerosis incidence and development. This programme of studies is 
the first, to our knowledge, to use the pulse wave velocity (PWV) and central blood 
pressure (cBP) measurements of arterial stiffness in Saudi Arabia and the Middle 
East. The vascular structural and functional characteristic measurements were novel 
for the current study. This study investigated the gaps in research in the area and 
contributed to a number of novel findings. As for the remainder of the gaps in 
knowledge in the area of vitamin D deficiency impact on cardiovascular health, 
suggestions have been provided to inform future research.  
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8.2. Final conclusion 
The current study confirms the continued prevalence of vitamin D deficiency in Saudi 
Arabia. The sources of vitamin D that showed the biggest impact on vitamin D status 
were the use of vitamin D supplements and diet. On the other hand, the measured 
markers of atherosclerosis and its risk factors were significantly correlated with one 
another except for the PWV. Nevertheless, this study did not observe associations 
between vitamin D status and atherosclerosis risk factors and incidence in the pooled 
sample. 25(OH)D was observed to be associated with some markers and this, only in 
sub-groups of vitamin D supplements users. Additionally some of the study 
measurements such as of age, WHR, CRP, FBG, LDL, TG, pSBP, cSBP, IMT, and IAD 
showed desired values with the participants’ health condition that defines their 
atherosclerosis status. This observational programme of studies investigated the 
bivariate associations without accounting for the multitude of other potential 
modulators of the relationships under investigation. Further research, such as 
longitudinal experimental studies, is needed to clarify the point at which vitamin D 
levels become critical to markers of atherosclerosis. 
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8.3. Study limitations 
The results of the current programme of studies might have been affected by some 
limitations. First is the study design, as an observational cross-sectional set of studies, 
there was an advantage in examining the cases without any additional factors that 
could affect the data. However, this made it difficult to distinguish any causal nature 
in any of the associations. One of the reasons for limiting the study to this design was 
that the hospital where the data was collected would not approve a longitudinal 
design. Additionally, a longitudinal design would have reqired at least six to eight 
months extra time for data collection and time was limited for this study. The use of 
medication (such as Statins) by some of the participants will have affected the results 
of the study. Moreover, the self-reporting questionnaire could have errors linked to 
responses affected by the social desirability effects. The use of carotid-radial instead 
of carotid-femoral PWV to assess arterial stiffness was one of the study limitations. 
Finally, the unequal number of participant between the sexes may have influenced 
the study’s power to determine any sex variations.   
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8.4. Recommendations for future work 
 Recommendations on sun exposure and vitamin D fortification and 
supplementation in Saudi Arabia have been published recently (in 2016) by 
the PMCO. However, the current study has highlighted the need for 
awareness and additional studies to test the best methods to reach optimal 
vitamin D levels. 
 The current study developed a model to measure sun exposure and total 
intake of vitamin D. Both models could be used in an awareness intervention 
study to test the effectiveness of sun exposure and dietary vitamin D intake.    
 The current study was an observational study that was free from any 
intervention that could affect the study results. The next step should be 
taking the novel design of the current study and use it in experimental, 
longitudinal studies by adding vitamin D supplements to the diet of the three 
clinical groups and observing the impact of these on the atherosclerosis 
disease markers used in the current study. In fact, a long duration (up to 12 
months) impact of sun exposure, diet, and use of supplements on 
atherosclerosis patients appears to be the preferable option for future work. 
 The current study tested serum 25(OH)D status, however, the availability of 
the vitamin D receptors needs to be tested on the endothelial function to 
better assess the association between circulating, free vitamin D, and its 
function through receptors on endothelial cells.   
 Assessment of vitamin D content in food items consumed in Saudi Arabia such 
as Camel’s liver and certain types of mushrooms should be conducted to 
cover the gap in literature regarding this data.
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